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Abstract 
Colorectal cancer (CRC) is one of the most prevalent malignancies in the Western world. It is 
a heterogeneous disease that begins from a benign polyp and progresses to invasive 
carcinoma via at least three distinct pathways. Prognosis of newly diagnosed cases mainly 
relies on the Dukes’ classification system, yet the 5-year survival rate of patients with CRC 
varies from 90% to 10% with tumour progression. The pursuit of biomarkers that can 
accurately predict patient prognosis has intensified in recent years. In our laboratory, we 
have previously shown that positive lamin A/C expression is a potential risk biomarker in 
CRC. Subsequent downstream investigations revealed that CRC cells overexpressing lamin A 
were significantly more motile compared to their GFP-only counterparts. This increase in 
motility was, in part, due to upregulation of the actin-bundling protein T-plastin (encoded by 
the PLS3 gene). The main aims of this thesis were to investigate PLS3 promoter methylation 
and plastin expression in CRC, using a combination of both epigenetic and 
immunohistochemical approaches. PLS3 promoter methylation was studied in CRC cell lines 
and a large cohort of CRC patients from the Netherlands Cohort Study on Diet and Cancer 
(NLCS) tissue archive. T-plastin expression was supressed because of promoter methylation 
and its expression was restored upon treatment with the DNA methylation inhibitor 5-aza-
2’deoxycitidine (p = 0.01; p = 0.05). Furthermore, T-plastin was methylated in ~50% of CRC 
patients but methylation status did not provide any prognostic value. However, there was an 
association between both methylation status and sex (p = 0.01) and methylation status and 
tumour location (p = 0.05). The expression of plastin proteins in CRC was studied by raising 
polyclonal antibodies against two plastin isoforms and determining their specificity using 
immunoblotting and peptide inhibition assays. The most promising antibody, Dann1a, was 
used to analyse the expression of plastin by immunohistochemistry, using patient sections 
obtained from the NLCS archive. Strikingly, plastin was absent from normal colonic mucosa 
but was aberrantly expressed in 80% of CRC patients and was frequently observed at the 
invasive front of the tumour. Finally, we identified and validated a candidate gene network 
using Ingenuity Pathway Analysis, based on the over expression of GFP-lamin A in CRC cells. 
This data suggests that lamin A is a master regulator of a pathway linked to cancer and cell 
motility. These studies will stimulate further studies into the role of specific plastins in 
epithelial cancers and provide a framework for the development of novel drugable targets 
for treatment of CRC. 
1 
 
Chapter 1: Introduction 
 
1.1 Colorectal cancer epidemiology 
Cancer is a group of more than 100 diseases characterized by uncontrolled cellular growth 
and has probably existed since antiquity. Indeed, some of the earliest evidence of cancer in 
humans was found in an ancient Egyptian papyrus written between 3000-5000 BC. It 
describes eight cases of tumours or ulcers of the breast. The manuscript concludes ‘there is 
no treatment’ and cauterization was given as a palliative measure. The origin of the word 
cancer (karkinos which translates into carcinos/carcinoma) is credited to the Greek physician 
Hippocrates (460-370 BC), who is thought to be one of the first to make the distinction 
between benign and malignant tumours. Over 200 years later, Galen (130-200 AD) coined 
the word oncos to describe tumours (which translates to swelling in Greek). Since these 
initial observations made thousands of years ago, our knowledge of tumour biology has 
improved tremendously.  
 
Despite decades of research and clinical practice, cancer is today the most common cause of 
death in the Western world (Jemal et al., 2011). According to recent global estimates, there 
are 12.7 million new cancer cases and 7.6 million deaths each year (Ferlay et al., 2010). Lung 
cancer is the most commonly diagnosed cancer (1.61 million cases) followed by breast 
cancer (1.38 million cases). Colorectal cancer (CRC) is the third most common malignancy 
with over 1.23 million cases per year. It is the third most common cause of cancer in men, 
and the second most common cause of cancer in women. 
 
Perhaps unsurprisingly, there are striking geographical differences in the global distribution 
of CRC (Jemal et al., 2011) (Figure 1.1). Age-adjusted incidence rates vary up to 25-fold 
between countries with the highest rates (Australia, New Zealand, USA and Western Europe) 
and those with the lowest rates (Africa and Asia) (Ferlay et al., 2010; Parkin et al., 2005) 
(Figure 1.2 A). Within Europe, Slovakia and Denmark have the highest CRC incidence rates 
for men and women (91 per 100,000 and 50 per 100,000 per year, respectively). By stark 
comparison, Greece has the lowest rates for both men (24 per 100,000) and women (17 per 
100,000) (GLOBOCAN, 2008) (Figure 1.2 B). Moreover, cancer incidence has risen 
dramatically over the past 40 years in Japan, Singapore and Eastern European countries; all 
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of which have significantly increased their gross domestic product (GDP) (Parkin et al., 2005). 
This can be attributed, in part, to aging populations and adoption of cancer-associated 
lifestyle choices such as smoking, increased alcohol consumption and sedentary occupations 
(Jemal et al., 2011). Similarly, migration studies indicate that populations which have made 
the transition to a ‘Western lifestyle’ are at increased risk of developing CRC (Kolonel et al., 
2004).  
 
Approximately 608,000 deaths from CRC occur each year, making it the 4
th
 most common 
cause of death from cancer (Ferlay et al., 2010). Mortality rates are higher in males than in 
females. Central and Eastern Europe have the highest mortality rates (20.3 per 100,000 for 
male, 12.1 per 100,000 for female), compared to Middle Africa, which have the lowest 
mortality rates for males and females (3.5 per 100,000 and 2.7 per 100,000 per year, 
respectively). In the UK, CRC is the third most common malignancy and the second most 
common cause of cancer-related death (Bray et al., 2002; Ferlay et al., 2010). Each year 
there are around 40,000 new cases and 16,000 deaths. Mortality rates vary considerably 
across the UK. This is thought be due to disparities within the public healthcare system, and 
environmental and socio-economic differences (Mayer et al., 2007; Mayor, 2010). Whilst 
age-standardised 5-year survival rates have improved over the last 20 years, approximately 
6% of the Western population will develop colorectal neoplasms during their lifetime and as 
such, CRC constitutes a major burden on public health organisations (Davies et al., 2005; 
Mayor, 2010). 
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Figure 1.1: Global estimated age-standardised incidence rates for CRC: both sexes. Australia and New Zealand have over 42.1 cases per 100,000; 
Uganda and India have less than 4.6 cases per 100,000 (GLOBOCAN, 2008).   
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: CRC incidence rates  
(A) Global age-standardised incidence rates (B) European age-standardised incidence rates (adapted 
from Cancer Research UK, 2011). 
 
A 
B 
5 
 
1.2 Colorectal cancer risk factors 
It is now well established that 5-10% of all CRC cases are due to genetic predisposition, and 
the remaining 90% of sporadic cases are intrinsically linked to environmental factors 
pertaining to diet and lifestyle (Smits et al., 2008). Epidemiological and pathological research 
has enabled the identification of several risk factors that may increase or decrease the risk of 
developing CRC. To date, the most comprehensive publication to examine such risk factors is 
the World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) 
report entitled ‘Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global 
Perspective’ (2007). In summary, they reported the probability of a causal relationship 
between exposure and outcome. Here, we briefly review the pertinent risk factors 
associated with developing CRC.  
 
1.2.1 Age 
The biggest risk factor associated with developing CRC is an individual’s age. The risk of CRC 
begins to increase at 40 years of age and rises dramatically beyond 50-55 years. Moreover, 
83% of all cases arise in people over 60 years old (Cancer Research UK, 2011). Likewise, CRC 
mortality is strongly associated with age (Figure 1.3). CRC takes between 10-15 years to 
develop, and symptoms do not present themselves until the disease has reached an 
advanced stage. Although CRC cases do arise in the younger population, these cases are 
predominantly due to well-defined hereditary CRC syndromes (Chapter 1, Section 1.3). 
 
 
 
 
 
 
 
 
 
Figure 1.3: Age-specific mortality rates of CRC, UK, 2008 (adapted from Cancer Research UK, 2011). 
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1.2.2 Gender 
Although the lifetime risk of CRC is similar between the sexes (Davies et al., 2005), age-
adjusted incidence and mortality rates are higher in men than in women (Ferlay et al., 2010). 
Thus, male gender is an important risk factor for the development of CRC. It is thought that 
lower consumption of vegetables and increased alcohol or tobacco consumption amongst 
men may partly explain why males have a higher risk of CRC than females (Cai et al., 2012). 
In addition, there are sex-specific differences with regard to tumour location (Section 1.4.1). 
The frequency of proximal (right-sided) CRC is higher in men than in women. Moreover, 
patients with right-sided CRCs usually have a more aggressive disease and worse prognosis 
than patients with left-sided (distal) CRCs. The mechanism that underlies the sex-specific 
differences remains to be elucidated (Benedix et al., 2010).  
 
1.2.3 Adult-attained height 
According the WCRF report, there is convincing evidence to suggest that adult-attained 
height increases the risk of CRC. Meta-analysis of cohort data from 16-case control studies 
revealed a 9% increased risk per 5cm of height. In Western society, populations have 
become collectively taller with the increase in nutritional intake. Height may act as a proxy 
for energy balance because it is a reflection of nutritional and environmental exposures that 
occurred in utero, early childhood and puberty. In addition, taller individuals have a longer 
intestinal tract, undergoing more cellular divisions. This may simply increase the likelihood of 
polyp formation and malignant transformation (Hughes, 2011). 
 
1.2.4 Obesity 
Obesity has reached epidemic proportions in the Western world. In the UK alone, the 
prevalence of obesity has increased dramatically. Figures indicate that 59% of women and 
69% of men have a Body Mass Index (BMI) of 25 or more. There is convincing 
epidemiological evidence, with a clear dose-response relationship, that subcutaneous fat (as 
indicated by BMI) and abdominal fatness (as indicated by waist circumference and or/hip to 
waist ratio) increases the risk of CRC. Meta analyses from 60 cohort studies demonstrated a 
15% increase in risk per 5 kg/m
2
. Meta-analysis of four cohort studies showed an increased 
risk of 5% per inch of waist circumference. Furthermore, meta-analysis of 5 cohort-studies 
showed an increased risk of 40% per 0.1 increment of waist to hip ratio.  
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Obesity in general is linked to type II diabetes. It is well established that abdominal fatness 
decreases insulin sensitivity which can lead to increase insulin production. This hyper-
insulinaemia increases the risk of CRC (Ortiz et al., 2012). The mechanisms that underlie the 
association between obesity and colon cancer remain to be fully established, but it has been 
suggested that the metabolic burden caused by an increased number of adipocytes creates 
an environment in which uncontrolled cell growth and survival are favoured (Sung et al., 
2011). In addition, obesity promotes the production of pro-inflammatory factors and 
facilitates activation of the NLRP3 inflammasome, an interleukin-1β family cytokine-
activating protein complex (De Nardo and Latz, 2011). Pro-inflammatory cytokines are 
produced by activated macrophages that are frequently found in the adipose tissue of obese 
individuals. A recent study of inflammatory cytokines in colorectal tumours found that at 
least nine inflammatory cytokine genes were dysregulated compared with normal tissue. 
This study also noted that macrophages found in the cancerous tissue had a pro-
inflammatory signature (McLean et al., 2011). The association between inflammation and 
CRC has also been investigated using knockout mice that lack regulators of inflammatory 
signalling. For example, the NOD-like receptor NLRP12 functions to downregulate many pro-
inflammatory cytokines, and mice lacking this receptor become susceptible to colon 
inflammation and increased colorectal carcinogenesis. This study also highlighted the 
emerging importance of macrophages in controlling inflammation and hence cancer 
development. 
 
1.2.5 Red and processed meat  
There has been a great amount of scientific interest related to the consumption of red meat 
and processed foods in relation to CRC risk. The epidemiological studies to date conclude 
that there is increased risk of 15% and 21% per 50 g/day of red meat and processed meat 
consumed, respectively. Cohort and case-control studies indicate a dose-response 
relationship, and a conclusion from the WCRF/AICR report is that both red and processed 
meats are ‘convincing’ causes of CRC. However, this notion remains controversial. Some 
publications suggest that epidemiologic evidence does not support a clear association 
between consuming processed meat and CRC. Several hypotheses have been proposed to 
explain the mechanism underlying the link between red meat and CRC development, most of 
which are based around the primary constituents of the meat such as protein, fat or possibly 
iron (Williams et al., 2010). It has also been suggested that heterocyclic amines and 
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polycyclic aromatic compounds could contribute to the onset of CRC. These compounds 
form during the cooking and processing of meat and are potent carcinogens. There is 
considerable variability on how processed meat is defined but it generally refers to any 
mechanical, chemical, enzymatic or microbiological treatment of meat. This includes 
smoking, curing, salting, and the addition of preservatives such as salt, nitrate and nitrites. 
Amino acid derivatives can react with nitrite and nitrate, forming potentially carcinogenic  
compounds and excess iron in the diet can also lead to the production of free radicals (Cross 
et al., 2003; Nelson, 2001). A recent risk analysis for those individuals that consume high 
amounts of meat suggests that reducing meat intake to 70 g/week should, in theory, 
decrease the risk of CRC by up to 25% (Norat et al., 2005). 
 
1.2.6 Alcohol  
Some epidemiological studies indicate that there is a positive association between alcohol 
consumption and CRC occurrence, but not all investigators agree (Crockett et al., 2011; 
Fedirko et al., 2011; Otani et al., 2003; Su and Arab, 2004). The AICR report concludes that 
there is convincing evidence that more than 30 g/day of alcohol increases CRC risk in men, 
whilst the risk is ‘probable’ in women. Men generally consume more alcohol than women. In 
addition, there are differences in types of alcoholic drink consumed between the sexes and 
there may be hormone-related differences in alcohol metabolism or susceptibility to alcohol. 
Ethanol is carcinogenic as it can inhibit DNA methylation (Liu et al., 2009), alter retinoid 
signalling (Kane et al., 2010), and produce toxic metabolites such as acetaldehyde (Seitz and 
Stickel, 2007). 
 
1.2.7 Smoking 
It is estimated that tobacco causes approximately 20% of all cancer deaths. Globally, around 
80% of lung cancer cases in men and 50% in women are caused by cigarette smoking. 
Cigarette smoke contains at least 80 known mutagenic carcinogens (e.g. cadmium, arsenic, 
ammonia, formaldehyde, benzopyrene) and is a source of oxidative stress. Whilst the 
association between smoking and lung cancer is universally accepted, the association 
between CRC has been controversial. Smokers have increased risk of CRC according to a 
recent study (Liang et al., 2009). In general, tobacco use is likely to increase tumour growth 
by inducing angiogenesis and suppressing the immune system (O'Byrne et al., 2000).  
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1.2.8 Energy restriction 
Energy restriction appears to be one of the most convincing interventions for lowering CRC 
risk (Kritchevsky, 1993). Numerous studies in animal models have demonstrated that this 
occurs through mechanisms such as inhibiting cell proliferation, accelerating apoptosis, 
enhancing DNA repair and lowering sex steroid hormones (Tammariello and Milner, 2010). 
Energy restriction at a young age appears to confer protection against CRC. Hughes et al. 
(2010) showed that exposure to the Hunger Winter period (1944-1945) in the Netherland’s 
Cohort Study on Diet and Cancer (NLCS) was associated with a lower risk of developing 
colorectal neoplasms.  
 
1.2.9 Physical activity 
Physical activity is a major aspect of energy expenditure, and according to the WCRF report, 
there is convincing evidence that physical activity decreases CRC risk and equally a sedentary 
lifestyle increases CRC risk. However, the exact mechanisms by which physical activity can be 
attributed to lowering cancer risk are not fully understood (Eheman et al., 2012). It has been 
suggested that sustained physical exercise raises the metabolic rate, which in turn reduces 
hypertension and insulin resistance and obesity. Moreover, physical activity may improve 
immune function, reduce free radicals, increase prostaglandins and increase gut motility. It 
has also been shown that physical activity decreases the risk of recurrence and improves the 
quality of life in CRC survivors (Denlinger and Engstrom, 2011).  
 
1.2.10 Fibre intake 
The notion that dietary fibre intake can reduce the risk of CRC is long-standing. This 
hypothesis was first proposed by Burkitt in 1971, based on findings that of low rates of CRC 
were found among rural Africans who consumed a fibre-rich diet (Burkitt, 1971). Dietary 
fibre might protect against CRC by increasing stool weight, reducing transit time of material 
in the colonic lumen and through dilution of carcinogens. Fibre digestion by the colonic 
microflora can produce butyrate, a compound known to stimulate apoptosis (Avivi-Green et 
al., 2000; Hague et al., 1993). However, a number of epidemiological studies have reported 
no association between dietary fibre and CRC risk (Sanjoaquin et al., 2004). This may be 
partially explained by the lack of reproducible data and the difficulty in delineating the 
effects of other dietary components such as folate, selenium and flavonoids that are found 
10 
 
in plant-rich material (Bingham et al., 2005). Taken together, the evidence suggests that 
dietary fibre may reduce the risk of CRC but more evidence is required. 
 
1.2.11 Aspirin  
Aspirin is an acetyl derivative of salicylic acid that was shown in classical experiments by 
John Vane to inhibit prostaglandin synthesis (Vane, 1971). Later experiments demonstrated 
that aspirin irreversibly inhibits COX1 and modulates the activity of the inducible COX2 
enzyme, which are primarily responsible for the production of prostaglandins and 
thromboxane by platelets. The original application for aspirin was as an analgesic and 
modulator of blood clotting in heart attacks and strokes (Vane and Botting, 2003). However, 
observational and epidemiological studies suggest that non-steroidal anti-inflammatory 
drugs (NSAIDs), including aspirin are associated with an overall reduction in the incidence of 
colonic polyps and the appearance of colorectal carcinomas (Thun et al., 2012). Two 
randomised control trials in the UK and Sweden showed that aspirin at a low dose of 75 
mg/day, when taken between 1 and 8.6 years of age, is associated with a 39% decrease in 
CRC. The mechanism(s) of aspirin action in the prevention of CRC are incompletely 
understood, but it is thought that aspirin and other NSAIDs suppress COX-2 and hence inhibit 
polyp growth (Baron et al., 2003; Sandler et al., 2003). Regular aspirin usage has side-effects, 
including of gastro-intestinal haemorrhage, so both trials concluded it was too early to 
recommend widespread use of aspirin as a chemopreventive agent to prevent CRC. 
 
1.2.12 Other dietary factors  
The WCRF/AIRC report also evaluates the effect of other dietary factors and the risk of 
developing CRC. It is probable that consumption of foods containing garlic reduces the risk of 
CRC (Dietrich et al., 2011; Norat, 2010). Garlic contains allyl sulphur compounds, including 
diallyl disulphide and S-allylcysteine, which are derived from unstable thiosulfinates such as 
allicin when garlic cloves are disrupted (Amagase et al., 2001). The complex chemistry of 
garlic sulphur compounds has made it difficult to assess mechanism in CRC prevention, but 
some of these substances have been tested in animal cancer models. For example, C57BL/6J 
mice provided with diallyl sulphide prior to chemical induction of CRC had reduced incidence 
of adenocarcinoma, as did animals given S-allylcysteine (Sumiyoshi and Wargovich, 1990; 
Wargovich, 1987). Despite initial hope from tests in animal models, few clinical trials with 
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cancer patients have been conducted using garlic compounds and these have provided 
mixed results (Ngo et al., 2007). One confounding issue is that in many trials, the level of 
garlic intake (and metabolic processing) is heterogeneous, making it difficult to define a 
dose. Garlic sulphur compounds are thought to protect against cancer by inhibiting 
carcinogen-induced DNA modifications, preventing unregulated cell growth, proliferation 
and angiogenesis, inducing differentiation, apoptosis and carcinogen-detoxifying enzymes 
(Ngo et al., 2007). Garlic also contains other substances, including selenium, vitamins A and 
C, and fructooligosaccharides which are likely to protect against cancer (Ngo et al., 2007). In 
addition to garlic, other dietary components are likely to influence the risk of developing 
CRC. For example, milk and calcium consumption reduces the risk of this type of cancer 
(Dietrich et al., 2011; Norat, 2010). Calcium is thought to trap CRC-promoting bile acids in 
the colon and it has been reported that this metal can increase apoptosis as well as decrease 
the proliferation of epithelial cells (Bernstein et al., 2005; Lupton et al., 1996; Whitfield et al., 
1995). Finally there is some evidence that fish consumption can protect against CRC. 
However, as with dietary fibre, there is heterogeneity in these epidemiological studies. This 
may be partly due to the wide variety of fish species and sources consumed, ranging from 
fresh fish to tinned and dried fish. Moreover, a high intake of fish may be associated with 
low meat consumption; a potential confounder that is not easy to adjust for. It is worth 
noting that whilst five portions of vegetables a day is recommended for a healthy diet, 
studies suggest that there is little or no association between fruit and vegetable 
consumption and CRC risk (Key, 2011). 
 
1.3 Hereditary colorectal cancer 
As previously mentioned, the majority of CRC cases (~90%) develop sporadically and are 
strongly associated with an ageing population. The remaining cases (~5-10%) are due to 
well-defined inherited cancer syndromes named familial adenomatous polyposis (FAP), 
hereditary nonpolyposis CRC (HNPCC) and hamartomatous polyposis syndromes (Potter, 
1999; Rustgi, 2007). Whist these conditions only affect a small number of the younger 
population, knowledge derived from investigating hereditary CRC has led to a vast increase 
in our understanding of the critical molecular pathways of sporadic CRC (to be discussed in 
Chapter 1, Section 1.4) (Kinzler and Vogelstein, 1996). In parallel fashion, the emergence of 
normal diagnostics and therapeutics has continued to develop (Rustgi, 2007). 
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1.3.1 Familial adenomatous polyposis coli (FAP) 
Familial adenomatous polyposis coli (FAP) is an autosomal-dominant CRC syndrome, with a 
prevalence of 1 in 13,000 individuals (Bisgaard and Bulow, 2006; Jasperson et al., 2010). The 
most compelling feature is the development of hundreds to thousands of adenomatous 
polyps in the colon and rectum, usually within the second decade of life (Bisgaard and 
Bulow, 2006; Nieuwenhuis et al., 2007; Nieuwenhuis and Vasen, 2007). However, the 
majority of patients are asymptomatic for years until the adenomas are large and numerous, 
causing rectal bleeding or anaemia (Half et al., 2009). In addition, FAP may present with 
extra-intestinal manifestations such as dental abnormalities, congenital hypertrophy of the 
retinal pigment epithelium, desmoid tumours and other extra colonic malignancies (Biasco 
et al., 2004; Rustgi, 2007; Speake et al., 2007). Approximately 70% of FAP patients have a 
family history of colorectal polyps and cancer, with an almost inevitable progression to CRC 
unless this is dealt with by surgical intervention (Galiatsatos and Foulkes, 2006). FAP 
manifests equally in both sexes, and accounts for 0.2-1% of all CRC cases. The disease is 
caused by a germline mutation in the adenomatous polyposis coli (APC) gene located on 
chromosome 5q21 (Groden et al., 1991; Herrera et al., 1986; Nishisho et al., 1991). APC is a 
classical tumour suppressor gene. FAP patients inherit one germ-line mutation and develop 
tumours from those cells in which loss of the other allele (a ‘second hit’) is somatically 
acquired (Knudson, 2001; Nieuwenhuis and Vasem 2007; Jasperson et al., 2010).  
 
The APC gene encodes a 2843 amino acid protein, consisting of a variety of functional 
domains involved in a multitude of cellular processes including transcription, cell adhesion 
and signal transduction (Burgess et al., 2011; Half et al, 2009) (Figure 1.4). Notably, APC 
forms part of a protein complex involved in ubiquitin-mediated degradation of β-catenin in 
the canonical Wnt signaling pathway (Goss and Groden, 2000) (Chapter 1, Section 1.4.4). To 
date, over 300 different mutations have been identified (Beroud and Soussie, 1996). The 
majority of these mutations (e.g. deletions, nonsense mutations) result in a truncated 
protein. The most common mutation, occurring in about 10% of FAP patients, is a deletion 
mutation in codon 1309. Over 60% of APC mutations are located between codons 1250-1484 
– the so-called mutational cluster region (MCR) (Beroud and Soussie, 1996; Bertario et al., 
2003). The fact that FAP is a caused by a wide range of mutations represents a problem for 
molecular genetic diagnosis (Half et al., 2009). Several studies have revealed an association 
between the location of the APC mutations and phenotype; however, the correlation is not 
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exact and differences do occur (Nishisho et al., 1991). Approximately 10% of FAP patients 
have a less aggressive version of the disease – termed attenuated FAP. Attenuated FAP is 
caused by mutations in either the extreme 5’ or 3’ ends of the APC exons and is 
characterized by delayed onset and fewer adenomatous polyps (typically less than 100), and 
a lower cancer risk (Burt et al., 2004). Importantly, since the discovery that germline 
mutations in APC give rise to FAP, it has been well documented that at least 70% of sporadic 
CRC cases also harbour mutations in APC, which has led to the association between APC and 
initiation of sporadic CRC (Powell, 1992) (Chapter 1, Section 1.4.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Adenomatous polyposis coli (APC) key functional domains 
APC has eight functional domains which have important roles in fundamental cellular process such as 
cell migration (microtubule binding via the basic rich domain) and transcription (B-catenin binding via 
20aa repeats). Severe FAP correlates with mutations between codons 1250-1884 found in the 
mutational cluster region (MCR), which is a common region for APC mutations in sporadic CRC. 
Attenuated FAP is highlighted by mutations in either the extreme 5’ or 3’ end of the APC exons. 
SAMP = serine alanine methionine proline. EB1 = end-binding protein 1. HDLG = Human Disc Large 
binding site (adapted from Half et al, 2009). 
 
1.3.2 Hereditary non-polyposis colorectal cancer (HNPCC) 
Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome, was 
first described in 1966 (Lynch et al., 2009). The condition accounts for approximately 5% of 
all cases making it the most common inherited CRC predisposition and increases a patient’s 
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life-time risk of cancer to 80% (Jasperson et al., 2010; Rustgi, 2007). HNPCC is characterized 
by an autosomal dominant inheritance of early-onset CRC (Lynch and Lynch, 2004; Stoffel et 
al., 2009). Patients have a markedly increased risk of developing other cancers including 
cancers of the endometrium, ovary, stomach, small bowel, urinary tract, pancreas and brain 
(Hampel et al., 2006; Kastrinos et al., 2009). The disease is caused by mutations in DNA 
mismatch repair (MMR) genes; predominantly MutL Homolog 1 (MLH1), MutS Homolog 2 
(MSH2), MutS Homolog 6 (MSH6) and Postmeiotic segregation increased 2 (PMS2). Over 
90% of HNPCC patients have germline abnormalities in MLH1 or MLH2. The MMR system 
performs important recognition and editing functions during DNA replication, and thus plays 
a fundamental role in maintaining genomic stability. Upon DNA damage (e.g. as a result of 
oxidative stress) or following replication-associated errors, MMR proteins can recognize and 
repair both base-pair mismatches and small nucleotide (1-4 bp) insertion deletion loops 
(Figure 1.5). Briefly, MSH2 and MSH6 form a heterodimer which recognize single base 
mismatches or deletions, and MSH2 and MSH3 dimerize and extend the capability of the 
MMR systems to recognize 1- 4bp mismatches and deletions. Subsequently, MLH1 and PMS2 
are recruited to form a complex with either MSH2-MSH6 or MSH2-MSH3 which ultimately 
triggers a cascade of events that leads to excision of the mismatched base(s), resynthesis 
and ligation. In HNPCC, mutations in MMR genes diminish the capacity to repair replication-
associated errors, and as such mutations accumulate in short DNA tandem repeats known as 
microsatellites. Microsatellite instability (MSI) is a hallmark of HNPCC and is also observed in 
15% of all sporadic CRCs (Chapter 1, Section 1.4.8). Ultimately, MMR deficiency mediates an 
overall increase in mutations that leads to the so-called ‘mutator phenotype’. This has 
detrimental effects on ‘normal’ regulatory process (e.g. apoptosis) in the colonic epithelia 
which leads to a selective growth advantage and allows for neoplastic transformation.  
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Figure 1.5: DNA mismatch repair system overview 
The MMR system in mammalian cells functions to recognise and correct base-pair mismatches and 
small nucleotide (1-4 bp) insertion/deletion mutations that occur during DNA replication. (A) Key 
proteins involved in the recognition and repair of single-base mismatches and insertion/deletion 
mutations and (B) in 1-4 bp mismatches and insertion/deletion mutations. MLH1 and PMS2 form 
complexes with both MLH2-MLH6 and MLH2-MLH3, culminating in the excision of the mismatches 
base(s), resynthesis and ligation (adapted from Rugsti, 2007). 
 
1.3.3 Hamartomatous polyposis syndromes 
The hamartomatous polyposis syndromes are a heterogeneous group of disorders 
representing only a small fraction of the inherited gastrointestinal predisposition syndromes 
(<1%) (Jasperson et al., 2010). Nevertheless, many of these conditions exhibit a substantial 
risk of colorectal as well as extracolonic malignancies. These syndromes are characterised by 
the propensity to develop hamartomatous polyps of the gastrointestinal tract. Several 
syndromes have been documented; Juvenile Polyposis Syndrome (JPS), Peutz-Jeghers 
Syndrome (PJS), Bannayan-Riley-Ruvalcaba Syndrome (BRRS), Cowden Syndrome (CS), 
Cronkhite-Canada Syndrome (CCS), and Hereditary Mixed Polyposis Syndrome (HMPS) and 
PTEN Hamartoma Tumour Syndrome (PHTS) (Gammon et al., 2009; Schreibman, 2005). 
Whilst harmatomatous polyps are in themselves benign, they are associated with 
considerable morbidity and mortality from non-malignant manifestations, such as bleeding 
and bowel obstruction. Moreover, the transformation of these polyps to carcinoma is not 
well understood and represents a different mechanism than that seen in other hereditary 
syndromes.  
B 
A B 
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1.4 The molecular basis of colorectal cancer 
 
1.4.1 Anatomy of the colorectum  
The colon is approximately 150 cm long and functions to absorb water and salts from faecal 
waste. In mammals, the colon comprises of four sections; the ascending colon, the 
transverse colon, the descending colon and the sigmoid colon (Figure 1.6). The ascending 
colon is positioned between the caecum and hepatic flexure. The transverse colon forms 
between the hepatic flexure and splenic flexure. The descending colon connects the splenic 
flexure to the sigmoid colon. Finally, the sigmoid colon terminates at the rectum. The walls 
of the sigmoid colon are muscular, and contract to increase the pressure inside the colon, 
causing the stool to move into the rectum. The rectum is approximately 12 cm long and 
functions as a temporary storage site for faeces. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Anatomic structure of colorectum 
Site distribution of CRC in England and Wales between 1971 and 1994 (adapted from Davies et al., 
2005). 
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Over the last two decades, numerous studies have documented clinicopathological 
differences between proximal (right-sided) CRCs (caecum, ascending colon, hepatic flexure 
transverse colon) and distal (left-sided) CRCs (splenic flexure, descending colon, sigmoid 
colon, rectum) (Benedix et al., 2010; Bufill, 1990). The majority of CRCs originate in the 
rectum (38%) and sigmoid colon (29%) (Davies et al., 2005) (Figure 1.6). However, since the 
1970’s, there is growing evidence of a so-called ‘distal-to-proximal shift’ in the location of 
tumours (Jass, 1991; Levi et al., 1993; Meguid et al., 2008; Obrand and Gordon, 1998). The 
reasons behind this change are not entirely clear. It has been suggested that improved 
detection methods and an aging population are the likely explanations (Rabeneck et al., 
2003). 
 
The adult gastrointestinal tract is radially organised into several histologically distinct layers 
as depicted in Figure 1.7; the mucosa (including the lamina propria, and muscular mucosa), 
submucosa (loose connective tissue), Muscularis propria (circular and longitudinal smooth 
muscle) and serosa (Greene, 2002). At least 95% of CRCs originate from the mucosa and are 
classified as adenocarcinomas. Two rarer types of adenocarcinoma that exist include 
mucinous adenocarcinoma (MAC) and signet cell ring carcinoma (SCC). The prevalence of 
MAC is ~11% and is characterised by extracellular deposition of mucus constituting >50% of 
the tumour mass. By contrast, SCC is noted for the presence of individual neoplastic cells 
containing intracytoplasmic vacuoles with pleomorphic nuclei and accounts for just 1% of all 
CRC (Verhulst et al., 2012). Other rarer types of CRC include carcinoids, sarcomas and 
lymphomas. CRC in the context of this thesis refers to adenocarcinomas unless otherwise 
stated. 
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Figure 1.7: Schematic representation of gastrointestinal tract 
(adapted from Centres for Disease Control and Prevention, 2011).  
 
1.4.2 The colonic crypt  
The colonic mucosa is a simple columnar epithelium adjacent to the luminal surface which is 
primarily composed of three differentiated cell types: goblet cells, enterocytes and 
enteroendocrine cells which function to lubricate the passage of waste material, absorb 
water and salts and secrete hormones, respectively (Marshman et al., 2002). Protruding into 
the lamina propria, the colonic epithelium forms millions of deep cavities termed colonic 
crypts (Potten and Hendry, 1995) (Figure 1.8). Each crypt consists of continuously renewing 
cells that are repeatedly exposed to a wide range of environmental perturbations. Cell 
turnover at the intercrypt table is very high, and the differentiated population at the crypt 
apex must be continuously replenished (Booth and Potten, 2000). This homeostatic 
environment is maintained by a stem cell niche, which cradles the base of the each crypt 
(Barker, 2007; Marshman et al., 2002). The colonic niche is composed of pericryptal 
myofibroblasts which surround the stem cell base (Powell, 1999). Pericryptal myofibroblasts 
probably influence the colonic stem cells by controlling their self-renewal and encouraging 
stem cell proliferation  through  a variety of signalling pathways, of which the canonical Wnt 
signalling pathway is of major importance (Bienz and Clevers, 2000; Pinto and Clevers, 2005; 
Zeki et al., 2011) (Chapter 1, Section 1.4.4). The stem cells undergo mitotic self-renewing 
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divisions and then migrate unilaterally up the crypt. They give rise to proliferating, 
undifferentiated progenitor (transit-amplifying) cells which continue to divide upwards 
towards the luminal surface where they function briefly to form the differentiated epithelial 
lining of the gastrointestinal tract (Marshman et al., 2002; Zeki et al., 2011). Eventually, the 
epithelial cells undergo apoptosis and are shed into the lumen. The entire process of 
proliferation, differentiation and apoptosis takes between 4-6 days. In essence, the colonic 
crypt has evolved as a defence mechanism against neoplastic formations (Weinberg, 2007). 
The stem cells are protected by their very location, and any cells harbouring mutations 
should be eradicated at the luminal surface. So why and how does CRC arise? 
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Figure 1.8: Colonic crypt architecture  
Schematic representation and proposed model of colonic crypt regulation. The stem cell niche is 
located at the base of the crypt, and consists of pericryptal myofibroblasts, which produce signalling 
factors (e.g. Wnt) that maintain the stem cells in an undifferentiated state and control their 
proliferation. The concentration for these signalling factors decreases with distance from the niche 
so that the signalling environment (and thus cell behaviour) differs throughout the different crypt 
locations. In the lower third of the crypt, the progenitor proliferating cells are enriched in nuclear β-
catenin, and hence they express β-catenin/TCF target genes. As the undifferentiated precursor cells 
migrate upwards towards the midcrypt region, β-catenin/TCF activity is downregulated. This 
ultimately results in cell cycle arrest and the transit amplifying cells subsequently differentiate to 
become the epithelial components of the gastrointestinal tract. Cells undergoing mutation in APC or 
CTNNB1 (which encodes β-catenin) become independent of the physiological signals controlling β-
catenin/TCF activity. As a consequence, they continue to behave as crypt progenitor cells in the 
surface epithelium, giving rise to aberrant crypt foci (ACFs) (adapted from van Wetering et al. 2002). 
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1.4.3 The adenoma-carcinoma sequence 
Historically, CRC has been considered a genetic disease, resulting from the stochastic 
accumulation of mutations in tumour suppressor genes (loss of function) and oncogenes 
(gain of function). In 1990, Fearon and Volgenstein proposed a classic model that describes 
the evolution of benign adenomas to carcinomas through a step wise histological 
progression sequence (Figure 1.9). These genetic aberrations (e.g. APC, KRAS, TP53) 
ultimately transform normal glandular epithelium, and result in the clonal expansion of 
neoplastic cells with phenotypic hallmark characteristics including limitless replicative 
potential, evasion of apoptosis and immune surveillance, sustained angiogenesis and the 
ability to invade and metastasize (Fearon, 2011; Fearon and Vogelstein, 1990; Hanahan and 
Weinberg, 2000).  
 
 
 
 
 
 
 
 
 
 
Figure 1.9: The colorectal adenoma-carcinoma sequence 
The multistep genetic model of colorectal carcinogenesis is a well-defined sequence of mutational 
events that characterize the progression of normal colonic epithelium through pre-malignant 
adenoma to invasive adenocarcinoma. The initial step in CRC development is the inactivation of 
tumour suppressor gene APC, leading to activation of the Wnt signalling pathway and formation of 
ACF. Subsequent progression into early adenomas and carcinomas requires mutations in proto-
oncogene KRAS and loss of tumour suppressor SMAD2/4. TP53 mutations tend to occur late in the 
histological progression sequence and results in increased resistance of cancer cells to apoptosis 
(adapted from Davies et al 2005).  
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Adenomas (also referred to as polyps) can be described as elevated masses that protrude 
into the intestinal lumen (Davies et al., 2005). Dysplastic (neoplastic) polyps can either be 
pedunculated (with a stalk) or sessile (without a stalk). The epithelium of adenomas can take 
the form of tubular (glandular), villous (finger-like projections) or tubulovillous adenomas (a 
permutation of both). Occasionally, adenomas can be flat or depressed which can 
sometimes prove difficult to detect (Davies et al., 2005). Polyps are considered pre-
malignant lesions and only a small percentage will actually progress to invasive 
adenocarcinomas (Kozuka et al., 1975). Moreover, the entire process of colorectal 
carcinogenesis takes somewhere in the region of 10-15 years. This has allowed for the 
identification and detailed analysis of the molecular events involved in the initiation and 
development of CRC (Soreide et al., 2009). 
 
The earliest identifiable neoplastic lesion in CRC formation is the aberrant crypt focus (AFC) 
(Alrawi et al., 2006; Ranjana P, 1987; Roncucci et al., 1991). ACFs display expanded luminal 
openings compared to surrounding normal colonic mucosa (Takayama et al., 1998). 
Importantly, dysplastic crypts harbour mutations in APC and are most likely to give rise to 
CRC (Grady, 2005). APC is the most frequently mutated tumour suppressor gene in CRC, with 
a prevalence of 70-80% (Powell, 1992; Vogelstein, 1988). Mutations in APC were first 
identified as a germ-line abnormality in patients with familial adenomatous polyposis 
(Chapter 1, Section 1.3.1), and were subsequently recognized as a crucial initiating 
‘gatekeeper’ mutation in sporadic carcinogenesis (Groden et al., 1991; Herrera et al., 1986; 
Nishisho et al., 1991; Powell, 1992). 
 
1.4.4 APC and the canonical Wnt signalling pathway 
APC is a negative regulator of Wnt signalling – a critical pathway that is considered to be at 
the heart of crypt homeostasis and CRC initiation (Bienz and Clevers, 2000) (Figure 1.10). In 
the normal colonic epithelium, Wnt factors emanate at the base of colonic crypt, imposing a 
proliferative phenotype though the stabilization of β-catenin and subsequent transcription 
of Wnt target genes. As the progeny of the colonic stem cells differentiate and migrate 
towards the lumen, Wnt signalling and thus nuclear accumulation of β-catenin decreases 
(Batlle, 2002; Pinto and Clevers, 2005; van de Wetering et al., 2002; Zeki et al., 2011). 
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Upon activation of the Wnt signalling pathway, Wnt ligands interact with Frizzled (Frz) and 
the co-receptor low-density lipoprotein receptor-related protein (LRP5/6), recruiting 
Dishevelled (Dsh) to the plasma membrane. The multi-protein degradation complex, 
consisting of Axin (a scaffold protein) and two serine/threonine kinases glycogen synthase 
3β (GSK3β) and casein kinase 1 (CK1), is therefore dissociated and cytoplasmic β-catenin 
cannot be marked for destruction. β-catenin is then free to translocate to the nucleus, 
where it displaces transcriptional repressor Groucho, and directly interacts with TCF/LEF 
transcription factors. This allows the transcription of Wnt target genes such as proto-
oncogenes CMYC and cyclin D1, and Wnt pathway feedback regulators such as AXIN2 and 
Dickkopf-1, ultimately maintaining a stem cell phenotype and proliferating progenitor 
population in the base of the crypt. In the absence of a Wnt signal, APC binds to Axin and 
presents β-catenin for phosphorylation and subsequent ubiquitination and proteosomal 
degradation. Thus, the transcription of the Wnt target genes is prevented (Bienz and Clevers, 
2000; van de Wetering et al., 2002). 
 
When APC is mutated in CRC, the resulting truncated protein is unable to bind to Axin, and 
so β-catenin is no longer marked for destruction, allowing the nuclear accumulation of β-
catenin and the constitutive activation of Wnt target genes (Burgess et al., 2011; Korinek et 
al., 1997). Cells that would normally move out of the crypt are reprogrammed by the 
activated Tcf4 to remain crypt cells as a direct consequence of the loss of APC. This results in 
an increase in the size of the proliferating cell pool, and hence polyp formation (Bienz and 
Clevers, 2000). 
 
APC is a multifunctional protein and controls other cellular activities in addition to regulation 
of β-catenin, for example, microtubule stability and cell migration (Burgess et al., 2011; 
Kroboth et al., 2007; Nathke et al., 1996). APC tagged with GFP has been shown to directly 
interact with microtubules and track along them to the cell periphery (Mimori-Kiyosue et al., 
2000). This ability is inhibited by stably binding β-catenin mutants resulting in a decrease in 
migratory capacity. APC truncation disrupts interactions with microtubules and the actin 
cytoskeleton, giving rise to changes in microtubule stability, cell orientation and migration 
(Etienne-Manneville and Hall, 2003; Nathke, 2006; Sansom, 2004). However, the mechanism 
underlying changes in cytoskeletal dynamics via APC loss and formation of ACFs has not yet 
been explored (Burgess et al., 2011). 
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Figure 1.10: Overview of the canonical Wnt signaling pathway 
In the absence of a Wnt signal, the APC destruction complex containing GSK-3β and CK1 degades 
cytoplasmic β-catenin in a proteasome-dependent manner. In the nucleus, Wnt target genes are 
silenced by Groucho interacting with TCF. When a Wnt ligand occupies Frz and the LRP co-receptor, 
this triggers the phosphorylation of LRP by CK1 and GSK-3β, sequestering axin on the phosphorylated 
LRP complex. Phosphorylation of β-catenin is inhibited, leading to translocation of β-catenin to the 
nucleus. Increased nuclear β-catenin displaces Groucho to drive the transcription of Wnt target 
genes via interaction with TCF and LEF transcription factors (adapted from Pino and Chung, 2010).   
 
1.4.5 KRAS and the MAPK pathway 
As discussed, APC inactivation is important for CRC initiation in the classic adenoma-
carcinoma model. However, APC mutations alone are insufficient for the progression of 
colorectal polyps into invasive adenocarcinomas (Smits et al., 2008). For example, oncogenic 
mutations in KRAS and BRAF occur in 37% and 13% of CRCs, respectively (Bos et al., 1987; 
Markowitz and Bertagnolli, 2009). KRAS is a member of the Ras family of guanine-
triphospate-binding signal transducing proteins. It is a down-stream effector of EGFR, and 
signals through BRAF (a serine/threonine kinase) to drive the mitogen-activated protein 
kinase (MAPK) signalling cascade. This pathway regulates various critical cellular events 
 
 
 
  
Proteasomal 
degradation 
Wnt target genes 
repressed 
Wnt target genes 
activated 
Destruction 
complex 
β-catenin 
accumulation 
25 
 
including cell proliferation, differentiation, senescence, and apoptosis (Bos, 1989; 
Rajagopalan et al., 2002). In addition to KRAS, RAS oncogenes include HRAS and NRAS all of 
which are constitutively active and hence mediate dysregulated signaling. Ras is a small 
protein that transduces signals from the EGFR family proteins. Binding of ligand to EGFR 
results in dimerization and receptor tyrosine phosphorylation, as indicated in Figure 1.11. 
Ras activates a signaling cascade through phosphoinositol kinases (PI3K) as well as RAF and 
thus acts as a central signaling node. Activation of PI3K inhibits apoptosis, whereas RAF 
activation stimulates cellular proliferation and is therefore important in cancer. KRAS 
mutations lead to constitutive changes that promote cell proliferation and survival 
independent of the EGFR receptor. Codon 12 is the most common codon affected, usually by 
a missense mutation, but there are a large number of other mutations that have been 
identified in a variety of cancers. Since KRAS is downstream from EGFR, EGFR is bypassed 
and drugs that act by inhibiting EGFR signaling are rendered ineffective. Normally, Ras works 
as a GTPase that can exchange GDP for GTP. In this state, Ras can activate Raf, a member of 
the MAP3K family of tyrosine kinases. A MAP3K activates a MAP2K, which in turn activates a 
MAPK. In the Ras/Raf pathway, the MAPK target is ERK, which can dimerise upon activation, 
enter the nucleus and phosphorylate client transcription factors such as Elk1. This drives the 
production of various factors involved in cell growth and differentiation (Bos, 1989; Pino and 
Chung, 2010; Rajagopalan et al., 2002) (Figure 1.11). 
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Figure 1.11: Overview of the Ras-Raf-MEK-ERK Pathway 
EGF binds to its receptor EGFR and induces receptor dimerization and tyr autophosphorylation. The 
Grb-SOS complex docks onto the phosphorylated Tyr residues, activating Ras, which exchanges its 
GDP for GTP. Ras-GTP binds to Raf and recruits it to the cell membrane where Raf is activated. 
Activated Raf1 phosphorylates MEK, which in turn phosphorylates and activates ERK. ERK has a 
variety of targets including the transcription factor Elk1, which promotes the expression of genes 
involved in cell growth (adapted from Kolch et al., 2002). 
 
1.4.6 Tumour suppressor TP53  
Mutations of the tumour suppressor gene TP53 are thought to be an almost universal 
hallmark of human tumours. TP53 encodes the transcription factor p53, a classical tumour 
suppressor and central orchestrator of cellular responses to stress (Levine, 1997). Often 
referred to as ‘guardian of the genome’, p53 is a master regulator that mediates the 
transcription of hundreds of genes involved in DNA metabolism, cell cycle control, apoptosis, 
senescence, angiogenesis and cell migration (Levine, 1997; Menendez et al., 2009; Pino and 
Chung, 2010). In the majority of tumours, the two TP53 alleles are inactivated, most 
commonly by a combination of two events: a missense mutation that inactivates the 
transcriptional activity of p53 and a 17p chromosomal deletion that takes out the second 
TP53 allele (Baker et al., 1989; Baker et al., 1990). Loss-of-function of TP53 is observed in 
approximately 50% of CRCs defining its role with the progression of adenomas to invasive 
carcinomas (Fearon and Vogelstein, 1990; Miranda et al., 2006). Mutant p53 disrupts cell 
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proliferation and leads to the failure of apoptotic mechanisms, resulting in high-level 
genomic instability and hence cancer progression. However, despite 30 years of 
investigation, the impact of this tumour suppressor gene on clinical outcome is far from 
conclusive (Munro et al., 2005). 
 
1.4.7 The chromosomal instability pathway  
Extensive research into the transition from benign adenoma to malignant carcinoma has 
revealed at least two distinct pathways underlying the development of CRC (Smits et al., 
2008). The most common genetic pathway which accounts for approximately 75-85% of all 
CRC cases is the chromosomal instability pathway (CIN), also referred to as the microsatellite 
stability pathway (MSS) (Hermsen et al., 2002; Lengauer et al., 1997). Tumours with CIN 
exhibit aneuploidy, chromosomal losses, amplifications, translocations and deletions. 
Furthermore, loss of heterozygosity (LOH) of 17p and 18q is frequent. Chromosomal loss at 
18q has been documented in up to 70% of CRC cases, and the DCC gene (deleted in 
colorectal cancer) which maps to 18q21 has long been implicated in colorectal 
carcinogenesis (Fearon, 2011). Furthermore, tumour suppressor genes SMAD2/4 are located 
on chromosome 18q. SMAD2/4 proteins are intracellular mediators of the transforming 
growth factor-β (TGFβ) pathway which is involved in the regulation of cell growth, 
differentiation and apoptosis. Loss of the SMAD proteins perturbs the TGFβ pathway as they 
are transcriptional activators of TGFβ responsive genes. SMAD2 and SMAD4 are depleted in 
20% and 10% of CRCs, respectively (Pino and Chung, 2010; Takagi et al., 1996; Takagi et al., 
1998).  
 
1.4.8 The microsatellite instability pathway  
The second pathway implicated in approximately 15–20% of sporadic CRC cases is referred 
to as the microsatellite instability pathway (MIN) (Thibodeau et al., 1993). MIN is 
characterized by inactivation of MMR genes (Chapter 1, Section 1.3.2). Such tumours exhibit 
frameshift mutations and base-pair substitutions that are commonly found in short, 
tandemly repeated nucleotide sequences known as microsatellites. MIN in hereditary and 
sporadic CRC occurs through two different mechanisms (Markowitz and Bertagnolli, 2009). 
The autosomal dominant condition HNPCC is believed to account for 5-15% of CRC cases and 
typically exhibits a germline mutation in a mismatch-repair enzyme (MSH2 and MLH1 MMR 
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genes). In sporadic MSI CRC, instability in microsatellite sequences is frequently due to loss 
of expression of the mismatch-repair gene (most commonly MLH1) caused by epigenetic 
silencing (Miyakura et al., 2003). 
 
Since the proposal of the classic adenoma-carcinoma model, our knowledge of CRC 
pathogenesis has advanced considerably. Numerous studies over the past few decades have 
revealed that there are 80 genes mutated in the average CRC genome, of which a subset of 
15 are so-called driver mutations that are important in the initiation, progression and 
maintenance of colorectal tumours (Sjoblom, 2006; van Engeland et al., 2011; Wood, 2007) 
This has led to numerous revisions of the initial model, and the idea that CRC does not only 
arise via CIN or MSI, but can arise by other distinct molecular mechanisms and pathways 
(Smits et al., 2008; van Engeland et al., 2011). 
 
1.5 Epigenetics and colorectal cancer 
 
1.5.1 The role of epigenetics 
As previously mentioned, CRC has been historically considered a genetic disease, 
characterised by sequential mutations in oncogenes and tumour-suppressor genes (Fearon 
and Vogelstein, 1990; Wood et al., 2007). It is now widely accepted that cancer initiation and 
progression can occur via an alternative epigenetic mechanism. The original definition of 
epigenetics was coined by Waddington in 1942 – the notion that ‘phenotypes arise from 
genotype through programmed change’. This idea was particularly important in the 
establishment of modern developmental biology. It is appreciated now that developmental 
processes are regulated largely by epigenetics, a consequence of this being that different cell 
types maintain their fate during cell division, even though the DNA sequence per se remains 
the same (Feinberg, 2007). Nowadays epigenetics is broadly defined as heritable changes in 
gene expression without changes in the DNA sequence itself (Feinberg and Tycko, 2004; Lao 
and Grady, 2011; van Engeland et al., 2011). These modifications can be imagined as a 
molecular signature superimposed on the DNA sequence that ultimately influences gene 
expression (Hughes, 2011). Epigenetic modifications play a key role in DNA regulation 
including replication DNA repair and transcription. Abnormalities in the epigenetic profile 
can lead to misregulation of these critical processes. Indeed, epigenetic silencing is 
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recognised as the ‘third hit’ in Knudson’s model of tumour-suppressor gene inactivation, and 
characterises a subgroup of CRCs with a distinct etiology and prognosis (Kondo and Issa, 
2004). The first epigenetic alteration in cancer was discovered by Feinberg and Vogelstein in 
1983. They reported the overall depletion in 5-methylcytosine, so-called global DNA 
hypomethylation, in CRC compared with normal colon. Since then, extensive research has 
revealed that the ‘epigenetic landscape’ is more complex than was first appreciated (Suzuki 
and Bird, 2008). There are a variety of epigenetic regulatory mechanisms that both up-
regulate and down-regulate gene expression in both normal and cancerous tissue. The 
overall epigenetic backdrop of a cell results from factors that determine the condensation 
state of chromatin. Chromatin status is a critical determinant of whether the DNA is 
accessible to the transcription factors and accessory molecules that control gene activity. Put 
simply, an open or relaxed chromatin (euchromatin) state permits a gene to be transcribed, 
whereas a closed or condensed state (heterochromatin) prevents gene transcription (Lao 
and Grady, 2011; Sharma et al., 2010). 
 
In cancer, epigenetic regulation is organised at multiple levels and includes: DNA 
methylation; loss of imprinting; post-translational histone modifications; chromatin looping; 
microRNA’s; and nucleosomal positioning (Kaneda and Feinberg, 2005; Kouzarides, 2007; 
Rana, 2007; Tiwari et al., 2008). Moreover, the mechanistic interaction between these 
epigenetic alterations coupled to genetic mutations is hugely complex, with abundant 
crosstalk (Lao and Grady, 2011). This thesis will focus mainly on DNA methylation, as by far 
the most extensively studied epigenetic alteration in CRC. However, the reader can be 
directed to an excellent review for describing the complex interplay between other 
epigenetic factors (van Engeland et al., 2011).  
 
1.5.2 DNA methylation and CpG islands 
DNA methylation is defined as the post-replicative addition of a methyl group to the 5-
carbon position on the cytosine ring, resulting in 5-methylcytosine (Lao and Grady, 2011; 
Smits et al., 2008; van Engeland et al., 2011). The transfer of a methyl group from S-
adenosylmethionine (methyl donor) to cytosine (methyl receptor) is mediated by enzymes 
called deoxynucleotide methyltransferases (DNMTs) including DNMT1, DNMT3a and 
DNMT3b, which recognise CG dinucleotide sequences called CpG dinucleotides (Bestor, 
2000; Jones and Baylin, 2002). CpG dinucleotides are found less frequently than expected by 
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chance alone in the genome, probably because they are vulnerable to spontaneous 
deamination of the –NH2 group of 5-methylcytosine (Herman and Baylin, 2003; McCabe et 
al., 2009). In humans, the majority of CpGs are methylated, with unmethylated CpGs 
typically restricted to small regions known as CpG islands. By definition, CpG islands are 0.5 
Kb – 2 Kb sequences with a G:C content >55% and a higher than expected ratio of > 0.6. CpG 
islands are associated with the promoter region in 60% of all genes (Gardiner-Garden and 
Frommer, 1987; Lao and Grady, 2011). 
 
Importantly, DNA methylation is present throughout the majority of the genome and is 
essential for normal mammalian development (Bird, 2002). This epigenetic alteration is 
associated with genomic imprinting, transcriptional inactivation of the X-chromosome and 
aging (Lao and Grady, 2011; Reik and Lewis, 2005). Homozygous deletion of the murine DNA 
methyltransferase, Dnmt1, results in demethylation and embryonic lethality, demonstrating 
that DNA methylation is critical during development (Li et al., 1992).  
 
1.5.3 Aberrant DNA methylation and colorectal cancer 
In CRC, epigenetic instability presents itself in a variety of ways including global DNA 
hypomethylation and aberrant promoter hypermethylation at CpG islands (Herman and 
Baylin, 2003; van Engeland et al., 2011). As previously mentioned, DNA hypomethylation was 
one of the first recognised epigenetic alterations in CRC and refers to the loss of 5-
methylcytosine content (Feinberg and Vogelstein, 1983). In contrast to normal tissues, 
cancer DNA is globally hypomethylated at CpG dinucleotides in repetitive sequences (e.g. 
satellite- and LINE- repeats, these being endogenous retroviral elements), and is locally 
hypermethylated at discrete CpG sites that normally exist in the unmethylated state (Baylin 
et al., 1998) (Figure 1.12). In the colon, changes in the DNA methylation pattern arise early 
on, initially in histologically normal mucosa (Toyota and Issa, 1999). For example, aberrant 
methylation of IGF2 (Insulin growth receptor), ESR1 (Estrogen receptor) and TUSC3 (Tumour 
suppressor candidate 3) has been shown to occur in histologically normal colon in age-
dependent manner (Fink, 1996; Issa, 1994; Toyota and Issa, 1999). Thus, it has been 
suggested that CpG islands may exhibit a stochastic predisposition to methylation. One 
notion is that for ‘old’ cancer cells, methylation could be a ‘molecular clock’ that denotes 
their advanced age (Kondo and Issa, 2004). This idea is supported by the fact that one of the 
estrogen receptor genes, ERalpha, becomes increasingly methylated as the colonic mucosa 
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ages, and is particularly densely methylated in CRC causing the gene to become 
transcriptionally silenced (Issa, 1994).  
 
 
Figure 1.12: CpG island DNA hypermethylation and global DNA hypomethylation in normal colonic 
epithelium and CRC 
Unmethylated CpG islands are correlated with an open chromatin structure (euchromatin), whereas 
methylated CpG islands are correlated with a condensed, closed chromatin structure 
(heterochromatin) and transcriptional silencing. Normal colonic epithelium predominantly contains 
unmethylated CpG islands in the promoter regions of genes, whereas aberrant hypermethylation of 
promoter associated CpG islands is a hallmark of colorectal neoplasms. In addition to the aberrant 
hypermethylation seen in CRCs, global hypomethylation at LINE-1 sequences is also observed which 
is frequently associated with genomic instability. Interestingly, an inverse association exists between 
CpG promoter hypermethylation and global LINE-1 hypomethylation with the progression of CRC 
(adapted from Lao and Grady, 2011). 
 
1.5.3.1 DNA Hypomethylation 
DNA hypomethylation has been attributed to genomic instability, which may predispose to 
CIN and aneuploidy. Loss of methylation at sites located close to the centromere may 
predispose the cell to chromosomal recombination and replication events. Evidence 
attributing genomic instability to DNA hypomethylation comes from experimental work in 
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mice. For example, Dnmt1 hypomorphic Apc
Min/+
 mice develop small adenomas associated 
with LOH of APC (Eads et al., 2002).  
 
In addition, DNA hypothemethylation has been associated with loss of imprinting (LOI) (Cui, 
2002; Sakatani, 2005). LOI is a key state that arises in cancer and refers to either 
inappropriate activation of a silent allele of an imprinted growth-promoting gene, or the 
silencing of a tumour suppressor gene that is normally expressed. An example of LOI in CRC 
is hypomethylation of the promoter of the insulin-like growth factor II (IGF2) gene which 
leads to its abnormal activation (Nakagawa et al., 2001). IGF2 expression then activates the 
IGF1 receptor (IGFR), which becomes autophosphorylated and triggers the PI3K and 
GRB2/RAS/ERK pathway. In this way, LOI can lead to inappropriate growth factor sensitivity 
and dysregulated growth factor receptor signalling. 
 
1.5.3.2 DNA promoter hypermethylation 
Aberrant promoter methylation is associated with transcriptional silencing and is 
functionally equivalent to coding-region mutations or deletions (Herman and Baylin, 2003; 
Lao and Grady, 2011). Numerous studies have revealed a wide range of epigenetically 
silenced genes by aberrant promoter CpG island methylation (Table 1.1). Many of the genes 
frequently affected are integral to a number of molecular/cellular events including cell cycle 
control, regulation of transcription, adhesion, invasion and metastasis, apoptosis and 
chromatin organisation (van Engeland et al., 2011). It is now widely acknowledged that 
epigenetic changes co-operate with the classical genetic changes to drive the progression of 
normal colonic epithelium towards invasive adenocarcinoma. In the average cancer genome, 
thousands of genes are thought exhibit aberrant methylation. However, only a proportion of 
these genes are likely to play fundamental roles in CRC pathogenesis (Smits et al., 2008).   
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Table 1.1: Representative genes commonly methylated and silenced in CRC 
*MINTs are ‘methylated in tumour’ loci and are not specific genes. Abbreviations: ADAM, A Disintegrin and 
Metalloproteinase; MMP; mitogen-active protein kinase; TNF, tumour necrosis factot. Table adapted from Lao 
and Grady, 2011. 
Gene  Protein Function Effect of loss of 
function 
APC                                   Adenomatous polyposis 
coli 
Wnt signalling pathway 
inhibition 
Increased Wnt/β-
catenin signalling 
MLH1 MutL homolog 1 DNA mismatch repair  Microsatellite 
instability 
MGMT O-6 methylguanine DNA 
methyltransferase 
Repair of alkylation in 
DNA damage 
Increased G>A 
mutation frequency 
RUNX3 Runt-related 
transcription factor 3 
Transcription factor Decreased TGFβ/BMP 
signalling 
MINT1* Methylated in tumour 
locus 1 
NA NA 
MINT31* Methylated in tumour 
locus 31 
NA NA 
CDH1 E-cadherin Calcium-dependent cell-
cell adhesion 
glycoprotein 
Loss of cell adhesion 
CDKN2A/p16 Cyclin-dependent kinase 
inhibitor 2A 
Regulated cell cycle G1 
progression 
Increased cell 
proliferation 
TIMP3 Tissue inhibitor of 
metalloproteinase 3 
Inhibition of MMPs and 
ADAMs 
Increased EGFR 
signalling and TNF 
signalling 
ID4 Inhibitor of DNA binding 
4 
Transcription factor Not Known 
IRF8 Inteferon regulatory 
factor 8 
Transcription factor  Inteferon signalling 
THBS1/TSP1 Thrombospondin 1  Cell-to-cell and cell-to-
matrix adhesive 
glycoprotein 
Decreased TGFβ1 
signalling 
DAPK Death associated protein 
kinase 
Induction of cell death Interferon gamma 
signalling, TNF alpha 
signalling 
VIM Vimentin Stabilising cytoskeleton No known biological 
effect 
SEPT9 Septin 9  GTPase, formation of 
filaments  
Impaired cytokinesis 
of loss of cell cycle 
control 
SFRP1 Secreted frizzled-related 
protein 1 
Wnt antagonist Increased Wnt/β-
catenin signalling 
SFRP2 Secreted fizzled-related 
protein 2 
Wnt antagonist Increased Wnt/β-
catenin signalling 
CDH13 Cadherin 13 Selective cell recognition 
and adhesion, 
antiapoptotic 
Increased 
PI3K/Akt/mTOR 
signalling, increased 
MAPK signalling 
HLTF Helicase-like 
transcription factor 
dsDNA translocase, fork 
remodelling activity, 
ubiquitin ligase 
Impaired DNA repair 
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Aberrant CpG island methylation of the MMR gene MLH1 is one of the best characterised 
epigenetic alterations in CRC (Herman et al., 1998). It is associated with both microsatellite 
instability and BRAF mutations in sporadic colorectal carcinogenesis, as well as the 
hereditary syndrome HNPCC. Once MLH1 is inactivated, the rate of progression to malignant 
transformation is rapid (Hughes, 2011). As previously discussed (Chapter 1, 1.3.2), 
dysregulation of MLH1 has profound clinical implications because of its critical role in DNA 
repair. Normally, the MLH1 protein dimerises with the PMS2, PMS1 or MLH3 proteins to 
form the DNA mismatch repair dimers MutLalpha, MutLbeta and MutLgamma, respectively. 
These complexes can form part of the BRCA1-associated genome surveillance complex in 
combination with a variety of other proteins. The specific role of MLH1 is to help activate the 
endonuclease activity of PMS2. PMS2 then introduces single strand breakages in 
mismatched DNA that can be recognized by the exonuclease EXO1, enabling the mismatched 
strand to be degraded. Furthermore, MLH1 may have a role in DNA damage signalling, which 
leads to cell cycle arrest and apoptosis if the damage cannot be repaired (Li, 2008). 
 
In addition, hypermethylation of O
6
-methylguanine DNA methyltransferase (MGMT) has 
been observed in histologically normal colonic tissue adjacent to tumour tissue, suggesting 
that MGMT methylation may occur early in the polyp-adenocarcinoma sequence 
(Giovannucci and Ogino, 2005; Shen et al., 2005). The O
6-
MGMT enzyme catalyses the 
removal of alkyl adducts from the O
6
 position of guanine, and thus prevents G:C > A:T point 
mutations. Vogel et al. (2008) showed that MGMT promoter hypermethylation is associated 
with G:C > A:T mutations in KRAS but not APC, suggesting that MGMT silencing may succeed 
APC mutation but precedes KRAS in the polyp-adenocarcinoma sequence.  
 
Two mechanisms have been proposed to explain the epigenetic silencing by CpG island 
promoter methylation. The first is by direct inhibition between methylated promoters and 
transcription factors such as activator protein-2 (AP-2), cAMP-response-element-binding-
protein (CREB) and nuclear factor кB (NF-кB) (Comb and Goodman, 1990; Kondo and Issa, 
2004). CpG island promoter hypermethylation can also mediate transcriptional silencing 
through the co-operative interactions with enzymes that induce changes in the chromatin 
structure. A family of methyl-CpG binding proteins including MeCP2, MBD1, MBD2 are 
involved in this process, and can bind to methylated DNA with high affinity (Lao and Grady, 
2011; van Engeland et al., 2011). These proteins initiate a sequence of events that can alter 
35 
 
the structure of chromatin by recruiting proteins that regulate histone acetylation e.g. 
HDACs (histone deacetylases) and chromatin remodelling, thereby condensing the 
chromatin and impeding the access of transcription factors to the promoter (Tsai and Baylin, 
2011). Experimental evidence for the importance of methyl-CpG binding proteins in CRC 
comes from APC
MIN/+
 mice, which suppress intestinal carcinogenesis in the absence of MBD2 
(Sansom et al., 2003). 
 
1.5.4 CpG island promoter methylator phenotype (CIMP) 
The discovery that some colorectal tumour subsets display widespread promoter 
methylation whilst others do not has led to the concept of a CpG island methylator 
phenotype (CIMP). CIMP was first suggested to be involved in colorectal carcinogenesis in 
1999 by Toyota et al., but the idea was met with initial scepticism (Issa et al., 2005; 
Samowitz, 2007b). However, the validity of this phenotype has now gained wide acceptance 
as the epidemiological and epigenetic evidence has accumulated (Ogino and Goel, 2008; 
Samowitz et al., 2005). Tumours characterised by CIMP probably arise through the serrated 
adenoma pathway and have a markedly different histology than adenoma-carcinoma 
pathway tumours of traditional origin (Smits et al., 2008). The ‘classic’ panel of markers that 
are used to assess CIMP status are MINT1, MINT2, MINT31, P16
INK4A
, and MLH1. It is now 
thought that there are actually two general types of CIMP that can be seen in sporadic 
tumours: CIMP high, which relate to BRAF mutations and MLH1 methylation; and CIMP low, 
which involve KRAS mutations (Jass, 2006; Ogino et al., 2006; Shen, 2007). Another 
commonly used panel is the Weisenberger CIMP panel, which focuses on methylation in 
CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 genes (Weisenberger, 2006). However, the 
clinical utility of CIMP in CRC has been controversial, because universally accepted standard 
definitions have been lacking (van Engeland et al., 2011). CIMP tumours have a high 
frequency of BRAF V600E mutations, tend to occur in the right (proximal) colon and are less 
common in men than in women. This is independent of the panel of CIMP markers that are 
used (Barault, 2008; Samowitz, 2007a; Weisenberger, 2006). Understanding the biological 
cause of CIMP will allow scientists to quantify and define CIMP and a better definition of 
relevant CIMP panels should lead to a substantial improvement on the development of 
diagnostics and treatments for CRC (Smits et al., 2008). 
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1.6 Clinicopathological staging of colorectal cancer 
There are two major staging systems currently employed throughout the world to classify 
cancer patients according to clinical and histopathological characteristics: the Dukes staging 
system and the Tumour Node Metastasis (TNM) system. Clinicopathological staging of newly 
diagnosed CRC is predominantly used to predict patient prognosis and ultimately plan the 
most effective treatment regimen (Compton and Greene, 2004). 
 
The Dukes’ staging system was originally devised by Cuthbert Dukes in 1932 and today 
remains one of the most influential strategies in the field of cancer therapeutics. The 
classification system was first used for rectal cancer, and was based on the degree of 
penetration into the wall of the rectum and metastatic spread to the surrounding lymph 
nodes. The original staging system consisted of three categories denoted A-C. Dukes’ A 
carcinomas were confined to the wall of the rectum with no lymph node metastasis, Dukes’ 
B carcinomas had progressed to the extra-rectal tissues with no invasion to regional lymph 
nodes and Dukes’ C tumours were classified as such if metastasis was present in the regional 
lymph nodes. This system was subsequently applied to all intestinal carcinomas. Since its 
inception, numerous modifications have been made, by Dukes himself and other 
investigators. In 1949, Kirklin and co-workers revised stage A to designate carcinomas 
limited to the mucosa and subdivided stage B into B1 and B2; carcinomas extending to the 
Muscularis propria and penetrating the Muscularis propria, respectively. Stage C was later 
subdivided into C1 (regional nodes contain metastases) and C2 (apical lymph nodes contain 
metastases) (Zinkin, 1983). 
 
The Aster-Coller staging system is an alternative staging system that was originally proposed 
in 1954. However, this method of classification is less frequently implemented, perhaps due 
to the misinterpretation that can arise. Aster and Coller extended Kirklin’s classification by 
dividing Dukes C into C1 (carcinoma confined to the wall with positive lymph nodes) and C2 
(carcinomas penetrating all layers with lymph node metastases) (Astler and Coller, 1954). 
These are, however, different to the C1 and C2 categories proposed by Dukes. In 1967, 
Dukes’ stage D was added by Turnbull et al. which refers to patients with distant metastasis. 
In 1974, the Aster and Coller system was further refined by Gunderson and Sosin who added 
the additional categories B3 (lesions adherent to and invading adjacent organs) and C3 
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(gross nodal disease with extension and invasion of distant organs). Taken together, the 
revisions to the original staging system constitute the Modified Aster Coller System (MAC). 
 
The other major classification system used globally is the International Union against Cancer 
(IUCC) and American Joint Committee on Cancer’s (AJCC) TNM staging, and is frequently 
described as having many advantages over the other staging system (Puppa et al., 2010). 
Although TNM assessment was originally developed to predict patient prognosis, its function 
has been expanded to aid in pre-operative clinical trials. Moreover, it is multidisciplinary in 
design and is continuously being updated to incorporate new data (Chapuis et al., 2011). The 
latest TNM manual describes 9 stages (I, IIA, IIB, IIC, IIIA, IIIB, IIIC, IVA and IVB). CRC patients 
are classified based on tumour penetration (T), lymph nodes involved (N), and extent of 
distant metastases (M).   
 
The 5-year survival rate for patients with CRC is intimately linked with the Dukes’ staging 
system, and varies significantly between Dukes’ A (>90%) to Dukes’ D (8%) patients (Table 
1.2). In intermediate-grade CRC (Dukes’ B and C), survival varies from approximately 75% to 
44% and therefore this group requires the most careful management (Smits et al., 2008). In 
addition to Dukes’ staging, several other tumour-related features have also been suggested 
to offer prognostic value. These histological factors include venous and lymphatic invasion, 
tumour budding, tumour border configuration/tumour budding and the number of lymph 
nodes examined (Deschoolmeester et al., 2010). However, tumour classification based on 
the Dukes’ staging system in the UK still remains the most significant prognostic factor for 
CRC. 
 
Table 1.2: Clinicopathological staging and 5-year survival of CRC patients 
 
 
 
 
 
Dukes’ stage Penetration Frequency of diagnosis 5-year survival 
A                                    Muscularis mucoase 11% >90% 
B Visceral tissues 35%  75% 
C Lymph nodes 25% 44% 
D Metastasis 29% 8% 
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1.7 Screening 
CRC prognosis is predominantly determined by clinicopathological staging, with early 
detection frequently resulting in excellent outcome. However, patients usually present with 
advanced stage disease as bleeding and/or other symptoms often occur when the adenomas 
are large and cause physical obstruction. CRC arises from a defined and predictable 
histopathological progression sequence, which lends itself to early detection by screening of 
asymptomatic individuals who are at high risk (e.g. those above 60 years or age). The 
majority of CRC originate from adenomatous polyps which if detected early, can be removed 
by surgical intervention to prevent malignant transformation. There is now universal 
agreement that population-based screening can significantly reduce CRC morbidity and 
mortality (Davies et al., 2005; Hawkes and Cunningham, 2010). However, the choice of 
screening modality remains contentious, with little evidence to favour one technique over 
another (Hawkes and Cunningham, 2010). Various procedures exist to facilitate the 
detection of early asymptomatic disease, including faecal occult blood testing (FOBT), 
double-contrast barium anaemia, flexible sigmoidoscopy and colonoscopy. Other 
approaches such as DNA testing of the stool and virtual colonography are also being 
developed though they require further testing and evaluation (Bressler et al., 2004; Davies et 
al., 2005; Seeff et al., 2004; Whitney et al., 2004). 
 
In the UK, national screening programmes were implemented between 2007 and 2010. At 
present, individuals in England aged 60-74 and in Scotland aged 50-74 are invited to take the 
stool-based FOBT biennially. The FOBT is a relatively cost-effective method with a sensitivity 
of detecting CRC at approximately 50%. The test is based on the peroxidise-like enzymatic 
activity of haemoglobin and is able to detect non-visible or occult blood in the stool (Ahlquist 
et al., 1985). If individuals test positive, patients are invited for a colonoscopic examination. 
Colonoscopy is frequently referred to as the ‘gold standard’ for diagnosis of CRC (Seeff et al., 
2004). This invasive procedure involves direct observation of the rectum and colon using a 
flexible fibre optic device. Colonoscopy has been shown to detect CRC with a sensitivity and 
specificity of 97% and 98%, respectively (Winawer et al., 2003). Although colonoscopy is 
considered by most experts to be the preferred method for detecting CRC, the use of this 
technique for average-risk populations (i.e. under 50 years of age) has been questioned 
because potential procedural complications may occur (such as perforation of bowel wall) 
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and the appropriate frequency for testing has not yet been established. In addition, concerns 
have been raised about high costs and variable capacities of the healthcare providers to 
make colonoscopy available routinely.  
 
In 2011, the NHS bowel cancer screening programme introduce flexible sigmoidoscopy 
screening to those aged 55 and over. This procedure enables the detection and removal of 
all visible colorectal adenomas and precursor lesions within the distal colon and rectum 
using a flexible endoscope (Davies et al., 2005). Flexible sigmoidoscopy is a relatively safe 
procedure (with perforation rates half that of colonoscopy) and is reported to be cost 
effective. However, a potential pitfall of this method of intervention is that, unlike 
colonoscopy, it does not examine the entire colon/colorectum, an important consideration 
given that 30% of tumours arises in the proximal colon (Smits et al., 2008). Nevertheless, the 
rationale for implementing this screening modality appears robust. Atkin et al. recently 
published the long-term follow-up data from a large randomised, controlled, UK-based trial 
assessing the use of flexible sigmoidoscopy. That study showed that flexible sigmoidoscopy 
screening reduces CRC incidence by 33% and mortality by 43% and that 489 people need to 
be screened to prevent one CRC death (Atkin et al., 2010).  
 
1.8 Treatment 
Improvements in therapeutics and surgical techniques have led to an overall change in the 
management of CRC and consequently a (small) increase in survival rates. Surgical resection 
is the mainstay of treatment for CRC patients. In the majority of cases surgical resection is 
performed with curative intent, with primary tumour, adjacent bowel and lymph node 
removal. However, the chance of survival by surgery alone decreases with advancing stage 
(Nelson et al., 2001). 
 
For early-stage CRC (Dukes’ A) patients, surgery alone is often effective at curing the disease. 
These patients show a 95% survival rate. For Dukes’ C patients, standard treatment requires 
adjuvant chemotherapy after surgical resection. Treatment with 5-FU (5-Fluorouracil) and 
leucovorin has reduced overall mortality rate by ~10% and the recurrence rates by 40-50% 
(Loupakis et al., 2008). More recently, oxaliplatin-based chemotherapy has been shown to 
further improve disease-free and overall survival (Andre et al., 2009). However, Dukes’ B 
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patients do not routinely receive adjuvant post-operative chemotherapy as the benefits 
have been difficult to prove and the treatment remains controversial (Macdonald, 1999). 
Even so, approximately 30% of Dukes’ B patients are likely to die within 5 years and hence 
this group would benefit from a strategy to identify individuals at high risk who may relapse 
and thus benefit from chemotherapy. It should also be noted that the majority of CRC cases 
affect the elderly (>60 years of age) and in this age group chemotherapy is considered 
dangerous and is avoided (Smits et al., 2008). 
 
It has been proposed that Dukes’ B patients with high risk features such as obstruction, 
tumour perforation, serosal tumour penetration (T4) and lymphovasular invasion may be 
more likely to relapse and should be considered for follow-up therapy (Figueredo et al., 
2008). The identification of novel high-risk features would help improve the management 
and screening of this group of patients.  
 
1.9 Prognostic biomarkers in colorectal cancer 
Significant advances in the diagnosis, treatment and management of CRC has been made in 
recent years. Nevertheless, CRC is still a major health burden with over 1 million cases in the 
world, and a disease specific mortality of 50% (Draht et al., 2012; Ferlay et al., 2010; Jemal et 
al., 2010). At present, the Dukes’/TNM classification system is the main tool for predicting 
patient prognosis and determining treatment regimen (Graziano and Cascinu, 2003). Whilst 
Dukes’ staging is very effective at predicting prognosis for Dukes’ A and Dukes’ D patients, 
there is considerable variability between the prognostic outcomes between intermediate 
stage CRC patients. Currently, in the UK Dukes’ B patients do not receive adjuvant 
chemotherapy as it is thought that these patients have a good prognosis. However, 30% of 
Dukes’ B patients will experience relapse and die within 5 years of diagnosis from CRC-
related causes (Fretwell et al., 2010; Smits et al., 2008). Moreover, there is considerable 
heterogeneity in the natural course of the disease and treatment response between patients 
with histologically identical tumours. This can be explained, in part, by the fact that CRC is a 
heterogeneous disease (Draht et al., 2012; Newton et al., 2010). At least three pathways 
through which CRC can arise have been described; CIN, MSI and CIMP. The genetic and 
epigenetic alterations described in these pathways are likely to be important for neoplastic 
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formation and cancer progression and thus are attractive for the development of biomarkers 
(George and Kopetz, 2011; Smits et al., 2008). 
 
A biomarker can be defined as an objectively measured substance used as an indicator of 
normal biological processes, or as a pharmacological response to a specified therapeutic 
intervention (George and Kopetz, 2011; Lee and Chan, 2011; Newton et al., 2010). 
Biomarkers are usually categorized as either prognostic or predictive. A prognostic 
biomarker is used to assess the clinical outcome, such as tumour aggressiveness or death, 
and can be considered to define the ‘natural history’ of the disease. Validation of prognostic 
biomarkers is usually performed using a retrospective cohort study (George and Kopetz, 
2011). By contrast, a predictive biomarker is used to indicate the likelihood of a given 
response or to judge the efficacy of a given therapeutic. Predictive biomarkers therefore 
require the analysis of prospective cohort studies to exclude prognostic effects (George and 
Kopetz, 2011; Lee and Chan, 2011; Newton et al., 2010). 
 
In recent years, research has intensified to identify prognostic biomarkers that improve the 
assessment of prognosis, and to identify Dukes’ B patients with risk of recurrence who would 
benefit from adjuvant chemotherapy (Smits et al., 2008). Carcinoembryonic antigen (CEA), a 
glycoprotein involved in cell adhesion, is one the first biomarkers suggested for CRC (Chau et 
al., 2004). However, the clinical utility of CEA as a prognostic biomarker remains 
controversial. Post-operative CEA expression has been championed as a prognostic 
biomarker in patients after resection of colorectal liver metastases (Oussoultzoglou et al., 
2008). However, a subsequent meta analyses suggested that whereas CEA is a highly specific 
biomarker, it the lacks sensitivity to predict recurrence of the disease (Tan et al., 2009). An 
additional complication is that elevated CEA levels are present in patients with breast, lung, 
and pancreatic cancer, diabetes type I and II, pancreatitis and liver cirrhosis (Newton et al., 
2010). It therefore remains unclear whether CEA is suitable for routine clinical practice, and 
hence the identification of more robust and reliable prognostic biomarkers remains a 
priority.  
 
1.9.1 Genetic Biomarkers 
Numerous genetic markers have been evaluated for their prognostic influence. Scientists 
have been particularly interested in the relationship between TP53 mutations and patient 
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prognosis (Lee and Chan, 2011). Inactivation of TP53 has been associated with poor CRC 
prognosis. However, the results are frequently inconsistent and inconclusive. One study 
showed that TP53 mutation status was associated with lower RFS in Dukes’ B and C cancer 
(RR = 1.49, p = 0.01) yet there was no difference in overall survival (Allegra et al., 2003). 
Conversely, Russo et al., showed that TP53 mutation was associated with lower overall 
survival in the Cancer International Collaborative Study that looked at 3583 CRC patients (p = 
0.06) (Russo et al., 2005). Similarly, chromosomal loss of 18q, which occurs in at least 70% of 
CRCs, is one of the best-studied prognostic biomarkers (Popat and Houlston, 2005). 
Numerous retrospective studies have demonstrated that loss of 18q is associated with 
poorer prognosis in Dukes’ B and Dukes’ C patients (Smits et al., 2008; Sun et al., 1999). 
Using a retrospective tissue archive, one group found that Dukes’ B and Dukes’ C patients 
with intact 18q had a significant 5-year overall survival advantage compared to those with 
allelic loss of 18q. Moreover, Popat and co-workers demonstrated that loss of 18q was 
associated with poor prognosis in a meta-analysis of 2189 patients (HR = 2.0; p = 0.0001). 
However, despite promising results from both studies, a recent prospective study showed 
that 18q status was not a prognostic factor in Dukes’ B and Dukes’ C CRC patients (Roth et 
al., 2009). The prognostic value of KRAS has also been evaluated, again showing conflicting 
results. A number of studies indicate that KRAS is linked to poor survival, and that this is 
independent of other prognostic factors such as Dukes’ stage. However, follow-up studies 
were not able to replicate these finding and the clinical relevance of KRAS mutation status is 
still uncertain (Anwar et al., 2004; Castagnola and Giaretti, 2005; McLeod and Church, 2003). 
Other biomarkers not implicated in the CIN pathway have also been investigated, for 
example, vascular endothelial growth factor (VEGF). VEGF is a pro-angiogenic factor whose 
downstream signalling cascades involve endothelial cell proliferation and migration and 
vascular permeability (Roskoski Jr, 2007). Studies have shown that increased expression of 
VEGF is associated with tumour aggressiveness, metastatic spread, and poor disease-free 
and overall survival (Zlobec and Lugli, 2008). However, data on the expression status of VEGF 
is limited and more studies are needed to confirm these findings (Lee and Chan, 2011). 
 
1.9.2 DNA methylation biomarkers 
In parallel to genetic markers being investigated, the expanding knowledge in our 
understanding of the CRC epigenome has led the pursuit of an epigenetic mark or signature 
which can accurately predict patient prognosis. Within this setting, DNA promoter 
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methylation has received the most attention. Methylation occurs at CpG islands and because 
these sequences are essentially fixed and stable, they lend themselves to analysis in most 
tissues and cell types. The advent of high throughput PCR and sequencing technologies 
means that the detection of CpG methylation is relatively fast and simple (Draht et al., 2012; 
Herman and Baylin, 2003).  
 
Methylation has been suggested to play a role in determining CRC prognosis, although the 
validity of some candidate markers is debated. Notably, one group found that epigenetic 
inactivation of the DNA-binding protein inhibitor ID4 is prevalent in CRC and is associated 
with poor tumour differentiation and overall survival (Umetani et al., 2004). However, 
Tanaka et al. found no correlation between ID4 methylation and recurrence-free or overall 
survival. In the same study, promoter methylation of the E3 ubiquitin-protein ligase CHFR 
was associated with a worse recurrence free-survival in patients (Tanaka et al., 2011). 
Another group observed that CRC patients with CpG island promoter methylation of genes in 
the extracellular matrix (ECM) remodelling pathway exhibited worse survival. The genes 
tested in this study included insulin-like growth factor-binding protein 3 (IGFBP3), Ena/VASP-
like protein (EVL), CD109 antigen precursor (CD109) and Filamin-C (FLNC). This data suggests 
that epigenetic regulation of the ECM pathway in general might constitute a prognostic 
signature in CRC (Yi et al., 2011). In addition, methylation of MGMT has previously been 
suggested to be a suitable prognostic biomarker, although results remain inconclusive. 
Finally, the role of CIMP (Chapter 1, Section 1.5.4) in predicting recurrence and disease-free 
survival remains controversial. 
 
The plethora of genetic and epigenetic alterations that drive CRC carcinogenesis has led to 
the emergence of numerous potential biomarkers that may offer prognostic or predictive 
value. However, the majority of studies to date on the clinical utility of biomarkers are far 
from conclusive. Problems with poor study design, methodological differences, lack of 
reproducibly, small sample sizes and discrepancies in the evaluation of immunoreactivity 
from antibody studies have held back large-scale prospective studies. Many challenges 
remain, including standardization of techniques, integration across laboratories and 
validation of new biomarkers against robustly accepted clinical and pathological parameters 
(Soreide et al., 2008; Newton et al., 2010; Lee and Chan, 2011). 
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1.10 Lamins and colorectal cancer 
 
1.10.1 Lamins and the nuclear envelope 
The nucleus is the hallmark of all eukaryotic cells (Dahl and Kalinowski, 2011). It is the site of 
many fundamental cellular processes including DNA replication, transcription and ribosome 
assembly (Lamond and Earnshaw, 1998). This multifaceted dynamic organelle encompasses 
a three-dimensional interphase chromatin structure which is encapsulated by the nuclear 
envelope (Dahl and Kalinowski, 2011). The nuclear envelope is composed of an outer nuclear 
membrane (ONM) that is continuous with the endoplasmic reticulum, and an inner nuclear 
membrane (INM), which contains an extensive array of proteins and provides a physical 
attachment point for chromatin. The ONM and INM are separated by a luminal space which 
acts as a physical barrier between the nucleoplasm and the cytoplasm, thus separating the 
various metabolic processes in the cell (Worman and Courvalin, 2005) (Figure 1.13). The 
nuclear envelope is punctuated by a multi-protein complex called the nuclear pore complex 
that tightly controls nuclear export and import (Lim and Fahrenkrog, 2006). In metazoans, 
underlying the inner nuclear membrane lies a dense, filamentous meshwork termed the 
nuclear lamina. The nuclear lamina is primarily composed of lamins and lamin-binding 
proteins (Broers et al., 2006; Hutchison and Worman, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: Overview of the structure of the nucleus (Maidment and Ellis, 2002). 
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1.10.2 Lamin structure and function 
Lamins are type V intermediate filament (IF) proteins, which consist of A- and B-type lamins 
that can be functionally and biochemically distinguished (Hutchison, 2002). In humans, 
several lamin polypeptides are encoded by three distinct genes: A-type lamins, 
predominantly A and C, are alternatively spliced products of a single gene (LMNA), whereas 
B-type lamins, lamin B1 and lamin B2, are encoded by two distinct genes (Dechat et al., 
2008). Lamin polypeptides have a conserved tripartite structure consisting of an alpha-
helical coiled-coil rod domain made of four segments of heptad repeats. This is flanked by a 
short amino-terminal head and a large globular carboxy-terminal tail domain which contains 
a nuclear localisation signal (NLS) (Hutchison and Worman, 2004; Krimm, 2002; McKeon, 
1991) (Figure 1.14). The NLS facilitates the targeting and transport of lamins into the nucleus 
(Broers et al., 2006). Lamins also contain a unusual Ig-like fold between the rod domain and 
C-terminal, which has been implicated in both lamin-protein interactions and lamin-DNA 
interactions. With the exception of lamin C, the lamin proteins are characterized by the 
presence of a CAAX motif at the C-terminus, which is subject to unique post-translational 
processing events (Rusiñol and Sinensky, 2006).  
 
 
 
 
 
 
 
 
Figure 1.14: General structure of lamin polypeptide (adapted from Hutchison and Worman 2004) 
 
B-type lamins are ubiquitously expressed in metazoan cells and are essential for cell survival. 
This is demonstrated by experiments in mice. Homozygous Lmnb1 mutant mice survived 
embryonic development but died at birth with lung and bone defects (Vergnes et al., 2004). 
Furthermore, lamin B1 depletion by RNAi severely inhibits RNA polymerase I and II activity in 
HeLa cells, showing that lamin B1 is essential for RNA synthesis (Tang et al., 2008). In 
contrast to the B-type lamins, A-type lamins are not essential for development but are 
required for certain functions, particularly for the muscle and heart. In vitro, cells are able to 
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survive and proliferate in the absence of lamin A/C. However, Lmna 
-/- 
mice suffer from 
muscular dystrophy and cardiomyopathy (Sullivan, et al. 1999). Furthermore, loss of A-type 
lamin expression compromises nuclear envelope integrity, leading to decreased bone 
formation as well as muscular dystrophy (Li et al., 2011; Nikolova, 2004).  
 
Described as ‘guardian of the soma’, the dense lamin meshwork acts as an elastic shell, 
which in essence functions to maintain the structural integrity of the nucleus, thus 
preserving genomic stability (Dahl and Kalinowski, 2011; Hutchison and Worman, 2004). In 
support of this concept, loss of lamin A/C has been shown to play a role in nuclear 
mechanical support which likely contributes to its importance in muscle and heart tissue 
(Dechat et al., 2008). Lmna
-/-
 mouse embryonic fibroblasts (MEFs) have a significantly 
decreased mechanical stiffness. When these mutant MEFs are mechanically stretched, the 
degree of nuclear deformation increases compared with wild-type MEFs (Lammerding et al., 
2004). In addition, nuclear rupture under high force is commonly seen in MEFs lacking Lmna, 
demonstrating the importance of lamin A/C to nuclear integrity (Lammerding et al., 2004). 
 
Research into lamins intensified after it was found that mutations in LMNA cause an array of 
human degenerative diseases termed laminopathies, including Hutchinson-Gilford Progeria 
Syndrome (Dechat et al., 2008; Gonzalez-Suarez and Gonzalo, 2010; Hutchison et al., 2001). 
A substantial body of evidence suggests that these proteins are fundamental to a myriad of 
molecular and cellular processes such as spatial organisation and anchorage of the nuclear 
pores and nuclear envelope proteins, chromosome segregation and cytokinesis, regulation 
of gene expression, DNA replication, DNA repair, the DNA damage response and aging 
(Gonzalez-Suarez and Gonzalo, 2010; Hutchison, 2002; Liu et al., 2005; Liu et al., 2000; 
Scaffidi and Misteli, 2006; Spann et al., 1997; Varela et al., 2005).  
 
An important aspect of lamin biology is how they help to connect the nucleus to the 
cytoskeleton. A-type lamins do this through their interaction with LINC (linker of 
nucleoskeleton and cytoskeleton) complexes allowing communication from the inside of the 
nucleus to the cytoskeleton (Burke and Roux, 2009). The so-called LINC complex is critical in 
forming the nucleo-cytoskeletal tether. This complex is comprised of SUN (Sad1 and UNC-84 
homology) domain proteins, located at the INM, and nesprins, which mainly sit in the ONM 
(Burke and Roux, 2009). SUN1 and SUN2 proteins, together with nesprins-1,-2 and -3α 
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interact via their KASH domains in the perinuclear space (Hodzic et al., 2004; Worman and 
Gundersen, 2006). A recent crystallographic study of the SUN2-KASH1/2 complex, published 
in Cell, has revealed that KASH2 peptides sit in three grooves that are formed between the 
SUN domains (Sosa et al., 2012). This trimeric arrangement is probably the building block for 
higher order SUN-KASH structures and likely provides the molecular basis for generating 
force that is required for the control of nuclear movement and chromosomal positioning. 
Studies have shown previously that mutations perturbing the LINC complex can lead to 
impaired nuclear positioning, defective cell migration and sensitivity to mechanical stress 
(Dahl and Kalinowski, 2011). Nesprins can connect to all major cytoskeletal components by 
either binding to actin directly (nesprin-1/2), or to intermediate filaments (nesprin-3) or 
microtubules (nesprin-1/2/4) via plectin and kinesin, respectively (Taranum, 2012). 
Importantly, this physical connection between lamins-SUNs-nesprins effectively creates a 
mechanical stress transducer that stretches from the plasma membrane to the nucleus via 
the cytoskeleton (Dahl and Kalinowski, 2011; Lammerding et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Schematic representation of the nuclear envelope 
Lamins are juxtapositioned at the INM and are therefore well positioned to form stable structures 
with the nuclear interior. In addition to SUN1/2, membrane proteins such as emerin and LBR are 
retained at the inner nuclear membrane through their interactions with lamins, chromatin and other 
nuclear proteins. Nesprins can interact with all three components of the cytoskeletal via SUN 
proteins (adapted from Friedl et al. 2011). 
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Having considered the role of lamins in the organisation of the nuclear envelope and in 
communication with the cytoskeleton, it should be noted that lamin A may also be 
important as a chromatin scaffold. A-type lamins and the lamin-binding LEM (LAP2, Emerin, 
MAN) domain proteins bind to BAF (barrier-to-autointegration factor) (BAF), which can bind 
DNA and organise chromatin structure (Holaska et al., 2003; Zheng et al., 2000). Densely 
packaged heterochromatin tends to correlate with gene silencing, and it has been suggested 
that the A-type lamins may help to organise chromatin into these active and inactive 
domains (Kind and van Steensel, 2010). Studies using anchored reporters have shown that 
genes at the nuclear periphery tend to be repressed, although this can vary depending on 
regulatory sequences and chromatin context (Finlan et al., 2008; Reddy et al., 2008). The 
function of A-type lamins in chromatin positioning and regulation of gene expression has 
been attributed to the lamin Ig domain, based on truncation and mutational studies 
(Ludérus et al., 1994; Taniura et al., 1995). 
 
1.10.3 A-type lamins and cancer 
Numerous studies have documented aberrant expression of A-type lamins in a variety of 
cancers including small cell lung carcinoma, skin basal cell and squamous carcinoma, 
leukaemia, lymphomas and CRC, and in some cases lamin expression has been linked to 
tumour progression and survival (Broers et al., 1993; Moss et al., 1999). Some studies 
suggest that a lack of lamin A/C expression is associated with poor prognosis. Wu et al. 
(2009) documented that lamin A/C expression is significantly lower in patients with gastric 
cancer tissue compared to non-cancerous gastric tissue, and that loss of lamin A/C 
expression correlates with histological classification and poor prognosis (Wu et al., 2009). 
Moreover, epigenetic silencing of LMNA and thus loss of lamin A/C expression has been 
correlated with a decrease in overall survival in patients with nodal diffuse large B-cell 
lymphoma (Agrelo et al., 2005). In contrast, another study found that lamin A was highly 
discriminatory between low and high-grade prostate tumours, and in this cancer type, up-
regulation of lamin A is a potential indicator of poor prognosis (Skvortsov et al., 2010). 
Recent studies in our laboratory have suggested that lamin A/C is a prognostic biomarker for 
CRC. By interrogating the Netherlands Cohort Study on Diet and Cancer (NLCS) tissue 
archive, Willis et al. found that patients expressing lamin A/C in their tumours were twice as 
likely to die of cancer related causes compared to clinicopathologically identical patients 
with negative expression (Hazard ratio [HR] 1.85; 95% confidence interval [C.I.] 1.16-2.97) (P 
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= 0.05) (Willis et al., 2008). In order to shed light on the potential mechanisms responsible 
for this observation, an in vitro model system approach was taken. Downstream 
investigations revealed that over-expression of lamin A in the SW480 CRC cell line caused 
the cells to adopt a significantly more motile phenotype. It was then shown that expression 
of GFP-lamin A led to an increase in expression of the actin-bundling protein T-plastin, which 
in turn gives rise to a decrease in expression of the cell-adhesion molecule E-cadherin 
(encoded by CDH1) (Willis et al., 2008). The study by Willis et al. (2008) suggest that lamin A 
may act as a master regulator of a metastatic pathway which promotes tumour invasiveness 
through dynamic reorganisation of the actin cytoskeleton. 
 
Loss of E-cadherin is a hallmark of cancer and frequently associated with epithelial to 
mesenchymal transition (EMT), resulting in increased metastatic behaviour and poor 
prognosis (Bhangu et al., 2012; Yilmaz and Christofori, 2009). EMT is an orchestrated series 
of events whereby stationary polarised epithelial cells, communicating by cell-cell junctions, 
break up their junctions and switch to a non-polarised, mobile and invasive mesenchymal 
cell state (Kalluri and Weinberg, 2009; Thiery and Sleeman, 2006). During EMT, the adhesion 
molecule repertoire of the cancer cell changes considerably, underpinned by developmental 
reprogramming that gives rise to a wholesale reorganisation of the actin cytoskeleton 
(Yilmaz and Christofori, 2009). These cytoskeletal rearrangements are accompanied by the 
formation of membrane protrusions, which are required for invasive growth. Once the 
cancer cell has detached from the primary tumour mass, it uses chemotactic signals to move 
through the extracellular matrix and secretes proteinases that assist the migration by 
breaking down the proteins of the matrix. EMT can be initiated by both intrinsic signals (e.g. 
gene mutations in CDH1) as well extrinsic signals (e.g. growth factor signalling) (Yilmaz and 
Christofori, 2009). Among the molecules that induce EMT in cancer are are TGFβ, Wnt, 
members of the EGF family and the transcription factor SNAI2 (also known as Slug), a 
repressor of E-cadherin gene expression (Cui et al., 1996; Huber et al., 2005; Kim et al., 2002; 
Savagner et al., 1997; Zavadil and Bottinger, 2005). 
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1.11 Plastins: actin bundling proteins 
 
1.11.1 The actin cytoskeleton: overview 
Actin is one of the most abundant cellular proteins and all eukaryotes maintain genes for 
actin (Pollard et al., 1994). The ancestral prokaryotic actin gene MreB arose over 3 billion 
years ago and as an ancient fundamental protein actin and its homologues are essential for 
cell viability (van den Ent et al., 2001a). In animals, actin filaments complement two other 
cytoskeletal components, microtubules and intermediate filaments, which together make up 
the cytoskeleton. The actin cytoskeleton of eukaryotic cells is a dynamic meshwork that is 
involved in fundamental biological phenomena such as cell shape, cell division, cell motility, 
contraction, cell substrate adhesion, intracellular transport, cytokinesis and signal 
transduction (Doherty and McMahon, 2008).  
 
First discovered in 1940s alongside myosin in muscle, early x-ray studies of actin showed that 
it formed highly organised arrays of filaments that hinted at its role in cellular organisation 
(Astbury, 1947). Vertebrates have three main actin isoforms, α-, β- and γ. There are three α-
isoforms of skeletal, cardiac, and smooth muscle actin and the β- and γ-isoforms are found in 
both nonmuscle and muscle cells. Actin isoforms differ by only a few amino acids, mostly 
toward the N terminus. Actin belongs to a structural superfamily defined by a characteristic 
375-amino-acid βββαβαβα fold together with sugar kinases, hexokinases, and Hsp70 
proteins (Bork et al., 1992). The family also includes the prokaryotic actin-like proteins MreB 
(van den Ent et al., 2001b) and ParM (van den Ent et al., 2002) and the actin-related Arp 
proteins (Robinson et al., 2001).  
 
Actin itself consists of two major domains, each comprising two smaller subdomains. The 
two major domains are known as the outer and inner subdomains, according to their 
arrangement within the actin filament. Monomeric actin (G-actin) is a globular 42 kDa ATP-
ADP-binding protein. Under physiological conditions, actin monomers spontaneously 
polymerise into long polarised filaments (F-actin), with a helical arrangement of subunits, as 
first visualised in vivo in striated muscle (Hanson et al., 1964). The actin filament is 
asymmetric and can be seen as either a short, single left-handed helix with consecutive 
lateral subunits staggered by a half monomer length, or as two long right-handed helices of 
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actin subunits ordered head-to-tail. Actin cytoskeletal dynamics within a cell are regulated 
by controlling the homeostatic balance between G-actin and F-actin states in response to 
extracellular environmental cues (Lee and Dominguez, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16: Monomeric and filamentous actin 
(A) The actin monomer consists of two major and structurally related domains, the outer and inner 
domains. Subdomains 1 and 2 (outer domain) and subdomains 3 and 4 (inner domain) are illustrated. 
A large cleft between subdomains 2 and 4 constitutes the nucleotide-binding site. The hydrophobic 
pocket opposite the ATP binding site is the site for interaction with most ABPs. (B) F-actin, modelled 
on diffraction studies of actin filaments and fitting of the actin monomer structure. The D-loop 
(shaded in A) is disordered in most structures of actin but is likely to be involved in actin-actin 
interactions in the filament. An actin monomer is represented by a black ribbon. (C) Model showing 
actin filament treadmilling. The barbed (+) end exposes subdomains 2 and 3 of the actin monomer 
and adds actin monomers bound to ATP. The pointed (-) end exposes subdomains 2 and 4 of the 
actin subunits. This region has net dissociation of actin-ADP monomers. In cells, however, actin 
filament treadmilling is tightly regulated by ABPs (adapted from Lee and Dominguez, 2010). 
A 
C 
B 
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In vitro, actin polymerisation initiates in a slow manner owing to the instability of small actin 
oligomers. However, once an actin trimer (the nucleus) is formed, actin polymerisation is 
rapid (Pollard and Cooper, 2009). Actin binds to its nucleotide (ATP or ADP) and as filament 
assembly is initiated, it hydrolyses the terminal phosphate from the bound ATP to provide 
energy for the polymerisation process. Actin filaments are polar because the subunits are all 
oriented in the same direction. Polymerisation is fast at the growing barbed (+) end, and is 
slower at pointed (-) end of the filament. Mechanical force is generated at the plus end by 
the incorporation of new actin subunits into the filament, generating membrane protrusions 
that give directionality to migrating cells (or contracting muscle cells) (Lee and Dominguez, 
2010; Pollard and Cooper, 2009). This dynamic yet steady-state mechanism of actin 
polymerization/depolymerization is called actin filament treadmilling. However, treadmilling 
does not explain the full picture of dynamic filament assembly observed in all cell types. 
Actin cytoskeletal dynamics are tightly controlled and regulated by a plethora of accessory 
proteins, known as actin-binding proteins (ABPs) (Lee and Dominguez, 2010; Pollard and 
Cooper, 2009). There are over 100 ABPs know to date which perform a multitude of 
functions including actin filament nucleation (e.g. Arp2/3 complex, formin), elongation (e.g. 
Ena/VASP), capping (e.g. gelsolin), severing (e.g. ADF/cofilin) and cross-linking (e.g. plastin) 
which is summarised in Figure 1.17 (Pollard and Borisy, 2003). The biological interplay 
between actin and all its accessory proteins is too vast an area to cover in the context of this 
thesis. Here, we will focus on a subset of ABDs know as actin-bundling proteins. Actin-
bundling proteins function to cross-link actin filaments into loose/tight networks or bundles 
and are often localised to dynamic actin-rich cellular regions (Delanote et al., 2005). Indeed, 
actin bundling proteins are important in the formation of specialised structures such as 
filopodia (long, thin actin-based protusions), lamellipodia (sheet-like protrusions), stress 
fibres (elastic contractile bundles of parallel actin filaments) and microvilli (finger-like 
projections) (Stevenson et al., 2012). In cancer, the ‘normal’ functions of the actin 
cytoskeleton and its constituent parts are subverted to promote tumour invasion and 
metastasis (Hall, 2009; Stevenson et al., 2012). A number of actin bundling-proteins have 
been linked to cancer progression, as summarised in Table 1.3. 
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Figure 1.17: Actin filament networks 
Three major types of actin network are shown above, including lamellipodia, filopodia and focal 
adhesions (shown at the ECM). These actin networks are regulated by rho-family GTPases signalling 
via ABPs and in response to various ligands that stimulate G-protein coupled receptors, receptor 
tyrosine kinases and integrins (adapted from Lee and Dominguez, 2010). 
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Protein  Structures and cell type Function Role in cancer 
α-Actinin-1 and 
α-actinin-4                                     
Cellular protrusions, stress fibres, 
lamellipodia, microvilli, 
invadapodia of multiple cells 
Crosslinks actin into parallel 
bundles by forming dimers head 
to tail 
Expression in breast, ovary, pancreas, 
astrocytoma cancers. Associated with poor 
prognosis and tumour resistance (ovary) 
Eplin Stress fibres in multiple cell types Actin filament bundling and side 
binding 
Eplin downregulation correlates with 
progression and metastasis in prostate cancer 
and eplin might be angiogenic. Potential 
tumour suppressor in breast cancer 
Fascin Neurons, dendritic cells, 
endothelial cells and cancer cells 
Crosslinks actin into parallel 
bundles. Thought to be a 
monomer with two actin-
binding sites 
Significant independent prognostic indicator of 
poor outcome of cancers of the liver, ovary, 
lung, pancreas, colon, head and neck squamous 
cell carcinoma and brain 
Filamin-A Cell cortex, filopodia of many cell 
types 
Crosslinks into orthogonal gels Prostate cancer metastasis correlates with low 
nuclear and high cytoplasmic filamin-A. A 
secreted variant of filamin-A  in the blood 
correlates with high-grade astrocytomas in 
metastatic breast cancer 
Formins  Stress fibres and filopodia of 
multiple cell types 
Actin nucleation and parallel 
bundling. Also interacts with 
microtubules 
Downregulation of formin-like-2 correlates with 
a poor prognosis in hepatocellular carcinoma. 
Higher expression correlates with tumour 
differentiation 
Spectrin Microvilli and terminal web of 
intestinal epithelial cells and cell 
cortex of many cell types 
Crosslinks actin into orthogonal 
networks by forming tetramers. 
Reduced expression of spectrin associated with 
poor prognosis in pancreatic cancer and 
progression in hepatocellular cancer 
Supervillin Stress fibres and focal adhesions 
of multiple cell types. Implicated 
in nuclear architecture. 
Actin bundling into parallel 
bundles 
Androgen receptor co-regulator that might be 
important in androgen-dependent prostate 
cancer 
Villin Epithelial cells of the 
gastrointestinal tract that possess 
brush border microvilli 
Crosslinks filaments in low Ca2+ 
and severs filaments at high 
Ca2+ 
Expression altered in Barrett’s oesophagus, 
bladder cancer, colorectal and intestinal cancer 
Table 1.3: Clinical correlations between actin-bundling proteins and cancer 
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1.11.2 Early biochemical studies of plastins 
Plastins belong to the family of actin-bundling proteins, which are conserved from lower 
eukaryotes to mammals. In general, plastins are found in cells with high actin turnover, 
associated with polarized actin filaments. Our understanding of the function of these 
proteins is largely inferred from early biochemical studies on chicken fimbrin which was 
discovered in 1979 as a protein that was involved in the organisation of microvilli in the 
intestinal brush border (Matsudaira and Burgess, 1979). Fimbrin was shown to localise with 
surface structures such as membrane ruffles and focal adhesions in chicken embryo 
fibroblasts (hence the name). Independent to the studies on chicken fimbrin, a related 
protein was identified from immortalised fibroblasts. The protein was given the name L-
plastin because it was found to be abundantly expressed in lymphocytes (Goldstein et al., 
1985). It was only with the advent of molecular cloning techniques, coupled with amino acid 
sequencing, that fimbrin and plastin were revealed to be two related members of the same 
family. Today, the terms fimbrin and plastin are used interchangeably. In humans, three 
plastin isoforms exist; T-, L- and I-plastin.  
 
Biochemical characterisation of chicken fimbrin was stimulated by the desire of researchers 
to understand the composition of brush borders, which were relatively abundant and easy 
to extract from chicken intestines (Bretscher and Weber, 1978). Initial studies showed that 
core microfilaments extracted in the absence of calcium contained three main F-actin-
associated proteins: villin, calmodulin and fimbrin (Glenney et al., 1980; Howe et al., 1980) 
The first evidence for the calcium binding ability of fimbrin came in 1981, when chicken 
fimbrin was purified by classical ammonium sulphate precipitation and sepharose/affinity 
chromatography and was shown to bind to 
45
Ca by equilibrium dialysis. The authors 
suggested a dissociation constant of 9 µM, and showed that fimbrin-bound calcium could be 
displaced by magnesium. The results suggested that there was one calcium binding site per 
protein. However, comparison of the three plastin sequences shows that the calcium binding 
sites between the plastins are weakly conserved (Giganti et al., 2005) provided some 
evidence to suggest that T-plastin is relatively insensitive to calcium levels, but more work is 
required to determine directly whether (and why) the plastins are differentially regulated by 
calcium (Giganti et al., 2005). 
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In the Glenney et al paper, the authors demonstrated (by sucrose density gradient 
centrifugation) that purified fimbrin could bind to purified actin at a ratio of one fimbrin 
molecule per two-three actin molecules (Glenney et al., 1980). This interaction was 
dependent on calcium/magnesium ions in vitro. Low speed centrifugation followed by 
electron microscopy of the pellets showed that fimbrin-actin mixtures formed polymerised 
fibrils. Including villin in the mixture enhanced polymerisation. Incubation of these filaments 
with the actin-binding domain of myosin also indicated that the filaments always maintained 
the same polarity. This was the first evidence that fimbrin could cross-link, organise and 
bundle actin, and that fimbrin contributed to the rigidity of the stereocilium (Bretscher, 
1981; Glenney et al., 1981). 
 
1.11.3 Plastin structure 
Understanding the structural basis of these early biochemical studies has been held back by 
the lack of complete and comprehensive crystal structures for the mammalian plastins. 
However, crystal structures of the N-terminal actin binding ABD1 domain (comprising the 
two calponin homology domains CH1 and CH2) have been solved for the yeast 
Saccharomyces cerevisiae plastin and the plant Arabidopsis thaliana plastin (Klein et al., 
2004). In addition, the N-terminal region of human T-plastin has been solved by X-ray 
crystallography (Goldsmith et al., 1997). Plastins have a modular structure comprising of two 
EF-hands, and two tandem actin-binding domains (ABDs), each consisting of two calponin 
homology (CH) domains (Korenbaum and Rivero, 2002) (Figure 1.18). Each CH domain is 
composed of four α-helical segments. Three of these stretches form a loose bundle of 
helices, with the fourth α-helix laying perpendicular to the main bundle. Similar CH domains 
are found in other actin binding cytoskeletal proteins such as dystrophin, α-actinin and 
spectrin; thus the CH domain has been repeatedly used during evolution as an actin binding 
module (Delanote et al., 2005; Shinomiya, 2012). The actin cross-linking core of plastin is 
compact, contacting actin through the CH1 domain and the CH4 domain using conserved 
residues at the CH1-CH4 interface. The regions that join the CH domains are poorly defined 
in the crystallographic studies, indicating that this region is highly dynamic. Having 
demonstrated that the binding sites for plastin on the actin molecule reside in two 
independent subdomains, workers have suggested that differential binding of plastin to 
actin may help control actin turnover and assembly, independent of plastins role as a simple 
bundling protein (Hanein et al., 1998). Recent support for this idea comes from a high-
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resolution cryo-EM structure of the human L-plastin ABD2 domain bound to F-actin, which 
suggests that ABD2 binding induces the closure of the actin cleft. This stabilisation effect is 
then transmitted co-operatively to neighbouring subunits to stabilise local regions of the 
filament (Galkin et al., 2008). The interaction of the plastin ABD1 domain with actin remains 
to be defined; thus high-resolution structures of the plastin ABD1-ABD2 domains in 
combination with F-actin will be required to establish how the two domains work together 
to bind, stabilise and subsequently protect F-actin from depolymerisation.  
 
Further evidence for a role for plastin beyond simple bundling comes from Giganti and 
colleagues, who suggested that T-plastin increased the Arp2/3 (actin-nucleating protein) 
induced movement of actin (Giganti et al., 2005). In this study, the authors used beads 
asymmetrically coated with the VCA domain of the WAS protein to establish an in vitro assay 
for actin motility. The mobility of the beads was observed by phase-contrast microscopy. The 
coated beads could bind to purified Arp2/3, and polymerized actin on the bead, showing 
directed movement when incubated in a HeLa cell free extract. Introducing T-plastin to the 
assay stimulated the movement of the beads by ~1.5 fold and stabilised actin comets. 
Interestingly, the T-plastin ABD1 domain also had the same effect as full-length T-plastin on 
bead velocity and actin comet length, even though alone it lacked actin-bundling activity. 
Taken together with the observations that T-plastin could displace coﬁlin, an actin-
depolymerizing protein, this paper supports the hypothesis that T-plastin does more than 
simply bundle the actin filament and may induce cell motility. However, comparative 
biochemical studies and crystal structures of T, L and I-plastin from the same organism, 
preferable in combination with actin, will be required to deduce whether the plastins show 
any degree of specialization in their binding to actin. 
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Figure 1.18: Schematic representations of human plastin isoforms 
Each plastin contains two amino-terminal EF hands, and two actin binding (ABD) domains. Each ABD 
consists of two calponin (CH) domains. Human T-plastin contains an NES, and L-plastin contains a 
phosphorylation site (adapted from Delanote et al., 2005). 
 
 
1.11.4 Tissue-specific expression and localisation 
In general, plastins normally localise to various actin-rich membrane structures involved in 
locomotion, signalling, adhesion and immune defense, including focal adhesions, ruffling 
membranes, filopodia and the phagocytic cup. Moreover, plastins are also located in highly 
specialized surface structures with ordered microfilament bundles such as stereocillia. This is 
of particular interest, as actin bundles formed by plastin may also have a mechanosensory 
function by sensing mechanical alterations in signals during chemosensory signal 
transduction (Daudet and Lebart, 2002). However, the three plastin isoforms (T, L and I) 
exhibit a tissue-specific expression pattern that suggests that they may have functional 
specialisation. T-plastin (encoded by PLS3) is normally expressed in cells derived from solid 
tissue and L-plastin (encoded by PLS2, also known as LCP1) is confined to hematopoietic cell 
lineages. In macrophages, for example, L-plastin is found in podosomes and filopodia. 
Finally, I-plastin (encoded by PLS1) is predominantly found in the small intestine, colon and 
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plastin 
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kidney (Grimm-Gunter et al., 2009; Lin et al., 1994) and is required for the regulation and 
morphology of brush borders, as demonstrated from studies of Pls1
-/-
 mice (Grimm-Gunter 
et al., 2009). During the early stages of intestinal epithelial cell differentiation, both T- and L 
plastin are expressed at the apical and basal membranes, respectively. However, these 
plastins disappear after day 16.5 and are replaced by I-plastin at the apical surface. This 
suggests that plastin isoforms play different roles during epithelial cell differentiation. It is 
thought that both T- and I-plastin are needed for the formation and extension of the 
intestinal microvilli, whereas L-plastin might be needed to control cell adhesion (Chafel et al., 
1995). I-plastin and T- plastin, but not L-plastin, are also found in cochlea auditory hair cell 
stereocilia (Daudet and Lebart, 2002). However, T-plastin is absent from mature hair cell 
stereocilia, suggesting that T-plastin could have a particular role in sterocilia formation. 
Importantly, human plastin isoforms share approximately 70% homology at the protein level 
but are encoded by three distinct genes located on chromosomes 3 (I-plastin), 13 (L-plastin), 
and X (T-plastin) (Delanote et al., 2005). The three plastin genes have evolved from a 
common ancestor, but their tissue specific expression is regulated differently. T-plastin is 
under the control of upstream enhancer elements and is methylated at a CpG island (Lin et 
al., 1999). Conversely, L-plastin is under control of a strong promoter, can be modulated by 
steroid hormone receptors, and is regulated by an upstream repressor (Lin et al., 1993a). 
 
1.11.5 Plastin function  
T- L- and I-plastin have similar sequences, but this does not mean that they are functionally 
equivalent. Arpin and colleagues overexpressed T- and L-plastin in the fibroblast-like cell 
line, CV-1, and in a polarized epithelial cell line, LLC-PK1 (Arpin et al., 1994). Both isoforms 
induced cell rounding and the reorganization of the actin cytoskeleton in both cell types. 
However, in epithelial cells, T-plastin altered the shape of microvilli and maintained its 
association with actin filaments even after detergent treatment. These studies demonstrate 
that the cell type and other cell-specific proteins can be important in determining the 
function of protein homologs. 
 
Both T-plastin and L-plastin have a role in immunity. L-plastin is involved in the motility of B 
cells, and has recently been shown to be required for marginal zone B cell development 
(Todd et al., 2011). These authors used L-plastin knockout mice to analyse the behaviour of B 
cells in the absence of L-plastin. They found that the B cells failed to respond properly to the 
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chemokines CXCL12 and CXCL13, as well as the lipid sphingosine -1-phosphate. As a result, 
the L-plastin knockout mice had a deficiency of B cells in the spleen, with a 40% reduction in 
the follicles and an 80% reduction in marginal zone B cells. These mice could not respond 
effectively to Streptococcus pneumoniae infections, demonstrating that L-plastin is required 
for proper function of the immune system. The importance of T-plastin in immunity is 
demonstrated by the fact that T-plastin is linked with Sezary's disease. Sezary's disease is a 
cutaneous lymphoma of the skin characterised by CD4+ T cells that overproduce 
mucopolysaccharides (Wong et al., 2011). Sezary’s disease is rare, affecting ~3 people per 
1,000,000 and its cause is unknown. T-plastin protein expression is not found in normal 
lymphocytes but is found in T cells from Sézary syndrome patients (Kari et al., 2003; Su et al., 
2003). However, no coding mutations associated with the PLS3 gene have been found in 
individuals with the disease. In preparation of this thesis, it was discovered that CpG 
dinucleotides within the PLS3 promoter are hypomethylated in T-plastin overexpressing 
patients (Jones et al., 2012). The mechanisms underlying this phenomenon in Sezary 
syndrome patients remain to be elucidated. 
 
Post-transcriptional regulation of T-plastin is important for its function, and has a crucial 
bearing on human health. For example, the survival motor neuron protein, SMN, modulates 
the half-life of T-plastin mRNA, as shown in both human cells and in a zebrafish model (Hao 
et al., 2012). In addition, a paper in Science showed that loss of SMN causes spinal muscular 
atrophy, identifying T-plastin as an important modifier of this motor neuron disease (Oprea 
et al., 2008). Expressing T-plastin in motor neurons rescues movement deficits in smn 
zebrafish mutants, raising the prospect that T-plastin could be used therapeutically for the 
human disease. Evidence has also emerged to support the regulation of T-plastin at the post-
transcriptional level by ROD1, a polypyrimidine tract binding protein that plays a role in the 
nonsense-mediated mRNA decay (NMD) pathway. Interestingly, cofilin1 and various nuclear 
pore/envelope proteins also emerge as putative targets for ROD1 from this study, suggesting 
that post-transcriptional regulation might influence nuclear-cytoskeletal remodelling 
processes (Brazao et al., 2012). 
 
Plastins are also regulated at the post-translational level. Intriguingly, L-plastin, but not T- or 
I-plastin, is phosphorylated (at the N-terminal residues Ser5 and Ser7) and high levels of 
phosphorylated L-plastin have been found in haematopoietic cells and in cancer cells (Jones 
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et al., 1998). Protein kinase A can phosphorylate L-plastin in vitro (Wang and Brown, 1999), 
but whether Protein kinase A is the in vivo phosphate donor is not certain. Other 
investigators have suggested that Protein kinase C phosphorylates L-plastin in the MCF-7 
breast cancer cell line (Janji et al., 2010). Although it has been suggested that 
phosphorylation of L-plastin is important in leukocyte function/adhesion and might regulate 
actin binding or interactions between L-plastin and other accessory proteins, the 
physiological significance of L-plastin modification by phosphorylation is not fully understood 
(Delanote et al., 2005). However, it does appear that in the MCF-7 cells, L-plastin 
phosphorylation increases during the reorganization of the actin cytoskeleton and may 
induce the transition of L-plastin to sites of de novo actin polymerization (Al Tanoury et al., 
2010). 
 
Plastins are expressed in all eukaryotes, including yeast and plants. In S. cerevisiae, the sole 
plastin homolog Sac6p co-localises with both actin cables and cortical actin patches (Drubin 
et al., 1988). Yeast lacking Sac6p have various temperature sensitive defects in morphology, 
endocytosis and sporulation (Adams et al., 1991; Kubler and Riezman, 1993). Although 
overexpression of Sac6p is lethal, yeast deficient in Sac6p can be rescued by the expression 
of human T and L-plastin, but not I-plastin (Adams et al., 1995). The functional dynamics of 
plastins have probably been best visualised in plant cells, in experiments where the actin-
binding domain 2 of Arabidopsis fimbrin has been tagged with GFP (Sheahan et al., 2004; 
Voigt et al., 2005). Although the fimbrin domain was essentially used as a probe in these 
studies, they do demonstrate that fimbrins are recruited to motile regions of the actin 
cytoskeleton. The same probe has been used in a recent study of the effect of calcium on 
actin-mediated organelle movement (Jung et al., 2012). An interesting point from this work 
is that ABD2-GFP localized to F-actin patches close to the nucleus when calcium 
concentrations were increased by UTP treatment. Although the functional significance of 
this observation was not investigated further, it would be consistent with a role for plastin(s) 
in cytoskeletal-nuclear communication. 
 
1.11.6 Plastins and cancer 
In cancer, remodelling of the cytoskeletal architecture is a vital step in the acquisition of 
invasive capabilities and metastasis. Given the function of plastins as important cross-linkers 
of actin filaments, it has been suggested that these proteins may play an important role in 
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cancer. Indeed, aberrant plastin expression has been documented in a number of 
carcinomas (Delanote et al., 2005; Lin et al., 1993b; Otsuka et al., 2001; Shinomiya, 2012). As 
discussed, human T-, L- and I-plastin are expressed in a tightly controlled tissue-specific 
fashion. For example, L-plastin is normally found in haematopoietic cells (e.g. peripheral 
blood leukocytes, B-lymphocytes, macrophages). Interestingly, many authors report that L-
plastin is frequently expressed in transformed cells of non-haematopoietic origin. A study by 
Lin et al. found aberrant expression of L-plastin was present in 69% of cancers investigated 
(Lin et al., 1993b). This is further supported by the presence of L-plastin in a number of 
human neoplastic cancer cell lines (Park et al., 1994). In addition, Zheng and co-workers 
demonstrated that L-plastin expression was regulated by steroid hormone receptors and 
linked to malignant progression of prostatic epithelial cells (Zheng et al., 1997). More 
recently, DNA microarray expression profiling revealed that L-plastin was significantly 
upregulated in tumour necrosis factor (TNF)-alpha resistant breast adenocarcinoma MCF-7 
cells. RNAi/overexpression experiments showed that L-plastin protected MCF-7 cells from 
TNFα induced cell death in a manner that required L-plastin phosphorylation (Janji et al., 
2010). This study suggests that upregulation of L-plastin can protect tumors from cytokine 
mediated cell death. The kinases upstream of L-plastin were not identified in this work, but 
could be explored further as targets to prevent EMT, since TNFα resistance correlates with 
the gain of mesenchymal behaviour. Importantly, L-plastin expression has also been 
observed in CRC. Using a tissue microarray of 58 clinically stratified CRC specimens, Otsuka 
and colleagues found that L-plastin expression was associated with tumour progression 
(Otsuka et al., 2001).  
 
In addition to L-plastin, T-plastin has been implicated in a number of cancers. Enhanced 
expression of T-plastin has been associated with both drug and radiation resistant cells. 
Firstly, T-plastin expression is enhanced in cisplatin-resistant human bladder, prostatic, head 
and neck cancers (Hisano et al., 1996). Secondly, increased expression of T-plastin has been 
observed in Chinese hamster ovary (CHO) cells in which G2 arrest has been induced by X-
radiation and by etoposide, a topoisomerase inhibitor. When T-plastin expression was down-
regulated, radiation induced G2 arrest was decreased in CHO cells, indicating a correlation 
between G2 arrest and cell cycle control. This group also showed that PLS3 promoter 
methylation controls gene expression in the CRC cell SW948.  A follow-up study showed that 
T-plastin was differentially expressed in various liver cancer cells, and that those cells with 
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low levels of T-plastin were also more susceptible to DNA damage (Ikeda et al., 2005; Sasaki 
et al., 2002b). Taken together, these results imply that down-regulation of T-plastin 
facilitates cancer development through the G2/M cell-cycle checkpoint in mammalian cells. 
The studies discussed above highlight an interesting idea; that T-plastin may influence 
cancer progression by perturbing the cell cycle, perhaps through changes in the nuclear-
cytoskeletal framework that impacts upon chromatin organisation and hence gene 
activation. This concept contrasts with the hypothesis that T-plastin solely contributes to cell 
motility as part of the actin machinery that enables cells to migrate and metastasise. 
 
Although various studies have reported that plastin expression may be dysregulated in 
epithelial cancers and immortalised cell lines, none to date have demonstrated a clear causal 
relationship between PLS3 promoter methylation and/or plastin expression and tumour 
development.  
 
1.12 Rationale and aims of thesis 
As outlined in the introduction, we have previously found that positive expression of A-type 
lamins is predictive of poor prognosis in CRC (Willis et al, 2008). In order to understand this 
finding, an in vitro model system based upon the expression of GFP-lamin A in CRC cells was 
established. Downstream investigations revealed that CRC cells overexpressing lamin A were 
significantly more motile, and this increase in motility was, in part, caused by upregulation of 
actin bundling protein T-plastin. Thus, T-plastin was identified as a candidate gene for 
further exploration. The main aims of this thesis were to investigate PLS3 promoter 
methylation and plastin expression in CRC, using a combination of both epigenetic and 
immunohistochemical approaches. Furthermore, we sought to examine their potential as 
prognostic biomarkers to be used in conjunction with lamin A/C. At the onset of this project, 
we hypothesised that the PLS3 promoter would be demethylated, and that plastin would be 
aberrantly expressed in colorectal carcinomas. In addition, we hypothesised that the high 
risk of mortality in CRC patients who exhibit A-type lamin expression in their tumours, arises 
because lamin A is a master regulator of a pathway that co-ordinates the cytoskeletal 
changes required for cell motility and tumour invasiveness. The main objectives of this thesis 
were: 
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1) To determine the methylation status of the CpG island within the PLS3 promoter in 
both CRC cell lines and tissues. 
2) To investigate whether there is an association between PLS3 promoter methylation 
and clinicopathological staging, using DNA samples obtained from the Netherlands 
CRC archive. 
3) To raise and test polyclonal plastin antibodies for their ability to detect T/L-plastin in 
cell lines and tissues. 
4) To use polyclonal plastin antibodies developed in objective 3 to investigate the 
expression pattern of T/L plastin by immunohistochemical analysis, and to determine 
its utility as prognostic biomarker in CRC 
5) To generate a candidate gene network based on the differential expression of genes 
when lamin A is introduced into a CRC cell line, and to validate this network by both 
real-time PCR and immunoblotting techniques.  
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Chapter 2: Materials and methods 
 
2.1 General chemicals and materials 
The majority of routine chemicals were purchased from BDH Laboratory Supplies (VWR 
International Ltd, Leicestershire, England), Melford (Melford Laboratories Ltd, Suffolk, 
England) and Sigma-Aldrich (Sigma-Aldrich Company Ltd, Dorset, England) unless otherwise 
stated. Chemicals from BDH were AnalaR® analytical grade and all other reagents were 
Molecular Biology Grade. All plastic ware for tissue culture was supplied by Greiner Bio-One 
Ltd, Gloucestershire, UK.  
 
2.2 The Netherlands Cohort Study on Diet and Cancer  
In 1986, a prospective cohort study on diet and cancer was initiated in the Netherlands. The 
study design is described in detail elsewhere (van den Brandt et al., 1990). Briefly, the cohort 
of 55-69 year old men (n = 58,279) and women (n = 62,573) originated from 204 municipal 
population registries throughout the Netherlands. At baseline, participants completed a self-
administered questionnaire on dietary habits and lifestyle. Subsequently, incident CRC cases 
were identified by monitoring the entire cohort for cancer through annual record linkage to 
the Netherlands Cancer Registry (NCR); nine regional cancer registries throughout the 
Netherlands and the Pathologisch Anatomisch Landelijk Geautomatiseerd Archief (PALGA); 
the nationwide registry for histopathology and cytopathology in the Netherlands (van den 
Brandt et al., 1990). For patient follow-up, the first 2.3 years were excluded due to 
incomplete nationwide coverage of PALGA. However, from January 1989 until January 1994, 
819 incident cases with histologically confirmed CRC were identified, and the patient follow-
up was complete and subsequently obtained for the period of 1
st
 January 1989 to 31
st
 
December 1996 (7 years).  
 
2.2.1 Tissue samples 
Tumour material of CRC patients was collected after approval by the Ethical Review Board of 
Maastricht University, PALGA and the Netherlands NCR. Tissue samples from 819 identified 
CRC patients were requested from 54 pathology laboratories throughout the Netherlands. 
Tumour tissue collection started in August 1999 and was completed in December 2001. 
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Forty four tumour tissue samples (5%) were untraced. Of the 775 traceable tissue samples, 
737 (90%) contained sufficient tumour material as confirmed by senior pathologist Professor 
Adriaan de Bruïne (University Hospital Maastricht, Netherlands) for histological and 
molecular analysis. All specimens had been previously processed according to standard 
Dutch pathology guidelines. Briefly, specimens were grossly dissected and immersed in 10% 
formalin fixative for 30 minutes at 35°C. Dehydration and embedding of tissues was fully 
automated and the procedure was as follows: 70% ethanol, 60 minutes at 35°C, 70% 
ethanol, 60 minutes at 37°C, 96% ethanol, 60 minutes at 37°C, 96% ethanol, 1 hour and 30 
minutes at 40°C, 100% ethanol, 1 hour 30 minutes at 40°C and 100% ethanol, 2 hours at 
45°C. Thereafter, samples were cleared in xylene for 15 minutes at 45°C, 15 minutes at 50°C, 
followed by another 30 minutes in fresh xylene at 50°C before embedding in paraffin at 60°C 
for two 60-minute periods, and finally for 1 hour 30 minutes. The clinical stage of the 
tumours was then confirmed histologically by a resident pathologist.  
 
2.2.2 The CREAM database and retrospective study 
Information regarding age at diagnosis, sex and other clinicopathological features was 
retrieved from the NLCS database. Information concerning tumour sub-localisation, 
Dukes’/TNM stage and differentiation state of the tumour was retrieved from the NCR 
database. DNA had been previously isolated from 737 tissue specimens for biochemical 
analysis. Information regarding the molecular status of tumours (e.g. KRAS oncogene 
mutations), along with clinicopathological characteristics described above, was collated and 
entered into a new database entitled the Colorectal Epidemiology and Mutation (CREAM) 
database. Within the CREAM database, a subset of 161 genomic DNA samples and 70 CRC 
tissue slides were analysed for PLS3 promoter methylation (Chapter 3) and T/L-plastin 
expression (Chapter 5), respectively.  
 
2.2.3 Statistical analysis 
The patients from the analysis included in this study developed cancer between 1989 and 
1994. Information on mortality from 1
st
 January 1989 until 1996 (7 years) was retrieved 
through linkage with the Central Bureau for Statistics. CRC-related death was concluded if 
CRC was determined to be either the primary cause of death or as a primary, secondary or 
tertiary complication, using the International Classification of Diseases (ICD) system. 
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Differences in patient, tumour and follow-up characteristics were analysed using the Chi-
square (χ²) test. In order to investigate survival, two statistical analyses were performed. 
Firstly, Kaplan-Meier curves were produced to estimate survival probability. Kaplan-Meier 
curves are an estimate of the survivor function. The time in the study represents a clinical 
endpoint, in this case death from CRC. The study baseline is t = 0. Survivor function S(t) is the 
proportion of the population still alive at time t. Secondly, Cox regression analysis using the 
Breslow method for ties was performed to estimate the cumulative hazard. Cox regression 
(or proportional hazards regression) is the method for investigating the effect of several 
variables upon the time a specified event takes to happen, i.e. death from CRC. The 
cumulative hazard at time t is the risk of dying between time 0 and time t, and the survivor 
function at time t is the probability of surviving to time t. Co-efficients or hazard ratios (HR) 
above 1 indicate a worse prognosis and a coefficient of less than 1 indicates a protective 
effect of the variable with which it is associated.  A coefficient of 1 indicates no effect of the 
variable on the likelihood of hazard occurrence. All analyses were performed using SPSS in 
collaboration with senior epidemiologist, Dr Kim Smits (University Hospital Maastricht, 
Netherlands).                                                                    
 
2.3 Mammalian cell culture and transfections 
 
2.3.1 Cell lines and subculture 
The human CRC cell lines SW480, SW620, and SW948 were originally obtained from the 
European Collection of Cell Cultures (ECACC), Wiltshire, UK, as growing cultures (Table 2.1). 
The SW480 cells had been stably transfected previously with DNA constructs encoding either 
EGFP-lamin A (SW480/lamA) or EGFP (SW480/cntl) (Willis et al, 2008). The GFP-lamin A full 
length cDNA was a kind gift from Dr M Izumi, Institute of Physical and Chemical Research, 
Saitama, Japan. Cells were routinely cultured in 75 cm² plastic tissue culture flasks under the 
following conditions: SW480, SW480/cntl, SW480/lamA and SW620 cells were cultured in L-
15 (Leibovitz medium) with 2 mM L-Glutamine (Invitrogen, UK) and HT29 and SW948 in 
DMEM (Dulbecco’s modiﬁed Eagle's medium) (Invitrogen, UK) supplemented with 10% 
foetal calf serum (FCS) lot 057K3395 (Sigma), 100 Uml
-1
 penicillin and 100 µgml
-1 
streptomycin. All cultures were maintained in a humidified environment at 37°C in either the 
presence of 5% CO2 (SW498) or absence of CO2 (SW480, SW480/cntl, SW480/lamA, SW620). 
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Upon 90% confluency, culture media was removed, cells were washed in Versene (137 mM 
NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, 1.5 mM EDTA pH 7.4) and subsequently 
detached from the flask in Versene containing 10% (v/v) trypsin in a humidified environment 
at 37°C for 3 minutes. Thereafter, cells were neutralised with either serum-containing L-15 
or DMEM media and centrifuged (Eppendorf 5810R) at 200 x g for 5 minutes. Supernatants 
were removed and cells were resuspended in fresh medium and seeded into new flasks. 
 
At the Department of Pathology, University Hospital Maastricht, Netherlands, human CRC 
cell lines HT29, LS and CaCo-2, all obtained from LGC (Teddington, UK), were cultured in 
DMEM supplemented with 10% FCS, 100 Uml
-1
 penicillin and 100 µgml
-1 
streptomycin (Table 
2.1). All cultures were maintained in a humidified environment at 37°C in the presence of 5% 
CO2. At approximately 90% confluency, cells were washed, trypsinised and seeded into new 
flask (as described above). Cells were routinely split 1:3 – 1:4. 
 
Table 2.1: CRC cell lines  
 
 
2.3.2 DAC treatment 
In order to investigate whether DNA methylation of the PLS3 promoter controlled T-plastin 
expression, two CRC cell lines (HT29 and SW948) were subjected to drug treatments that 
enable the detection of epigenetic modifications. Cells were seeded and allowed to reach 
30% confluency. At 30% confluency, HT29 and SW948 cells were treated with both 0.5 µM 
Cell line Description Dukes’ 
Stage 
Age Gender  Ethnicity Reference 
SW480 Human colon 
adenocarcinoma  
B 50 Male Caucasian (Leibovitz et al., 1976) 
SW620 Derived from a 
metastasis of the same 
tumour from which the 
SW480 was derived 
C 51 Male Caucasian (Leibovitz et al., 1976) 
SW948 Human colon 
adenocarcinoma 
C 81 Female Caucasian (Leibovitz et al., 1976) 
HT29 Human colon 
adenocarcinoma 
- 44 Female Caucasian (Chen et al., 1987) 
LS Human colon 
adenocarcinoma 
B 58 Female Caucasian (Rodrigues  et al., 1976) 
CaCo-2 Human colon 
adenocarcinoma 
- 72 Male Caucasian (Fogh et al., 1987) 
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and 2.0 µM of the methylation inhibitor 5-Aza-2’-deoxycitidine (DAC) (Ikeda et al., 2005).  
The culture medium containing DAC was replenished every 24 hours. Control cells were left 
untreated and replenished with fresh media. At 96 hours, cells were harvested, washed in 1 
x phosphate buffered saline (PBS), and RNA was isolated in order to examine T-plastin 
expression by quantitative real-time PCR (Chapter 2, Section 2.6). 
 
2.4 Nested methylation-specific PCR (N-MSP) 
 
2.4.1 Primer design 
Methylation specific PCR (MSP) is a quick and cost effective method which can rapidly assess 
the methylation status of a group of CpG sites within a given CpG island (Herman et al., 
1996). The assay consists of initial modification of DNA by sodium bisulphite, which converts 
all of the unmethylated cytosines to uracil, whereby methylated cytosines remain 
unchanged (Derks et al., 2004). This is followed by detection of unmethylated versus 
methylated DNA by PCR using primers specific for both. Since the DNA was obtained from 
formalin-fixed, paraffin-embedded tissues, a two-stage nested MSP was performed. Nested 
PCR was used because it can detect methylation more effectively in clinical samples, where 
DNA quality and quantity is limited (1 methylated allele in 50,000 unmethylated alleles). The 
first round of primers are designed to amplify sodium bisulphite-modified DNA and do not 
discriminate between methylated and unmethylated DNA (Table 2.2). Careful primer design 
is crucial for ensuring the success and specificity of MSP. Primers were designed with the 
following considerations: 
(a) The primers should be 23-30 bp in length to ensure specificity. 
(b) Primers should contain one to three CpG dinucleotides in the 3’ region of the primers. 
This allows for discrimination between methylated (M) and unmethylated (U) DNA and 
ensures specific annealing.  
(c) Primers must contain non-CpG cytosines in their sequence to retain specificity for sodium 
bisulphite converted DNA.  
(d) Both U and M primers should have similar melting temperatures (Tm). The GC content of 
the U primers is decreased upon sodium bisulphite conversion, so the U primer should to be 
extended into the 5’ region. Although this leads to variation in the start site it allows paired 
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analysis in a single thermocycler and ensures that products can be easily recognised after gel 
electrophoresis.  
(e) Primers for both methylated and unmethylated DNA should contain the same CpG sites 
to ensure sensitivity and specificity.  
(f) To facilitate MSP on fragmented DNA from formalin-fixed, paraffin embedded tissue 
sections, amplicons should be no more than 150 bp.  
 
Table 2.2: N-MSP PLS3 primer set 
 
2.4.2 DNA isolation 
A 4 µm section of each tissue block was previously stained with hematoxylin and eosin and 
reviewed by the senior pathologist, Professor Adriaan de Bruïne. Five sections (20 µm thick) 
were deparafinised and subjected to genomic DNA extraction by using a Puregene® DNA 
isolation kit (Qiagen) according to the manufacturer’s instructions. This method was also 
used to isolate DNA from CRC cell lines SW480, SW620, SW948, LS, CaCo2 and HT29. Briefly, 
CRC cells were harvested at 70% confluency then cell pellets were resuspended in culture 
medium in a 15 ml tube. Thereafter, cells were centrifuged at 500 x g for 3 minutes. The 
supernatant was removed leaving behind 100-200 µl residual liquid. The tubes were then 
vortexed to resuspend the cells in the residual supernatant. 3 ml of Cell Lysis Solution was 
added to each sample and pipette-mixed until no cell particulates were visible. Once the 
lysates were homogenous, 15 µl RNase A Solution was added to each sample, inverted 25 
times then incubated at 37°C for 1 hour. Once the samples had cooled to room temperature 
(RT), 1 ml Protein Precipitation Solution was added and vortexed vigorously for 20 seconds 
to mix the Protein Precipitation Solution uniformly with the cell lysates. Following this, 
samples were centrifuged at 2000 x g for 10 minutes. The supernatant containing the DNA 
was poured into a 15 ml tube containing 3 ml 100% isopropanol (2-propanol)                                   
then inverted gently 50 times. The samples were then centrifuged at 2000 x g for 3 minutes. 
Thereafter, the supernatant was discarded and the tube drained briefly on clean absorbent 
paper. Three ml 70% ethanol (EtOH) was added to the pellet and the tube inverted several 
Outside Flank up Flank down 
 YGGAGAAATTTTAGTTGGAGTTTT CCACTTAATACAATAAAATACAAAAAAC 
Inside Unmethylated (U) Methylated (M) 
Sense TGGAGTTTTTGGGTGTTTGGT TTTCGGGCGTTCGGGC 
Antisense CTTAATACAATAAAATACAAAAAACATATCTACA AATACAATAAAATACAAAAAACGTATTCTACG 
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times to wash the DNA. Samples were then centrifuged a final time at 2000 x g for 1 minute. 
The EtOH was carefully discarded and the tube pellet was allowed to air dry for 15 minutes. 
Following this, 250 µl of DNA Hydration Solution was added to each sample, and heated at 
65°C for 1 hour (tapping the tube periodically to aid in dispersing the DNA). The DNA was 
stored at 4°C. 
 
2.4.3 Sodium bisulphite conversion 
Sodium bisulphite modification, which converts unmethylated cytosine residues to uracil 
residues, was carried out on 500 ng genomic DNA isolated from CRC and normal tissue 
sections, in addition to CRC cell lines (HT29, SW620, SW948, SW480-GFP, SW480/lamA, 
CaCo2) with the use of an EZ DNA methylation™ kit (Zymo Research Co) according to the 
manufacturer’s instructions. Briefly, DNA samples were diluted to a concentration of 500 ng 
in a volume of 45 µl with sterile H2O. Five µl of M-Dilution Buffer was added to 45 µl of DNA 
samples in 1.5 ml DNase-free tubes, mixed gently by pipetting up and down and incubated at 
37°C for 15 minutes. Meanwhile, 750 µl of sterile water and 210 µl of M-Dilution Buffer was 
added to 1 tube of CT Conversion Reagent and mixed by vortexing for 10 minutes. 
Subsequently, 100 µl of the prepared CT Conversion Reagent was added to each sample and 
lightly vortexed. Samples were incubated at 55°C for 16 hours in the dark, followed by 
incubation on ice for 10 minutes. Thereafter, 400 µl of M-Binding buffer was added to each 
sample pipette mixed. The samples were transferred to Zymo-Spin I Columns, and the 
columns were placed into 2 ml collection tubes and centrifuged at 12,000 x g for 15-30 
seconds. The flow-through was discarded. Two hundred µl of M-Wash Buffer was added to 
each column, centrifuged for 30 seconds, and again the flow through was discarded. Then 
200 µl of M-Desulphonation Buffer was added and the samples were incubated at RT for 15 
minutes. After incubation, the samples were centrifuged at 12,000 x g for 30 seconds. 
Following this, samples were washed again with M-Wash Buffer and centrifuged at 12,000 x 
g for 30 seconds. The flow-through was discarded and the washing step was repeated, with 
columns centrifuged for an additional 1 minute to remove any excess buffer and dry the 
samples. The columns were then placed in fresh 1.5 ml sterile tubes, and 20 µl of M-elution 
buffer was added directly to the column matrix. Finally, samples were spun at 12,000 x g, the 
columns were discarded and the eluted DNA was stored at -20°C. 
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2.4.4 N-MSP 
In order to examine PLS3 promoter methylation, N-MSP was performed on sodium bisulfite- 
modified DNA. The PCR procedure requires both an outside and an inside primer pair and 
thus two ‘nested’ reactions. N-MSP was carried out in Multiplate® 96-well PCR plates (Bio-
Rad). For the outside MSP, 50 ng (4 μl) bisulphite treated DNA was added as a template to a 
total volume of 21 μl of the following reaction mix: 11.75 μl nuclease-free H2O, 2.5 μl 10x 
Magic buffer (166 mM NH4SO4, 670 mM Tris pH 8.8, 67 mM MgCl2, 100 mM beta-
mercaptoethanol), 1.25 μl of 6.25 mM dNTPs, 2.5 μl sense and antisense primers at a 
concentration of 20 μM and 0.5 μl Immolase™ DNA polymerase (Bioline) at 1U ul
-1
. The 
reaction mix was subjected to the following PCR conditions: 95°C for 3 minutes; then 35 
cycles of 95°C for 30 seconds, 56°C for 30 seconds, 72°C for 30 seconds, followed by 72°C for 
4 minutes. The PCR products from the outside reaction were subjected to a second ‘inside’ 
round of PCR, with unmethylated and methylated reactions being prepared separately. Each 
PCR product was diluted 1:1000 in 0.1x TE (1 mM Tris, 0.1 mM EDTA, pH 8.0). Four μl of 
template was added to 21 μl of the following reaction mix: 16.5 μl nuclease-free H2O 2.5 μl 
10x Magic buffer [166 mM NH4SO4, 670 mM Tris pH 8.8, 67 mM MgCl2, 100 mM beta-
mercaptoethanol], 0.25 μl dNTPs at 6.25 mM, 0.5 μl 50% glycerol, 0.5 μl each of sense and 
antisense primer (U or M) at 20 μM and 0.5 μl of 1U ul
-1
 Immolase™. The mix was subjected 
to the following PCR conditions: 95°C for 3 minutes; 35 cycles of 95°C for 30 seconds, 66°C 
for 30 seconds, 72°C for 30 seconds, followed by 72°C for 4 minutes. After thermocycling, 
the PCR products were stored at 4°C prior to analysis by agarose gel. 
 
2.4.5 DNA gel electrophoresis  
All amplified PCR products were run on 2% agarose gels in 0.5x TBE (45 mM Tris, 45 mM 
Boric acid, 1 mM EDTA pH 8.0) containing 5μl/100 ml GelStar™ stain to visualise DNA, at 100 
Volts (V) for 20 min. A loading dye was not required because Immolase™ is coloured. 
Product size was compared to a 100 bp DNA ladder (Promega Cat #G2101) and bands were 
visualised using a Gel Doc™ transilluminator and Quality One™ software, version 4.0.3 (Bio-
Rad). 
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2.5 Bisulphite sequencing 
 
2.5.1 Primer design 
In order to validate the N-MSP data, bisulphite sequencing was performed on sodium 
bisulphite modified DNA, as previously described. This assay allows for the exact positions of 
the 5-methylcytosine to be determined. The bisulphite sequencing primers are shown in 
Table 2.3. Primers were designed taking the following criteria into consideration: 
(a) To prevent unbiased amplification of either methylated or unmethylated DNA the 
primers should not hybridise across CpG sites.  
(b) Primers must contain an adequate number of non-CpG cytosines in their sequence to 
retain specificity for sodium bisulphite converted DNA. 
(c) Primers must flank the N-MSP primer site. 
(d) Primers products should be ~400 bp in length and contain a minimum of five CpG sites 
for analysis.  
 
Table 2.3: Bisulphite sequencing primers   
 
 
 
2.5.2 Amplification of sodium-bisulphite modified DNA and ligation 
into pCR®2.1 vector 
Bisulphite-modified DNA containing the PLS3 promoter was amplified from SW948 and 
SW620 cell lines, or patient normal and tumour tissue, using methylation specific primers 
just described. The PCR reaction was comprised of 18.75 μl water, 2.5 μl 10x Magic buffer 
(166 mM NH4SO4, 670 mM Tris pH 8.8, 67 mM MgCl2, 100 mM beta-mercaptoethanol), 0.25 
μl dNTPs at 5 mM, 0.5 μl each of forward and reverse primers at 2.5 μM and 1 μl of 1U μl
-1
 
Immolase™ with 2 μl of sodium bisulphite-treated template. The PCR protocol consisted of 
an initial denaturation at 95°C for 3 minutes; followed by 40 amplification cycles of 30 
seconds at 95°C, 30 seconds at 62°C, 30 seconds at 72°C and a final extension at 72°C for 10 
minutes. PCR products were checked by 2% agarose gel (as described in Chapter 2, Section 
2.4.5) and products from positive PCR reactions were directly ligated into the pCR®2.1 
cloning vector using a TOPO TA® Cloning Kit (Invitrogen, Breda, the Netherlands) according 
Gene ID Forward Reverse 
PLS3 AGTYGGGTTAGATTTAGGATTTTG ACCACTTAATACAATAAAATACAAAAAAC 
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the manufacturer’s instructions. Briefly, the 10 μl ligation reaction was composed of 1 μl PCR 
product, 0.5 μl Ligation buffer, 0.5 μl (2U) T4 DNA ligase, 1 μl linearised vector and 2 μl 
water. The ligation reactions were incubated at 14°C for 4 hours or overnight.  
 
2.5.3 Transformation 
The ligation mix (described in the Section 2.5.2) was used to transform TOP10 (Invitrogen) 
competent bacteria according to the following procedure. An aliquot of bacterial cells was 
thawed on ice and 1 μl ligation reaction was added gently to 15 μl of bacterial suspension. 
The mixture was left on ice for 30 minutes followed by heat shock for 30 seconds at 42°C. 
The cells were replaced on ice for 5 minutes prior to the addition of 125 μl SOC medium 
(0.5% yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 
mM glucose). The mixtures were incubated for 1 hour at 37°C in an Innova 4430 Incubator 
Shaker (Brunswick Scientific). Thereafter, 100 μl of the transformed bacterial suspension was 
spread onto LB (10 g bacto-tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar per litre, pH 7.5) 
agar plates containing 40 μl of 40 mg ml
-1
 X-gal dissolved in dimethylformamide. The plates 
were incubated at 37°C overnight. The next morning, the ratio of blue/white colonies was 
examined, with 5-25 blue colonies normally expected. A ratio of less than 1:10 blue:white 
colonies indicated an efficient transformation.  
 
2.5.4 Colony PCR 
The validity of recombinants were checked by PCR using universal M13 primers. 
Approximately 20 white colonies per plate were picked with a toothpick and used to 
innoculate both a PCR reaction mixture and 120 μl LB containing 100 μg ml
-1
 ampicillin.  The 
culture plates were incubated at 37°C with shaking at 270 rpm for several hours and the 
cultures were kept until the results from the PCR were known. The PCR reaction was 
composed of: 2.5 μl of PCR Buffer, 0.6 μl of 50 mM MgCl2, 1 μl of 5 mM dNTPs, 0.5 μl of 10 
μM of both M13 forward and reverse primers, 0.4 μl of Platinum® Taq (Invitrogen) and 15 μl 
water. The PCR profile consisted of a 95°C denaturation step for 10 minutes; 32 cycles of 
94°C for 30 seconds, 48°C for 45 seconds and 72°C for 45 seconds; followed by 10 minutes at 
72°C. The PCR products were analysed on a 2% agarose gel and compared with empty vector 
(245 bp). PCR products containing the correct insert (~550 bp) were selected for DNA 
sequencing.  
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2.5.5 Purification of recombinant DNA 
Two ml LB supplemented with 100 μg ml
-1
 ampicillin was inoculated with 5 μl of the 
appropriate miniculture suspension from the 96 well plate. After overnight growth at 37°C in 
a 270 rpm shaking incubator, purification of recombinant plasmids was performed using a 
GenElute™ Plasmid Mini-Prep Kit according to the manufacturer’s instructions (Sigma). The 
bacteria were pelleted at 12,000 x g for 1 minute and the supernatant removed. The cells 
were resuspended in 200 μl Resuspension Solution to which 200 μl lysis solution was added. 
Samples were inverted gently and allowed to clear for ~5 minutes. Following this, 350 μl 
Neutralisation Solution was added to each sample, inverted 4-6 times to mix and the debris 
removed by centrifugation at maxiumum speed for 10 minutes. A binding column was 
prepared by adding 500 μl of Column Preparation Solution and centrifuging the column at 
12,000 x g for 1 minute. The flow through was discarded and the lysate added to the column, 
prior to centrifugation at 12,000 x g for 1 minute. The column was washed with 750 μl wash 
solution, and centrifuged again at 12,000 x g for 1 minute, discarding the flow through. After 
drying the column by centrifugation at 12,000 x g for 1 minute, each column was transferred 
to a fresh collection tube. The DNA was eluted using 50 μl of nuclease-free water, by 
centrifuging the column for 1 minute at 12,000 x g. The DNA concentration of the eluate was 
measured using a NanoDrop spectrophotometer (Thermo Fisher Scientific, UK) and the DNA 
was stored at -20°C. 
 
2.5.6 DNA amplification and sequencing analysis 
The DNA amplification and sequencing was performed in collaboration with Mr Peter 
Moerkerk, University Hospital Maastricht, Netherlands. One hundred ng of recombinant 
DNA was used as a template for PCR in the following reaction mixture: 1.5 μl ABI reaction 
buffer, 1 μl ABI reaction mix, 3.2 μl of 1 μM M13 forward and reverse primers, made up to 
10 μl with nuclease-free water. The template was amplified by PCR according to the 
following parameters: 96°C for 3 minutes, 25 cycles of 96°C for 30 seconds, 50°C for 5 
seconds and 60°C for 3 minutes. The PCR products were purified on sephadex G50. Two 
grams of G50 were mixed with 25 ml water and swollen for several hours at RT or overnight 
at 4°C. Three hundred μl of mixed sephadex solution was pipetted into a 96 well filter plate 
with a dummy elution plate fixed beneath it. The plates were centrifuged for 3 minutes at 
1840 rpm and the flow through discarded. The dummy plate was replaced by a Corning 
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elution plate. Ten microlitres of water was added to each well of the filter plate containing 
sephadex, followed by loading of the DNA samples. The plates were spun at 1840 rpm for 3 
minutes to elute the DNA and the elution plate was sealed and taken for DNA sequencing by 
an automated DNA sequencer (Applied Biosystems, Foster City, CA).  
 
2.6 Quantitative real-time PCR 
 
2.6.1 Primer design 
Quantitative real-time PCR (qPCR) was performed to analyse mRNA expression levels of T-
plastin in 0.5 and 2.0 µM DAC-treated HT29 and SW948 CRC cell lines (Chapter 3.2.1). In 
addition, qPCR was also chosen to examine the mRNA expression levels of 11 genes from a 
microarray dataset (Chapter 6). To assist primer design, the PrimerBank was utilised to 
search for validated qPCR primers corresponding to the genes of interest, taking into 
account the possibility of alternatively spliced transcripts. PrimerBank is a public database 
containing over 300,000 human and mouse primer pairs for the detection and quantification 
of mRNA expression (http://pga.mgh.harvard.edu/primerbank). The programme selects 
suitable primers based on the following parameters: 
(a) Primers should be 19-23 nucleotides in length, to facilitate gene specificity and minimise 
the potential for primers to cross-react. 
(b) the primer GC content should be between 35-65%. 
(c) the ΔG threshold value for the last five residues at the 3’ end should be -9 kcalmol
-1
 to 
minimise non-specific primer extension. 
(d) Tm values of should be similar (between 60-63°C) to reduce non-specific amplification. 
(e) PCR products should be 150-350 bp. 
(f) Primer cross-reactivity should be minimised by checking the primers by BLAST analysis 
(g) Primers giving secondary structures in the target or primer should be avoided to 
maximise PCR efficiency. 
 
Gene Runner
© 
(Hastings Software Inc.) was used to facilitate the examination of possible 
secondary structure formations (e.g. hairpin loops, self-dimers) between and within primer 
pairs. In some cases, primers were optimised by removing or adding 1-2 extra nucleotides to 
the end of the sequence. The final primer sequences used in this chapter are detailed in 
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Table 2.4. Fifty nmol primers were synthesised (Invitrogen) and the primers were diluted in 
sterile water to produce a 10 μM working solution. 
 
Table 2.4: Primers for qPCR analysis 
 
 
 
 
 
 
 
 
 
 
 
2.6.2 Total RNA isolation 
Total RNA was isolated from SW480/cntl, SW480/lamA, HT29 and SW948 CRC cell lines using 
the RNeasy mini kit (Qiagen) according to the manufacturer’s instructions. Briefly, CRC cells 
were grown to approximately 70% confluency in 75 cm² tissue culture flasks and harvested 
as described in Chapter 2, Section 2.3.1. Cells were washed in 4 ml PBS prior to 
centrifugation at 200 x g for 5 minutes (Eppendorf 5810R). After the supernatant was 
removed, the cell pellets were resuspended in 600 µl RLT buffer and lysates were 
homogenised by vortexing for 1 minute. Subsequently, 600 µl of RNase-free 70% ethanol 
(molecular biology grade) was added to each homogenised lysate and pipette mixed. 
Samples were transferred to an RNeasy spin column placed in a 2 ml collection tube, then 
centrifuged for 15 s at 8,000 x g. The flow through was discarded. Thereafter, 700 µl RW1 
buffer was added to the spin column and centrifuged for 15 s at 8,000 x g. Again, the flow 
through was discarded. Following this step, 500 µl RPE buffer was added to each spin 
column and centrifuged for 15 s at 8,000 x g. The membrane was washed again in 500 µl RPE 
buffer and centrifuged for 2 minutes at 8000 x g. After discarding the flow through, the spin 
column was placed into a fresh 2 ml collection tube and centrifuged at 12,000 x g for 1 
minute ensuring that no residual RPE buffer was left and the membrane was fully dry.  The 
Gene ID Forward Primer Reverse primer 
AREG CCCAAAACAAGACGGAAAGTGA GCTGACATTTGCATGTTACTG 
BMP4 TGGTCTTGAGTATCCTGAGCG CTGAGGTTAAAGAGGAAACGA 
CDH1 TCTTCCCCGCCCTGCC CTAGCAGCTTCGGAACCGC 
COL18A1 GGCTGGCCTACGTCTTTGG CGGATGTGGAACAGCAGTGAG 
EGFR AAGGAAATCCTCGATGAAGCCT TGTCTTTGTGTTCCCGGACATA 
EIF4E AGGATGGTATTGAGCCTATGTGG CACAGAAGTGTCTCTAGCCAAAA 
EREG GCTCTGACATGAATGGCTATTGT TGTTCACATCGGACACCAGTAT 
FN1 GGCCTGGAACCGGGAACCGA AGGGTGGGTGACGAAAGGGGT 
GAPDH CATGAGAAGTATGACAACAGCCT AGTCCTTCCACGATACCAAAGT 
IGF2 CCTCCAGTTCGTCTGTGGG CACGTCCCTCTCGGACTTG 
PLS3 ACTCATGCTGGATGGTGACA GTTCCACCCAGAGCACAAAT 
SERPINE1 CATCCCCCATCCTACGTG CCCCATAGGGTGAGAAAACC 
SNAI2 ATACCACAACCAGAGATCCTCA GACTCACTCGCCCCAAAGATG 
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spin column was carefully removed and place into a new 1.5 ml collection tube. The RNA 
was eluted by added 30 µl RNase-free water and centrifuging for 1 minute at 8000 x g. 
Samples were stored at -80°C. 
 
2.6.4 Quantification and purity of RNA 
The concentration and purity of RNA was measured using a NanoDrop spectrophotometer 
(Thermo Fisher Scientific, UK). Briefly, 1 µl of sample was loaded onto the optical pedestal, 
the absorbance at 260 nm and 280 nm was measured, and the concentration of RNA was 
calculated. The A260:A280 ratio was used to assess RNA purity, with a value of 1.7-2.0 taken to 
indicate that the sample was sufficiently pure.   
 
2.6.3 cDNA synthesis 
Synthesis of cDNA was performed using an iScript kit (Biorad) in accordance with the 
manufacturer’s instructions. Briefly, 4 µl 5x iScript buffer, 1 µl iScript MMLV reverse 
transcriptase and 11 µl nuclease-free water were added to 4 µl (2 µg) of RNA template in 0.5 
ml PCR tubes. Reactions were incubated at 25°C for 5 minutes, followed by 42°C for 30 
minutes and then 85°C for 5 minutes. Synthesized cDNA samples were diluted in nuclease-
free water (Sigma) to give a final concentration of 20 ngµl
-1
. Aliquots were stored at -80°C. 
 
2.6.5 qPCR primer validation 
Prior to performing qPCR on the biological samples of interest, it is important assess the 
efficiency of the primers. For each primer set, qPCR was performed on a cDNA dilution series 
(0.1 ng – 100ng diluted to 1000x dilution). Quantitative real-time PCR was carried out in a 
MicroAmp® optical 96 well reaction plates (Applied Biosystems). Twelve point five µl Fast 
SYBR ®Green Master Mix (Applied Biosystems, Nieuwekerk a/d Ijssel, NL), 5 µl cDNA, 5.5 µl 
nuclease-free water, 1 µl forward primer (1000 μM) and 1µl reverse primer (1000 μM) were 
added to each well. A negative control containing no cDNA was run for each primer pair that 
was used. MicroAmp® optical adhesive film (Applied Biosystems) was placed on the top of 
the 96 well reaction plate to reduce contamination and evaporation. The plate was 
centrifuged briefly to remove bubbles. Reactions were run in a 7500 Fast Real-Time PCR 
System (Applied Biosciences). The qPCR profile was as follows: 95°C for 20 seconds, 40 cycles 
of 95°C for 3 seconds followed by 60°C for 30 seconds. Following this, a melt curve stage was 
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performed in which the samples were heated to 95°C for 15 seconds, cooled to 60°C for 1 
minute, slowly heated up to 95°C, and cooled to 65°C for 15 seconds. The baseline and 
threshold values were checked to confirm the validity of the automatically generated 
parameters. In a qPCR reaction, the fluorescence signal is measured during the exponential 
amplification phase because it provides the most accurate data for quantification. Cycle 
threshold (CT) values indicate the amplification cycle at which the fluorescent signal exceeds 
a threshold above the background signal (baseline). Thus, the lower the CT value, the higher 
the gene expression. A standard curve was plotted where X axis = log10[cDNA] and Y axis = 
CT values. Primers passed quality control testing if the gradient of the graph was between -
3.3 +/- 0.3 as this indicates that the efficiency of the PCR reaction is 100% +/- 10% and hence 
allows for meaningful gene comparison. All primers used within this thesis were deemed 
suitable for qPCR analysis (Supplementary Figure S1 A). 
 
2.6.6 qPCR  
Quantitative real-time PCR was carried out as described in 2.6.5 with 30 ng cDNA added to 
each well on the PCR plate. A negative control containing no cDNA was also run for each 
primer used. Three to five biological replicates were run in separate plates and three 
technical replicates were carried out in each individual plate. In order to establish the 
integrity of the qPCR product, melt curve analysis was automatically performed by the 7500 
Software v2.0.5 (Applied Biosystems). After the PCR cycling was complete, the temperature 
was raised at 1°C increments from 65°C to 95°C. As temperature rises, the PCR products 
denature, leading to a decrease in fluorescence. A single peak represents the decreased 
fluorescence at the melting point of the qPCR product, whereas primer-dimers or non-
specific products may appear as multiple peaks. Within our experimental data, single peaks 
were observed confirming the specificity of the primers and integrity of the qPCR products. A 
representation of melt curve analysis is shown in Supplementary Figure S1 B. Furthermore, 
the progression of the qPCR reaction can be observed in realtime in the form of an 
amplification plot where Y= ΔRn and X = number of cycles [ΔRn = (ROX™ fluorescence/SYBR 
Green fluorescence) – baseline] (Supplementary Figure S1 C). ROX™ is a reference dye within 
the mastermix that provides an internal fluorescence reference against which the SYBR 
green fluorescence can be normalised. A baseline can be obtained from the first cycles of 
qPCR in which fluorescence remains relatively constant. The CT values (as described above) 
can be obtained from this graph and were used to calculate the relative changes in gene 
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expression using the 2
-∆∆CT
 method (Livak and Schmittgen, 2001a). Relative quantification 
compares the gene expression in two or more samples and contrasts with absolute 
quantification, which calculates the number of copies of a specific RNA. The relative changes 
were normalised to an endogenous control gene, GAPDH. 
 
2.7 Generation of plastin polyclonal antibodies 
 
2.7.1 Animal selection 
Polyclonal antibodies are commonly produced in mammalian and avian species. To raise 
antibodies against plastins, the rabbit was chosen as it responds to a wide range of 
immunogens and yields large quantities of antibody. Two animals per antigen were selected 
in order to maximise the likelyhood of a strong and specific response to the antigen. 
 
2.7.2 Peptide immunogen design 
Peptides were used to raise the plastin antibodies (Table 2.5). In a peptide of 15-20 residues, 
there will be a limited number of potential epitopes and thus polyclonal sera raised against a 
short peptide sequence may have specificity and affinity characteristics similar to a 
monoclonal antibody. Plastin protein sequences were sent to Cambridge Research 
Biochemicals and three antigenic peptides were chosen using standard bioinformatic 
algorithms. Potentially immunogenic plastin peptides were designed to minimise unwanted 
cross-reactivitity with unrelated proteins. The sequences of the peptides and testing of the 
resulting sera are discussed in detail in Chapter 4. The antigenic peptides were designed 
bearing in mind the following principles: 
 (a) Peptides should correspond to loops in the parent protein to mimic the exposed 
sequences in the native protein. 
(b) Hydrophilic sequences are likely to be exposure at the surface. 
(c) N and C termini tend to be surfaced exposed. 
(d) Y and P residues help give structure to the peptide. 
(e) Repetitive sequences (three or more identical residues) should preferably be avoided as 
this often results in poor quality peptide and non-specific antibodies. 
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(f) Ideally, peptides should not include aspartic acid, as these residues may form 
aspartimides. 
(g) Long amino acid repeats, such as poly Q residues, should be avoided as hydrogen 
bonding can occur resulting in poor peptide synthesis and low solubility. 
 
Table 2.5: Peptides sequences for generation of plastin polyclonal antibodies 
 
 
 
 
2.7.3 Conjugation and antibody production 
Peptides are small molecules which would only elicit a very weak immune response. To 
circumvent this problem, 5 mg of antigen was conjugated to 5mg of a carrier, keyhole limpet 
haemocyanin (KLH), via the side chain thiol (-SH) of a cysteine residue with m-
Maleimidobenzoic acid N-hydroxysuccinimide ester (MBS). A standard CRB immunisation 
schedule was followed to yield a high affinity antibody after the secondary immune 
response. The antibodies were affinity purified on peptide conjugated sepharose beads to 
remove additional serum proteins and help reduce background staining. The antisera from 
the final bleed were purified using a peptide affinity column and eluted using a TEA buffer at 
pH 10. The purified antibody eluates were stored at -20°C at the following concentrations; 
Dann1a: 1.76 mgml
-1
, Dann1b: 1.11 mgml
-1
, Dann2a: 2.73 mgml
-1
, Dann2b: 0.96 mgml
-1
, 
Dann3a: 1.20 mgml
-1
 and Dann3b at 0.55 mgml
-1
. The antisera from all immunised animals 
were screened for anti-peptide antibody responses using an Enzyme-Linked Immunosorbent 
Assay (ELISA) in which the peptide antigen was adsorbed onto the ELISA plate (performed by 
Cambridge Research Biochemicals, UK). ELISA methods are immunoassays used for the 
detection and quantification of a substance based on antibody:antigen interactions 
(Hornbeck, 2001). Antibody binding to the peptide was quantified using an alkaline 
phosphatase labelled secondary antibody which was detected by the action of the enzyme 
on a chromogenic substrate (p-nitrophenyl phosphate). Affinity-purified antibodies were 
characterised by ELISA over a range of dilutions up to 1/100,000 and compared with the 
crude antisera. In addition, unbound antisera and TEA pH 4 eluates were tested against the 
immunising peptides. The antibody titre was determined by calculating the point at which 
Ab name Residues Peptide sequence 
Dann1 110-127 SELSSEGTQHSYSEEEKY 
Dann2 310-322 APKGQKEGEPRID 
Dann3 674-589 SGNLTEDDKHNNAKYA 
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absorbance of the chromagenic substrate was 50% of maximum. Antiserum obtained from 
each animal showed a relatively high titre of anti-peptide antibody, varying from 1:4283 
(Dann1a) to 1:43658 (Dann2a) (Supplementary Figure 2). The results from the ELISA analysis 
suggested that antibodies had been successfully raised against all three plastin peptides.  
 
2.8 Immunohistochemistry 
 
2.8.1 Antigen retrieval 
Formalin-fixed, paraffin-embedded tissue specimens obtained from the NLCS archive were 
previously sectioned into 4 µm slices and left overnight at 50°C to bond to Starforst® 
adhesive microscope slides (Knittel Glaser, Braunschweig, Germany). CRC tissue sections 
were then de-paraffinised in xylene, 2 x 5 minutes followed by 100% EtOH 2 x 5 minutes. 
Endogenous peroxidase activity was quenched by submerging the slides in 0.3% H2O2 in 
methanol for 20 minutes, followed by 3 minutes in distilled H2O. Thereafter, antigen 
retrieval was performed by immersing the tissue sections in Tris-EDTA buffer (10 mM Tris, 1 
mM EDTA pH 8) or in 0.01 M citrate buffer (pH 6) that had been pre-heated for 3 minutes in 
a microwave (850W). The slides were heated for 10 minutes at 360W. Following this the 
slides were allowed to cool to room temperature (RT) for 30 minutes before washing in 1 x 
PBS. Non-specific antibody binding was blocked using 5% bovine serum albumin (BSA) in 
PBS. After 30 minutes of blocking, slides were gently tapped onto blotting paper to remove 
the blocking solution.  
 
2.8.2 Antibody incubation and antigen visualisation 
Primary antibodies were diluted in 0.5% BSA in PBS and each section was incubated with 120 
µl primary antibody at 4°C overnight. Negative controls were incubated in 0.5% BSA/PBS, 
omitting the primary antibody. Post incubation, unbound primary antibody was removed by 
washing 3 x 3 minutes in PBS. Thereafter, each slide was incubated with 120 µl BrightVision 
(ImmunoLogic, NL) poly-HRP-anti-mouse/rabbit/rat IgG for 30 minutes at RT. Slides were 
then washed 3 x 3 minutes in PBS. Immunological detection was achieved by adding 120 µl 
activated 3,3-diamino-benzidine-tera hydrochloride (DAB) chromagen (Sigma). DAB was 
applied directly to tissue sections, and reactions were stopped by immersing sections in 
distilled H2O.  
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2.8.3 Counterstaining and mounting  
In order to visualise cell nuclei, sections were counterstained in haematoxylin for 20 seconds 
then rinsed in tap water for a few minutes. Slides were then dehydrated through a graded 
ethanol series: 70% EtOH for 3 minutes, 96% EtOH for 3 minutes and 2 x 100% EtOH for 1 
minute. Thereafter sections were cleared in 2 x xylene for 3 minutes. Specimens were 
mounted and covered with Entellan® (Merck kGaA, Darmstadt, Germany) and left to dry 
overnight.   
 
2.8.4 Photography 
CRC tissue sections were analysed using a Nikon Diaphot inverted microscope (Nikon 
Corporation, Tokyo, Japan) equipped for bright field microscopy with Plan 4x/0.13, 10x/0.25, 
20x/0.4 and 40x/1.3 lenses. Images were taken with a Nikon DXM1200 digital camera 
controlled by Nikon Act-1, version 2.20 software. Image processing was carried out using 
Adobe® Photoshop® 7.0 imaging software (Adobe Systems Inc, San Jose, CA, US). 
 
2.9 One-dimensional SDS-PAGE and immunoblotting 
 
2.9.1 Preparation of recombinant plastin proteins 
E. coli expressing GST fusion proteins of T-plastin (human), I-plastin (human) and L-plastin 
(mouse; the N-terminal half of the protein), plus a GST-only expressing control, were a kind 
gift from Dr Francisco Rivero, University of Hull. The fusion proteins have a molecular mass 
of ~96 kDa, with exception of the GST-L-plastin fusion protein (40 kDa). Stabs from each of 
these E.coli strains were grown up in a shaking incubator at 37°C in 5ml of sterile LB medium 
(10 g tryptone, 5 g yeast extract, 10 g NaCl per litre) supplemented with 100 μg ml
-1
 
ampicillin. Fusion protein synthesis was induced by the addition of 1 mM Isopropyl β-D-
thiogalactoside (IPTG) and 1 ml aliqouts were harvested at 0 hour, 1 hour, 2 hours and 3 
hours post-induction. The aliquots were centrifuged at 500 g for 5 min at 4°C. The 
supernatants were removed and the pellets were resuspended in 500 μl PBS, spun down at 
12,000 g for 2 minutes at 4°C and the pellets freeze-thawed using liquid nitrogen. The 
thawed pellets were resuspended in bacterial lysis buffer (PBS supplemented with 20 μg ml
-1
 
DNase, 0.1% Triton X-100, 100 μg ml
-1
 lysozyme and 1 μg ml
-1
 of protease inhibitor cocktail). 
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Aliquots of the bacterial lysate were taken up in an equal volume of  2X Laemmli sample 
buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue and 
0.125 M Tris HCl, pH 6.8.) for SDS PAGE/Western blotting analysis or were snap frozen for 
future use. Glycerol stocks of the E. coli strains were made by diluting 250 μl of exponentially 
growing cultures with an equal volume of sterile glycerol. The glycerol stocks were stored at 
-80°C. 
 
2.9.2 Preparation of mouse tissue 
Mouse tissue from liver, kidney, muscle and spleen was obtained from C57BL/6 mice. The 
tissues were rinsed in PBS, drained of excess fluid, cut into small pieces where necessary and 
snap frozen in liquid nitrogen. Frozen tissue was weighed, pulverised in a cold pestle and 
mortar and resuspended in lysis buffer (20 mM MES, 30 mM Tris, 100 mM NaCl, pH 7.4) with 
1% Triton X-100, supplemented with 20 μg ml
-1
 DNase and the following protease inhibitors: 
10 µgml
-1
 each of chymostatin, leupeptin, antipain and pepstatin A (Sigma). Lysates were 
homogenised with a syringe and needle and supernatants obtained by centrifugation for 10 
min at 4°C, 12,000 x g. The amount of protein present in the lysates after centrifugation was 
confirmed by colloidal Coomassie staining (Chapter 2, Section 2,9.6).  
 
2.9.3 Preparation of whole cell extracts 
Cultured SW480/lamA, SW480/cntl and SW620 cells in 72 cm
2
 dishes at 70-80% confluency 
(~ 8 x 10
6 
cells per cell line) were washed in PBS, and scraped in lysis buffer (20 mM MES, 30 
mM Tris, 100 mM NaCl, pH 7.4, with 1% Triton X-100 (Sigma), supplemented with the 
following protease inhibitors: 10 µgml
-1
 each of chymostatin, leupeptin, antipain and 
pepstatin A) using a blunt-ended plastic scraper. The cell lysates were transferred to 1.5 ml 
tubes and centrifuged at 12,000 x g for 10 minutes at 4°C to remove debris. Post nuclear 
supernatants were transferred to fresh tubes and either snap frozen in liquid nitrogen for 
later use, or mixed with an equal volume of 2X Laemmli buffer [125 mM Tris-HCL (pH 6.8), 
2% Sodium dodecyl sulphate (SDS), 2 mM dithiothreitol (DTT), 20% glycerol, and 0.25% 
bromophenol blue (w/v)] and boiled for 5 minutes prior to  SDS-PAGE analysis. The amount 
of protein present in the lysates after centrifugation was verified by Bradford assay or 
Coomassie staining described below in Sections 2.9.4 and 2.9.6, respectively.  
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2.9.4 Bradford assay 
A BioRad DC assay kit (Biorad) was used to assess protein content prior to SDS-PAGE. 
Standard curves were obtained using BSA as a protein standard. BSA solutions were made up 
from 0.5 mgml
-1
 to 1.5 mgml
-1
 in lysis buffer. Twenty microliters of Reagent S (5% SDS) were 
added to each ml of Reagent A (alkaline copper tartrate) that was required for the assay. 
Twenty µl of standards or samples were pipetted into fresh tubes, to which 100 µl of reagent 
A(S) was added. After vortexing, 800 μl reagent B (Folin reagent) was added and the tubes 
were vortexed again. After 15 minutes, the samples were transferred to cuvettes and the 
absorbance was read at 750 nm using a Biophotometer (Eppendorf).  
 
2.9.5 SDS-PAGE 
Cells or tissues were lysed in lysis buffer as previously described. Nuclei and cell debris were 
pelleted by centrifugation at 12,000 x g (Eppendorf) for 10 minutes at 4°C. Post-nuclear cell 
lysates, murine tissue supernatants or proteins from E. coli were taken up with an equal 
volume of 2X sample buffer (4 ml 10% SDS, 2 ml glycerol, 1.2 ml 1 M Tris, pH 6.8, 2.8 ml 
distilled H2O, 0.01% bromophenol blue) and 50 mM DTT as a reducing agent, heated at 95°C 
for five minutes and analysed by SDS-PAGE. The SDS-PAGE resolving gel consisted of 10% 
ProSeive® 50 acrylamide gel solution (Cambrex Bio Science Wokingham Ltd., Berkshire, UK), 
0.375 M Tris pH 8.8, 0.1% SDS, 0.1% APS, 0.04% TEMED. The stacking gel consisted of 5% 
ProSeive®, 0.125 M Tris pH 6.8, 0.1% SDS, 0.075% APS and 0.075% TEMED. The proteins 
were separated on a mini-gel system (Biorad) using Tris-Glycine SDS running buffer (25 mM 
Tris, 192 mM glycine, 0.1% SDS, pH 8.6, Sigma). The gels were run at a 100 V per gel for ~2 
hours, until the dye front reached the bottom of the gel. Page Ruler pre-stained ladder was 
used as a molecular weight marker (Fermentas). 
 
2.9.6 Coomassie blue staining 
 
To visualise proteins post-SDS-PAGE, colloidal Coomassie staining was used. First, SDS-PAGE 
gels were fixed in 7% glacial acetic acid in 40% (v/v) methanol for 1 hour. The gels were 
transferred to colloidal Coomassie solution (Sigma product B2025) activated in 20% 
methanol and incubated with rocking for 4 hours or overnight. Gels were destained with 
10% acetic acid in 25% (v/v) methanol for 60 seconds, rinsed twice with 25% methanol and 
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destained for up to 24 hours. The destained gels were briefly rinsed with distilled water prior 
to drying down onto Whatman paper (GE Healthcare) with a gel drier for 40 minutes at 80°C.  
 
2.9.7 Western blotting 
Proteins run on SDS-PAGE gels were transferred to PVDF (Millipore) membranes for 2 hrs 
using a wet mini-blotting apparatus and powerpack (Biorad PowerPac 300) set at 240 mA. 
The PVDF membranes were preprimed for 20 seconds in methanol and rinsed in transfer 
buffer (190 mM glycine, 25 mM Tris in 20% methanol). PVDF membranes were subsequently 
washed once in Tris buffered saline (25 mM Tris, 137 mM NaCl, 2.7 mM KCl, pH 8.0) with 
0.1% Tween®20 and blocked in 4% milk/TBST overnight at 4°C with constant agitation. After 
blocking, PVDF membranes were washed once in TBST. 
 
Detection of proteins was accomplished using a series of antibodies (Table 2.6). Membranes 
were incubated with primary antibodies diluted to their optimum working concentrations in 
a 50 ml tube containing 3 ml 1% milk/TBST for 1 hour at RT on a roller. After washing a five 
times with TBST, membranes were incubated with corresponding secondary antibodies 
GAMPO (Goat anti-mouse peroxidase) or SARPO (swine anti-rabbit peroxidase) from DAKO 
at 1:3000 in 1% milk/TBST for 1 hour. Thereafter, PVDF membranes were washed five times 
in TBST and visualised by ECL Plus (GE Healthcare). Solutions A and B from the ECL plus kit 
were mixed in a ratio of 40:1, with 500 μl solution being applied per membrane. After brief 
incubation under saranwrap (Dow) the membranes were drained of excess fluid, sandwiched 
in fresh saranwrap. Immunoreactivity was measured by recovering the signal of 
chemiluminescence on Biomax Light film (Kodak). Multiple exposures were made in the 
range of 20 seconds to 15 minutes and the films were developed using a compact X4 
Automatic X-ray Film Processor (Xograph Imaging Systems Ltd, Gloucestershire, UK).   
 
2.9.8 Peptide inhibition assay 
To test antibody specificity of the Dann antibodies raised against plastin, the following assay 
was used. Recombinant proteins were resolved on 10% SDS-PAGE gels as described above in 
Section 2.9.5. The separated proteins were transferred electrophoretically onto PVDF 
membranes and subjected to western blotting, as described in Section 2.9.7. After transfer 
and blocking with 4% milk/TBST, the membranes were incubated with antibody alone 
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(positive control), or antibody pre-blocked with peptide, for 30 minutes at RT with constant 
agitation. Since the plastin antibodies were used at an optimal dilution of ~1 ug ul
-1
, the 
peptides were used at a concentration of ~3 μg ml
-1
 (2x) and 30 μg ul-
1
 (10x). Non-specific 
peptides were used as a control. The peptides used in the assay were the same as those 
used for immunisation to generate the Dann1, Dann 2 and Dann 3 antibodies (Chapter 4). 
After incubating the PVDF membranes with antibody or with antibody blocked with peptide 
for 1 hour, the membranes were probed with swine anti-rabbit peroxidase (SARPO; DAKO) 
and developed by ECL Plus as described in Section 2.9.7.  
 
Table 2.6: Primary antibodies for Western blotting 
 
 
2.10 Bioinformatics 
 
2.10.1 DNA microarray dataset 
A genome-wide DNA microarray was previously carried out on SW480/cntl and SW480/lamA 
cell lines using the Human Genome U133 Plus high-density oligonucleotide Affymetrix 
GeneChip® array technology (Affymetrix, Santa Clara, CA, UDS) by Dr N Willis and Dr Thomas 
Cox, Durham University. The Affymetrix guidelines for the HG-U133 Plus 2.0 GeneChip were 
Antibody Target Antibody type Dilution Source 
AC-40 β-actin Mouse monoclonal 1:2000 Sigma 
Jol 2 Lamin A/C Mouse monoclonal 1:200 Dyer et al., 1997 
HECD-1 E-cadherin Mouse monoclonal 1:500 Abcam® 
ab54532 Cofilin Mouse monoclonal 1:200 Abcam® 
sc-8979 PAI-1 Rabbit polyclonal 1:200 Santa Cruz 
sc-03 EGFR Rabbit polyclonal 1:200 Santa Cruz 
L40C6 SNAI2 Mouse monoclonal 1:1000 Cell signalling 
HC10 MHC class 1 Mouse monoclonal 1:100 Kind gift from Dr Adam Benham 
ab45769 T-plastin Rabbit polyclonal 1:1000 Abcam® 
LPL4A.1 L-plastin Mouse monoclonal 1:500 Abcam® 
Dann1a Plastin Rabbit polyclonal * Cambridge Research Biochemicals 
Dann1b Plastin Rabbit polyclonal * Cambridge Research Biochemicals 
Dann2a Plastin Rabbit polyclonal * Cambridge Research Biochemicals 
Dann2b Plastin Rabbit polyclonal * Cambridge Research Biochemicals 
Dann3a Plastin Rabbit polyclonal * Cambridge Research Biochemicals 
Dann3b Plastin Rabbit polyclonal * Cambridge Research Biochemicals 
*assay dependent (see Chapter 4). 
88 
 
consulted to help filter and normalise the data, using the Affymetrix GeneChip Operation 
Software (GCOS). The microarray dataset analysis was briefly carried out in collaboration 
with Dr Dan Swan, Newcastle University and Dr Clare Foster, Durham University. Each gene 
on the microarray is represented by a probe set composed of eleven probe pairs, which 
provides for separate measurements of each transcript. These sequences are 25 bases long 
and cover ~600 bases of target sequence. The probe pairs include Perfect Match (PM) and 
Mismatch (MM) oligonucleotides, which differ in the central base pair only. The MM probes 
control for non-specific hybridisation. Constitutively expressed human genes are present on 
the microarray, as normalisation controls. 
 
The data arising from the microarray analysis was obtained as Cell Intensity files. These files 
contained the results of the microarray experiment as intensity calculations of the pixel 
values. The data were interrogated with GeneSpring GX10 (Agilent) and processed with the 
MAS5 algorithm to give the following values: Present (if the transcript was detected), 
Marginal (if the transcript was barely detectable) and Absent (if the transcript was 
undetected). Probes with one or more Present or Marginal values were analysed further 
after renormalisation using GCRMA (Guanine Cytosine Robust Multi-Array Analysis). This 
produced an intensity value for each set of probes. Genes were considered differentially 
expressed if there was a 2-fold or greater change in value between probesets when 
comparing the two cell lines. 
 
2.10.2 Ingenuity Pathway Analysis 
In order to extract the most relevant biological information, computational analysis of 
probesets showing greater than a 2.5-fold differential expression was performed by 
Ingenuity Pathway Analysis (IPA®). IPA is a web-based application which makes use of a 
database of biological interactions derived from an extensive network of modelled 
relationships between proteins, genes and metabolites as well as complexes, cells, tissues 
and diseases. The dataset was uploaded into IPA® and analysis was performed using 
standard settings to examine significance against biological functions, disease and canonical 
pathways (using Fischer Exact tests, and a p-value of <0.05). Eligible molecules or genes were 
algorithmically clustered into networks based on literature-curated interactions (Chapter 6).  
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Chapter 3: PLS3 promoter methylation in 
colorectal cancer   
 
3.1 Introduction 
Despite therapeutic innovations and increasing education on diet and lifestyle, CRC remains 
one of the most prevalent malignancies in the Western world (Jemal et al., 2010; Smits et al., 
2008). Prognosis of newly diagnosed cases principally relies on the Duke’s classification 
system, yet the 5-year survival rate of patients with CRC varies from 90% to 10% with 
tumour progression. Much effort has been made to identify molecular biomarkers that can 
predict patient prognosis and/or response to therapy (McLeod (Anwar et al., 2004; McLeod 
and Church, 2003; Zlobec and Lugli, 2008). Although many publications have claimed that 
various biomarkers offer prognostic or predictive value, the results are often inconclusive 
due to publication bias against negative results, false-positives and inappropriate study 
design owing to a lack of large sample sizes (Soreide et al., 2008; Newton et al., 2010; Lee 
and Chan, 2011). Discovering sensitive and specific biomarkers that enable the stratification 
of patients into appropriate screening or surveillance programmes will improve the 
detection, treatment and prognosis of CRC (Zlobec and Lugli, 2008). It is now well 
established that CRC is a heterogeneous disease, and can arise via at least three distinct 
pathways, CIN, MSI and CIMP (Draht et al., 2012). Whilst epigenetic alterations have 
received less attention than their classical genetic counterparts, they are perhaps more 
interesting as they can potentially be reversed by therapeutic intervention (Smits et al., 
2008). This, coupled with improved high-throughput technologies for the detection of 
methylation in cancer cells, offers great potential for use in the clinic (van Engeland et al., 
2010).   
 
DNA methylation is the most studied epigenetic alteration in CRC. It refers to the post-
replicative addition of a methyl group to the carbon 5’-position of cytosine, resulting in 5-
methylcytosine. DNA methylation is catalysed by DNMTS, which recognises CG dinucleotide 
sequences. CpG dinucleotides are not uniformly distributed throughout the genome, but 
instead are concentrated in CpG dinucleotide dense regions called CpG islands (Bird 1986). 
CpG islands are generally defined as 0.5 Kb – 2Kb sequences with a G:C content of >55%, 
located at the 5’ region in approximately half of all genes. In cancer, many of these CpG 
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islands become aberrantly methylated which results in transcriptional silencing. This is 
recognized as an important mechanism for the inactivation of tumour suppressor genes 
(Momparler, 2003). In contrast to normal tissues, cancer DNA is both globally 
hypomethylated at CpG dinucleotides in repetitive sequences (e.g. satellite repeats, 
endogenous retroviral elements) and is locally hypermethylated at discrete CpG sites that 
normally exist in the unmethylated state (Baylin et al., 1998). The recognition that a clinically 
distinct subset of tumours have a high degree of DNA methylation has led to the concept of 
CIMP (Issa, 2004). Tumours characterised by CIMP are thought to arise by the serrated 
adenoma pathway and have a different histology than tumours of the adenoma-carinoma 
pathway (Hughes, 2012).  
 
Previous studies in our laboratory have revealed that lamin A/C is a prognostic biomarker of 
CRC (Willis et al., 2008). Subsequent downstream investigations revealed that over-
expression of lamin A in the SW480 CRC cell line caused the cells to adopt a significantly 
more motile phenotype. In addition, T-plastin (encoded by the PLS3 gene) was upregulated 
in SW480/lamA compared with SW480/cntl cells, thus identifying PLS3 as a candidate gene 
for further exploration. T-plastin belongs to a family of actin binding proteins and is normally 
expressed in epithelial and mesenchymal cells but not in the colon; I-plastin is detected in 
the small intestine and colon but L-plastin is chiefly found in hematopoietic cells (Delanote 
et al. 2005). T-plastin has been implicated in a number of malignancies, and its expression is 
raised in cisplatin-resistant human bladder, prostatic, head and neck cancers (Hisano et al., 
1996). T-plastin is differentially expressed in some liver cancer cell lines, and cells with low 
levels of T-plastin become susceptible to DNA damage (Sasaki, et al. 2002; Ikeda et al, 2005). 
It has been suggested that down-regulation of T-plastin assists cancer development by 
encouraging entry into mitosis, but a mechanism to explain this theory has not been 
established. 
 
The PLS3 gene (which encodes T-plastin) is located on chromosome Xq23, spans 60 kilobases 
and contains 16 exons. The PLS3 promoter contains one CpG island (Lin et al., 1999). It has 
previously been shown that PLS3 gene expression was suppressed in a human CRC cell line 
because of promoter-specific DNA methylation (Sasaki et al. 2002). To our knowledge, PLS3 
promoter methylation has never before been studied in primary human colorectal tumours. 
The aim of this chapter was to investigate PLS3 promoter methylation in both CRC cell lines 
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and primary human CRCs using the NLCS tissue archive and to test the hypothesis that 
aberrant methylation of the PLS3 promoter leads to dysregulation of T-plastin gene 
expression (Figure 3.1). Given the importance of lamin A/C and T-plastin in CRC, we explored 
the potential of PLS3 methylation as a risk biomarker to be used in combination with lamin 
A/C. 
 
 
 
         
                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Study design of the Netherlands Cohort Study on Diet and Cancer (NLCS) (adapted from 
Hughes, 2011). 
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3.2 Results 
 
3.2.1 PLS3 promoter methylation and mRNA expression in CRC cell 
lines 
The promoter region of the PLS3 gene (National Centre for Biotechnology Information [NCBI] 
accession number NM_005032.3) contains a 431 bp CpG island located in the promoter from 
nucleotides -70 to +361 relative to the transcription start site (TSS) (Figure 3.2). Primer sets 1 
and 2 were designed in a region within the promoter and tested by nested methylation-
specific PCR (N-MSP) on sodium-bisulphite treated genomic DNA. These primers were tested 
by a Masters student in Maastricht. It was concluded that primer pairs 1 and 2 were not 
suitable for further use as they were unable to amplify and discriminate between 
methylated and unmethylated DNA (data not shown). Consequently, we designed and 
optimised primer set 3b (Supplementary Figures S3-S5). This primer pair was determined to 
be optimal with 35 cycles of amplification and an annealing temperature of 66°C (data not 
shown). 
 
Figure 3.2: PLS3  promoter structure and N-MSP primer location 
Schematic representation of the PLS3 (T-plastin) promoter. A CpG island is located between 
nucleotides -70 to +361 relative to the transcription start site (TSS). Vertical lines represent the 
approximate locations of the CpG dinucleotides, the orange rectangle represents the open reading 
frame (ORF) of PLS3, and paired arrows indicate the location of the amplicons identified by N-MSP.  
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To assay this region for potential methylation, we examined six CRC cell lines by N-MSP using 
primers located from nucleotides +239 to +351 relative to the transcription start site (TSS). A 
representative panel of CRC cell lines were chosen for analysis: the male cells lines SW480, 
SW620 and CaCo-2 and the female cell lines LS, HT29 and SW498 (Chapter 2, Table 2.1). The 
PCR products were analysed on a 2% agarose gel. The PLS3 promoter was found to be 
methylated in SW948 and HT29 CRC cell lines. All the other cell lines (SW620, SW480, LS, 
CaCo-2) were unmethylated (Figure 3.3). In order to validate this finding and investigate the 
pattern of CpG methylation within the PLS3 promoter, we designed sequencing primers to 
detect sodium bisulphite-modified genomic DNA isolated from SW620 (PLS3 promoter 
methylation negative) and SW948 (PLS3 promoter methylation positive) (Supplementary 
Figure S6). This assay allows the analysis of the PLS3 promoter methylation at single 
molecule resolution. The promoter region spanning 26 CpG sites (+47 to +355 relative to the 
TSS) was amplified by PCR using sodium bisulphite-modified genomic DNA as a template 
(Figure 3.4). PCR products were ligated into the pCR®2.1 cloning vector using a TOPO TA® 
cloning kit and transformed into E. coli (Chapter 2, Section 2.5.2-2.5.3). Colony PCR was 
performed to check the integrity of the recombinants (Supplementary Figure S7). Plasmid 
DNA minipreps were prepared from six independent bacterial clones harbouring the inserts. 
The clones were sequenced to determine the sites that had been methylated using an 
automated DNA sequencer (Supplementary Figures S8-S10). Bisulphite sequencing 
confirmed the N-MSP PCR data in that SW948 cells showed almost complete methylation. 
For example, one clone had 26/26 sites methylated whereas SW620 cells showed no 
methylated CpGs (Figure 3.5). It should be noted that some CpG islands in the PLS3 
promoter from SW948 cells were always methylated (e.g. sites at 71, 99, and 102 bp) 
whereas other sites were variably methylated. Next, we sought to examine the relationship 
between aberrant promoter methylation and gene expression. Cells lines that were 
methylated (SW948 and HT29) (Figure 3.3) were subjected to epigenetic drug treatment. 
CRC cell lines HT29 and SW948 were incubated with and without the DNA methylation 
inhibitor 5-aza-2’deoxycitidine (DAC). DAC is an analogue of cytosine, that when 
incorporated into DNA, irreversibly binds to DNA methyltransferase. This prevents the 
enzyme from functioning, resulting in passive de-methylation and gene restoration (Santi et 
al., 1983). In both cell lines, endogenous T-plastin mRNA was significantly higher in DAC 
treated cells than in untreated cells, as determined by quantitative real-time PCR (qPCR). For 
example, in the SW948 cells, 0.5 μM treatment of DAC led to approximately 4-fold increase 
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(p = 0.05) and 2 μM led to 8-fold increase (p = 0.01). Similar results were obtained for the 
HT29 cell line, showing a 3-fold and 4-fold increase in T-plastin mRNA expression after 0.5 
μM and 2 μM DAC treatment, respectively (p = 0.02 and 0.001) (Figure 3.6). 
 
 
 
 
 
 
 
 
 
Figure 3.3: PLS3 promoter methylation in CRC cell lines 
Electrophoretic analysis of N-MSP amplification products in six CRC cell lines: SW620, SW948, SW480, 
LS, HT29, and CaCo-2. IVD (in vitro methylated) and NL (normal lymphocytes) are methylated 
controls and HUVEC (human umbilical vein endothelial cells) is an unmethylated control. U = 
unmethylated, M = methylated. Data shows that the PLS3 promoter is methylated in SW948 and 
HT29 CRC cell lines. 
 
 
 
 
 
 
 
 
 
Figure 3.4: Amplification of bisulphite-modified DNA from CRC cell lines  
Electrophoretic analysis of bisulphite-modified DNA containing the PLS3 promoter from SW948 and 
SW620 cell lines. Negative H2O control indicates no contamination in the samples. The 309 bp PCR 
products were ligated into the pCR®2.1 cloning vector using a TOPO TA® Cloning Kit for subsequent 
transformation into E. coli and bisulphite sequencing analysis. 
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Figure 3.5: Bisulphite sequencing of SW948 and SW620 CRC cell lines 
Schematic representation of bisulphite sequencing in SW948 (upper panel) and SW620 cell lines (lower panel). Six different bacterial clones per tissue sample 
were sequenced. Each row represents an individual cloned allele that was sequenced following sodium bisulphite DNA modification. Each box indicates a CpG 
dinucleotide (black box = methylated CpG site, white box = unmethylated CpG site). Data shows that the PLS3 promoter in the SW948 cell line is predominantly 
methylated, whereas the PLS3 promoter in the SW620 cell line is exclusively unmethylated. Red boxes indicate the end of the amplicons. 
+47 +355 
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Figure 3.6: T-plastin mRNA expression is restored after treatment with 5-aza-2’-doxycytidine 
T-plastin mRNA expression in SW948 and HT29 CRC cells with and without treatment with the DNA 
methylation inhibitor 5-aza-2’-doxycytidine (DAC). Quantification is presented as mean values 
relative to untreated cells from three independent experiments (normalisation was against GAPDH). 
Statistical analysis was performed using the student t-test (two-sided). Error bars correspond to the 
standard error of biological replicates. * = statistical significance. Data shows that in the SW948 and 
HT29 cell lines, T-plastin was increased approximately 3-4 fold with 0.5 μM of DAC compared to 
controls cells (SW498; 0.5 μM p = 0.05, 2 μM p = 0.01. HT29; 0.5 μM p = 0.02, 2 μM p = 0.001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SW948 HT29 
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3.2.2 PLS3 promoter methylation in normal colonic mucosa and 
primary colorectal carcinomas 
After establishing that the PLS3 promoter was methylated in CRC cell lines SW948 and HT29, 
PLS3 promoter methylation status was investigated in non-cancerous colonic mucosa and in 
a subset of genomic DNA samples extracted from the NLCS tissue archive. We performed N-
MSP using the same primer pair used to assess the methylation status in CRC cell lines 
(Figure 3.2). This was done firstly on non-cancerous (normal) colonic mucosa. As methylated 
controls, in vitro methylated DNA and DNA from normal lymphocytes was used. DNA from 
human umbilical cord was used as a negative control (as in Figure 3.3). The frequency of 
promoter methylation in normal mucosa was 13/20 (65%) (Figure 3.7). Next, the prevalence 
of PLS3 promoter methylation was examined in bisulphite-treated genomic DNA from 161 
primary tumours (a subset from the CREAM archive, Figure 3.1). A selection of the results 
from this analysis is shown in Figure 3.8 and the entire data set is shown in Table 3.1. The 
frequency of methylation in this cohort was approximately 50%.  
 
As with the cell lines, we wanted to validate the N-MSP data by bisulphite sequencing and 
provide a high-resolution map of the methylated sites within the PLS3 promoter in both 
normal and tumour tissue. The bisulphite sequencing primers that were shown to work 
previously (see Figure 3.4 and 3.5) were used to amplify a 309 bp product within the CpG 
island located in the PLS3 gene promoter. Initially, we tried to amplify a 309 bp region from 
the patients DNA (previously isolated from ‘fixed’ paraffin-embedded, formalin-fixed tissue). 
However, it was not possible to detect any amplification products from either methylated or 
unmethylated examples with the sequencing primers, due to poor quality, fragmented DNA 
(Figure 3.9 lanes 5-8). In contrast, DNA could be amplified from frozen material (Figure 3.9, 
lanes 1-4) and from the cell lines that were analysed previously (Figure 3.9), confirming that 
the PCR itself worked. As it was not possible to obtain DNA from any fixed samples, it was 
decided to investigate and compare the pattern of methylation between frozen tumour 
material and the corresponding normal colonic mucosa. To do this, an additional subset of 
CRC and matching normal colon tissue (unfixed, frozen material) was screened for their 
methylation status (Figure 3.10). Five of the eight patients were methylated at the PLS3 
promoter in both normal and tumour tissues. However, three of the eight patients showed 
methylation differences. Patient 1 lacked any methylation of both tumour and normal tissue 
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whereas patients 4 and 7 were methylated in normal colonic tissue and were unmethylated 
in the tumour tissue. These were taken for further analysis. The relative T-plastin mRNA 
expression of these three patients was measured by qPCR (Figure 3.11). Data shows that 
there was no difference between T-plastin mRNA expression between normal and tumour 
tissue in Patient 1 (Figure 3.11 A). In contrast, the relative expression of T-plastin was 
significantly higher in tumour tissue from patients 4 and 7, compared to their corresponding 
normal colonic mucosa (p = 0.03 and 0.04, respectively). These results are consistent with 
the methylation data shown in Figure 3.10 and suggest that the PLS3 promoter is 
demethylated in CRC, which results in aberrant expression of T-plastin. 
 
The PCR products of normal and tumour DNA from patients 1, 4 and 7 were subjected to 
bisulphite sequence analysis, using the same primer set as previously described. The 
promoter region spanning 26 CpG sites (+47 to +355 relative to the TSS) was amplified by 
PCR using sodium bisulphite-modified genomic DNA as a template (Figure 3.12). PCR 
products were ligated into a TOPO-TA cloning vector, and transformed into E. coli. Colony 
PCR was performed to check the validity of the recombinants (Supplementary Figure S11). 
Plasmid DNA minipreps were prepared from six independent bacterial clones harbouring the 
correct inserts. These clones were subsequently sequenced using an automated DNA 
sequencer (Supplementary Figures S12-S13). Data showed that there was no methylation in 
the PLS3 promoter region in any of the clones analysed (Figure 3.13). This was unexpected 
and does not confirm the N-MSP data. This may be due to the fact that bisulphite 
sequencing is not sensitive enough to detect low levels of methylation from formalin-fixed 
DNA samples.  
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Figure 3.7: PLS3 promoter methylation in normal colonic mucosa 
Electrophoretic analysis of MSP amplification products of normal colonic mucosa from 20 patient 
samples. IVD (in vitro methylated DNA) and NL (normal lymphocytes) are methylated controls and 
HUVEC (human umbilical vein endothelial cells) are an unmethylated control. U = unmethylated, M = 
methylated. Data shows that the prevalence of methylation in normal colonic mucosa was 65%. 
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Figure 3.8: PLS3 promoter methylation in primary colorectal tumours 
Electrophoretic analysis of MSP amplification products in 28 patient tumour samples. Numbers refer 
to the patient sample identity. IVD (in vitro methylated DNA) and NL (normal lymphocytes) are 
methylated controls and HUVEC (human umbilical vein endothelial cells) is an unmethylated control. 
U = unmethylated, M = methylated. Data shows that the prevalence of PLS3 methylation is 
approximately 50%. 
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Table 3.1: Prevalence of PLS3 promoter methylation in 161 CRC patient samples
3 U 98 U 232 U 312 I 382 U 544 M 643 M 765 U 
4 M 110 U 234 M 315 U 384 I  546 I 645 M 768 U 
6 M 112 U 237 U 318 M 390 U 548 U 650 M 774 U 
7 U 119 M 238 M 319 I 395 U 558 M 652 M 778 M 
8 U 122 M 239 M 321 M 405 U 560 I 657 U 784 U 
11 M 123 M 241 M 334 U 406 M 563 M 660 U 785 U 
12 M 137 U 242 M 336 U 408 U 564 U 665 M 790 M 
13 U 150 U 243 M 338 I 411 U 566 I 666 M 791 U 
14 U 153 U 251 M 340 I 418 U 567 U 675 U 802 U 
17 I 154 U 256 I 342 U 432 I 571 U 681 M   
22 M 164 U 257 M 344 M 435 U 574 U 689 M   
23 I 166 U 260 M 345 M 446 U 576 I 693 U   
25 U 168 M 263 M 348 U 448 M 579 I 696 U   
27 M 169 M 273 U 350 U 450 M 581 M 697 U   
32 U 173 I 275 U 353 U 458 M 587 U 699 M   
37 U 174 M 277 U 359 U 459 M 590 U 700 M   
43 U 184 M 279 M 360 M 462 M 594 U 712 U   
47 U 185 M 280 M 364 M 473 U 598 I 717 U   
54 M 187 M 281 U 368 I 488 M 600 U 719 M   
59 M 194 U 286 M 371 M 491 U 602 M 731 U   
61 M 196 U 287 M 374 M 503 I 606 U 738 U   
68 U 198 I 298 U 375 M 505 M 618 M 739 U   
80 U 213 M 308 M 376 M 509 U 623 M 744 U   
82 U 221 M 309 M 379 U 532  I 626 M 748 I   
84 I 230 M 310 U 380  I 540 M 642 M 754 M   
I = Insufficient DNA 
n = 161 
Methylated (M) = 
78 (48%) 
Unmethylated (U) 
= 83 (52%) 
102 
 
 
 
 
 
 
 
 
 
Figure 3.9: Amplification of bisulphite-modified DNA from human CRC tissue and cell lines 
Electrophoretic analysis of bisulphite-modified DNA containing the PLS3 promoter from sequencing 
amplification products from frozen tissue (lanes 1-4), formalin-fixed tissue (lanes 5-8) and CRC cell 
lines (SW948 and SW620). No PCR products were obtained for fixed tumour material (paraffin-
embedded), compared with unfixed (frozen) material and CRC cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: PLS3 promoter methylation in colorectal carcinomas and corresponding normal colonic 
mucosa from a small independent subset 
Electrophoretic analysis of N-MSP amplification products from carcinomas and adjacent normal 
colon from eight colorectal cancer patients. All material is from fixed samples. IVD (in vitro 
methylated DNA) and NL (normal lymphocytes) are methylated controls and HUVEC (human 
umbilical vein endothelial cells) is an unmethylated control. U = unmethylated, M = methylated.  T = 
tumour, N = normal. Data shows that five of the eight patients were methylated at the PLS3 
promoter in both normal and tumour tissue. Three patients exhibited differences in their 
methylation pattern. 
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Figure 3.11: T-plastin mRNA expression in colorectal carcinomas and corresponding normal  
colonic mucosa from three patients 
T-plastin mRNA expression measured by qPCR in human tumour versus normal tissue from (A) 
patient 1 (B) patient 4 and (C) patient 7 (from Figure 3.10). For each patient, the level of T-plastin 
expression in normal mucosa tissue was set to 1. Data are presented as mean values relative to 
normal mucosa from 3 independent experiments. Normalisation was against GAPDH. Error bars 
correspond to standard error of technical replicates. Statistical analysis was done using the student t-
test (2-sided). * = statistical significance. Data shows that relative T-plastin expression is elevated in 
tumour samples from patients 4 and 7 compared to their corresponding normal mucosa. Patient 1: p 
= 0.69; Patient 4: p = 0.03, Patient 7: p = 0.04. 
 
 
 
 
 
 
 
 
Figure 3.12: Amplification of bisulphite-modified DNA from frozen normal and tumour tissue and 
CRC cell lines 
Electrophoretic analysis of bisulphite sequencing amplification products. CVRC cell lines (SW948 and 
SW620) and tumour versus normal tissue from patients 1, 4 and 7 (Figure 3.11) was analysed. PCR 
products were obtained from all samples. Negative H2O control indicates no contamination in the 
samples. The 309 bp PCR products were ligated into the pCR®2.1 cloning vector using a TOPO TA® 
Cloning Kit for subsequent transformation into E.coli and bisulphite sequencing analysis. 
 1             4            7 
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Figure 3.13: Bisulphite sequencing of normal colon versus tumour tissue from three CRC patients 
Bisulphite sequencing of tumour (T1, T4 and T7) and the matched normal colonic mucosa (N1, N4 and N7) from three CRC patients. Six different bacterial 
clones per tissue sample were sequenced. Each row represents an individual cloned allele that was sequenced following sodium bisulphite DNA 
modification. Each box indicates a CpG dinucleotide (black box = methylated CpG site, white box = unmethylated CpG site). No methylated residues were 
found in any of the replicates. Red boxes indicate the end of the amplicon. 
N1 
T2 
N4 
N7 
T7 
T4 
N4 
+47 +355 
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3.2.3 Patient analysis 
The 161 patients from the N-MSP analysis included in this study developed cancer between 
1989 and 1994. Information on mortality from 1
st
 January 1989 until 1996 (7 years) was 
retrieved through linkage with the Central Bureau for Statistics. CRC related death was 
concluded if CRC was determined to be either the primary cause of death or as a primary, 
secondary or tertiary complication, using the ICD system. Differences in patient, tumour and 
follow-up characteristics were analysed using the Chi-square (χ²) test. Kaplan-Meier analysis 
was selected to investigate survival. This is a more comprehensive statistical approach 
compared with Chi-square (χ²) cross-tabulation. This is due to the fact that Kaplan-Meier 
analysis takes into account censored data, that is otherwise lost from the sample before the 
final outcome is observed (e.g. if a patient dies before the end of the follow-up, but not as a 
result of CRC). Hazard ratios (HR) (an estimate of the relative effect of a variable [e.g. PLS3 
methylation status] on an event [e.g. CRC mortality]) and corresponding 95% confidence 
intervals (CI) for CRC-related mortality according to plastin status were estimated using Cox 
regression analysis. All analysis was perfomed using SPSS. This work was carried out in 
collaboration with senior epidemiologist, Dr Kim Smits, University Hospital Maastricht.  
 
3.2.3.1 PLS3 methylation versus tumour progression and location  
Initial baseline analysis was performed on all patient and tumour characteristics in relation 
to CRC-related mortality (outlined in Table 3.2). The study population characteristics 
appeared to be normal with 53% (n = 84) of patients being male and 47% (n=77) of patients 
being female. Interestingly, there was a statistically significant difference between PLS3 
promoter methylation status and sex (Figure 3.14 A; Table 3.2). Male patients were 
predominantly unmethylated for PLS3; 72/84 (86%) and female patients were predominantly 
methylated for PLS3; 66/77 (85%) (p = <0.0001). There was no difference in age at diagnosis 
and CRC-related mortality (p = 0.566). Similarly, there was no statistically significant 
difference between CRC-related death and methylation status (p = 0.512).  
 
Classification using Dukes’ staging system were as follows: Dukes’ A, 49% methylation (n = 
17), Dukes’ B, 42% methylation (n = 22), Dukes’ C, 52% methylation (n = 27) and Dukes’ D, 
60% methylation (n = 9) of the PLS3 promoter. There was no association between PLS3 
promoter methylation plastin expression status and Dukes stage (p = 0.557) (Figure 3.14 B). 
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However, there does appear to be a striking difference between PLS3 promoter methylation 
status and tumour location (p = 0.044). Methylation of the PLS3 promoter is highest in the 
proximal (right-sided) colon with a prevalence of 58% and decreases to 28% in the rectum 
(left-sided). Conversely, the PLS3 promoter is unmethylated with a prevalence of 42% in the 
proximal (right-sided) colon which increases to 72% in the rectum (Figure 3.15).  
 
Table 3.2: PLS3 promoter methylation in relation to clinicopathological characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PLS3 (U)  PLS3 (M) p-value 
CRC related death, No 50 43  
CRC related death, Yes 33 35 0.512 
Lamin A/C expression 43 43  
Lamin A/C lack of expression 34 24 0.309 
Age at diagnosis, mean (SD) 68.1 (4.3) 67.8 (4.3) 0.566 
Proximal 24 32  
Distal 23 28  
Rectosigmoid 12 9  
Rectum 23 9 0.044 
Dukes’ A, N 18 17  
Dukes’ B, N 31 22  
Dukes’ C, N 25 27  
Dukes’ D, N 6 9 0.557 
Male patients, N 72 12  
Female patients, N 11 66 <0.0001 
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Figure 3.14: PLS3 promoter methylation in relation to sex and Dukes’ stage 
(A) Histogram of PLS3 promoter methylation by sex assessed using 161 patient tumour samples. 
There is a statistically significant difference between PLS3 promoter methylation and sex (p = 
<0.0001). (B) Histogram of PLS3 promoter methylation by Dukes’ stage. There is no association 
between the prevalence PLS3 promoter methylation and Dukes’ stage (p = 0.557). Statistical analysis 
was performed using the Chi (χ²) test. All p-values are two-sided. 
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Figure 3.15: PLS3 promoter methylation in relation to tumour location 
Histogram of PLS3 promoter methylation by tumour location assessed using 161 patient samples. 
There is a statistically significant difference between PLS3 promoter methylation and tumour location 
(proximal, distal, rectosigmoid and rectum) (p = 0.044). Statistical analysis was performed using the 
Chi (χ²) test. All p-values are two-sided. 
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3.2.3.2 PLS3 promoter methylation and patient survival  
In order to examine whether PLS3 promoter methylation could be an independent 
prognostic biomarker, two statistical analyses were carried out. Firstly, Kaplan-Meier curves 
were produced to estimate survival probability. Kaplan-Meier curves are an estimate of the 
survivor function. The time in the study represents a clinical endpoint, in this case, death 
from CRC. The study baseline is t = 0. Survivor function S(t) is the proportion of the 
population still alive at time t. Secondly, Cox regression analysis using the Breslow method 
for ties was performed to estimate the cumulative hazard. Cox regression (or proportional 
hazards regression) is the method for investigating the effect of several variables upon the 
time a specified event takes to happen, i.e. death from CRC. The cumulative hazard at time t 
is the risk of dying between time 0 and time t, and the survivor function at time t is the 
probability of surviving to time t. Co-efficients or hazard ratios above 1 indicate a worse 
prognosis (i.e. the hazard, CRC-related mortality, is more likely to occur) and a coefficient of 
less than 1 indicates a protective effect of the PLS3 promoter methylation. A coefficient of 1 
indicates no effect of PLS3 promoter methylation on the likelihood of hazard occurrence. 
Data shows that there is no statistically significant correlation between PLS3 promoter 
methylation in a population where expression of lamin A/C is a biomarker for CRC cancer 
(Willis et al., 2008) (Figures 3.16-3.17; Table 3.2).  
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Figure 3.16: Kaplan-Meier survival analysis for all Dukes’ stages 
(A) Kaplan-Meier plots of cumulative survival for CRC patients in relation to lamin A/C expression. 
Data shows that there is a statistically significant correlation between lamin A/C expression and 
survival. Relative hazard ratio (HR) = 0.48 (95% C.I. = 0.27 – 0.73), p = <0.001 (adjusted for gender 
and age at diagnosis). (B) Kaplan-Meier plot of cumulative survival for CRC patients in relation to 
differential PLS3 promoter methylation. Data shows that there is no statistically significant 
correlation between PLS3 methylation and survival. Relative hazard ratio (HR) = 1.13 (95% C.I. = 0.58-
2.23, p = 0.438) (adjusted for gender and age at diagnosis). 
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Figure 3.17: Kaplan-Meier survival analysis for Dukes’ A, B and C patients 
 (A) Kaplan-Meier plots of cumulative survival for CRC patients in relation to lamin A/C expression. 
Data shows that there is a statistically significant correlation between lamin A/C expression and 
survival. Relative hazard ratio (HR) = 0.52 (95% C.I. = 0.27-0.86), p = 0.0003 (adjusted for gender and 
age at diagnosis). (B) Kaplan-Meier plot of cumulative survival for CRC patients in relation to 
differential PLS3 methylation. Data shows that there is no statistically significant correlation between 
PLS3 promoter methylation and survival. Relative hazard ratio (HR) = 0.89 (95% C.I. = 0.41-1.93, p = 
0.767) (adjusted for gender and age at diagnosis). 
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3.3 Discussion 
Aberrant CpG island promoter hypermethylation can result in transcriptional silencing, and 
this phenomenon has been widely investigated with respect to both CRC progression and 
prognostic and therapeutic applications (Lao and Grady, 2011). In this study, the aim was to 
investigate PLS3 promoter methylation in CRC. N-MSP was the method of choice as this 
approach allows robust and sensitive genomic DNA from formalin-fixed, paraffin-embedded 
clinical samples (Derks et al., 2004). However, it should be noted that the PLS3 gene contains 
only one CpG island of just 431 bp (Figure 3.2). Designing appropriate primer pairs to assess 
the methylation within the CpG island was difficult, due to the small size of this stretch of 
DNA. However, following successful optimisation of previously established protocols, we 
showed that methylated and unmethylated alleles could be discriminated, and that the 
technique was both reliable and reproducible. Of the CRC lines analysed by N-MSP, two 
were methylated in the PLS3 promoter (SW948 and HT29; Figure 3.3). However, although N-
MSP is quick and simple to use, there are limitations. It is not a quantitative assay and should 
normally be confirmed by bisulphite sequencing, which allows for quantitative analysis of 
methylation status at single molecule resolution. To this end, unmethylated (SW620) and 
methylated (SW948) CRC cell lines were chosen for bisulphite sequencing analysis. Bisulphite 
sequencing primers were successfully designed, allowing for the examination of 26 
methylation sites. Data confirmed that the PLS3 promoter in the SW948 cell line is indeed 
methylated and exclusively unmethylated in the SW620 cell line (Figure 3.5).   
 
In order to investigate the relationship between PLS3 promoter methylation and gene 
expression, SW948 and HT29 cells were subjected to epigenetic drug treatment. Our data 
demonstrates that epigenetic silencing of the PLS3 promoter by methylation occurs in CRC 
cell lines and can be reversed by inhibiting DNA methyltransferases (Figure 3.6). This is 
consistent with the finding by a Japanese group, who demonstrated by PCR that the PLS3 
gene in SW948 cells is deactivated by methylation (Sasaki et al., 2002; Ikeda et al., 2005). 
 
In the SW948 clones that were analysed, there were clearly two methylation ‘hotspots’ 
towards the transcription initiation start site. Whether PLS3 promoter methylation initiates 
at a particular region within the CpG island then spreads downstream toward the 
transcription start site cannot be deduced from these data. It would be interesting to see 
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whether methylation-associated transcriptional silencing occurs in a region-specific manner. 
Moreover, it would be useful to explore how these sites relate to the binding of transcription 
factors, and also how the methylation machinery gains access to the PLS3 CpG island. It is 
also worth bearing in mind that the methylation pattern in SW948 varies between the six 
replicates (Figure 3.5). This is common in methylation analysis, and reflects the fact that the 
assay is an ‘average’ of material from heterogeneous cells, which may all have slightly 
different methylation patterns (Herman et al., 1996; Derks et al., 2004). Improvements in 
single cell PCR and sequencing techniques, coupled with laser capture micro-dissection, will 
eventually allow us to visualize the methylation landscape of PLS3 (and other promoters) in a 
tumour in finer detail in the future. 
 
In order to investigate the PLS3 methylation in human CRC, we analyzed a subset of DNA 
samples from the NLCS archive. To the best of our knowledge, no-one has investigated PLS3 
promoter methylation in a large cancer series to date. This study allowed PLS3 promoter 
methylation to be investigated in a population in which lamin A/C was known to be a 
predictor of poor prognosis. Again, utilising the N-MSP method, we found that the 
prevalence of PLS3 promoter methylation was 65% in normal colonic mucosa (13/20) and 
48% (78/161) in tumour tissue (Figure 3.7; Table 3.1). Given that T-plastin is reported to be 
absent from normal colonic epithelia (where the I-plastin isoform is normally expressed), the 
frequency of PLS3 promoter methylation is expected to be higher. However, sample sizes for 
normal colon (n=20) were much lower the tumours (n=161). Moreover, there are likely to be 
other mechanisms controlling gene expression and an unmethylated gene promoter does 
not necessarily mean that T-plastin expression is switched on in any given cancer cell. 
Additional mechanisms such as mRNA and protein half-life, or regulation by microRNAs 
could be involved in modulating T-plastin expression. Indeed, a small nucleolar RNA, 
SNORA64, lies just upstream of the PLS3 gene; one possibility is that the methylation status 
of the PLS3 promoter (and the surrounding DNA) might influence the transcription and 
activity of SNORA64 (Kiss, 2002). It would be informative to explore whether SNORA64 
transcription is reduced in SW948 compared with HT29 cells, and if so whether inhibition of 
methylation restores its expression. 
 
We attempted to validate the methylation status of PLS3 in the human DNA samples by 
bisulphite sequencing analysis. However, a limitation of this approach is that it is often 
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difficult to retrieve enough DNA for sequencing from formalin fixed tissue held in historical 
archives. This proved to be the case for the analysis of PLS3 promoter methylation in tumour 
samples (Figure 3.9). To solve this problem, a prospective, rather than retrospective, study 
could be performed and the methylation status of PLS3 could be analyzed using DNA from 
fresh frozen tissue. However, the disadvantage of such a prospective study would be that 
little or no survival data would be available at the time of sampling, and as such, may be of 
limited statistical use. 
 
By using qPCR, we showed that T-plastin mRNA expression in two CRC patients was 
significantly elevated in tumour tissue, compared with its normal counterpart (Figure 3.11). 
The N-MSP analysis corroborated this finding (Figure 3.10), suggesting that PLS3 promoter 
methylation may silence gene transcription. However, this conclusion was made on the 
assumption that methylation status, as determined by N-MSP, is indeed correct. Surprisingly, 
bisulphite sequencing analysis did not confirm the N-MSP data; the PLS3 promoter from 
patients 4 and 7 appeared to be methylated by N-MSP analysis, but unmethylated by 
bisulphite sequencing analysis (Figure 3.12). This discrepancy could be due to several 
reasons. Firstly, although bisulphite sequencing is highly specific, the information obtained 
for each clone is from one amplicon. PCR products from the N-MSP however, represent 
thousands of amplicons. Thus, if there are only small levels of methylation in the patient 
material, it may be difficult to detect using the bisulphite sequencing approach. Secondly, it 
is possible that CpG sites up or downstream of the promoter are methylated and that the full 
landscape of PLS3 methylation is different from the region that has been sequenced in this 
chapter. It has recently been shown that methylation of CpG sites outside of the well-
defined CpG island can be responsible for gene inactivation (Rach et al., 2011). This may call 
into question the definition of a CpG island (Fernandez et al., 2011). 
 
It is clear from the data in this chapter that PLS3 promoter methylation is involved in 
silencing T-plastin expression in vitro (Figure 3.6), although we saw no prognostic effect in 
tumour samples (Table 3.2). Analyses of clinicopathological characteristics revealed that 
there was no association between PLS3 promoter methylation and survival. However, some 
of the observations made during the analysis in this chapter merit further investigation. For 
example, there was a remarkable difference in PLS3 promoter methylation between the 
sexes (p = <0.0001) (Figure 3.14). Over 85% of the female samples analysed were methylated 
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for PLS3 and over 85% of male samples were unmethylated for PLS3. The T-plastin gene is 
expressed on the X-chromosome, so it would be very interesting to see whether X 
chromosome inactivation of PLS3 occurs and how this is affected by the onset of CRC. Of the 
cell lines examined in this Chapter, two female cell lines (HT29 and SW498) were methylated 
whereas one female cell line (LS) was unmethylated, suggesting that there is no simple 
relationship between X-inactivation and PLS3 methylation. Interestingly, a recent meta-
analysis of 5 genome-wide association studies (GWAS) identified a new common variant 
linked to CRC risk on the X chromosome at Xp22.2 (Dunlop et al., 2012). The risk loci on 
Xp22.2 does not reside near the PLS3 gene but is close to the SHROOM2 gene, whose normal 
function is to regulate melanosome biogenesis and endothelial morphogenesis. Of note, 
Shroom2 localises to cell-cell adhesion loci and binds to cortical actin (Etournay et al., 2007; 
Farber et al., 2011). Farber and co-investigators showed that loss of Shroom2 activity leads 
to an increase in migration and angiogenesis. The Nature Genetics report (Dunlop et al., 
2012) was the first published example of an X-chromosome variation in a non-sex linked 
cancer. This lends weight to the notion that T-plastin, a gene on the X-chromosome, can be 
involved in both male and female cancer development.  
 
It was also notable from our study that PLS3 methylation status appeared to differ between 
tumour locations, there being least methylation in the left-sided (LCC) and more methylation 
in right-sided (RCC) CRC (Figure 3.15). It has been known since the 1980s that are sex-specific 
differences between left-sided and right-sided CRCs. More women than men tend to have 
RCC, RCCs tend to be more advanced and survival of patients with LCCs tends to be greater 
(Benedix et al., 2010). Our finding that PLS3 is more likely to be methylated in females and 
more likely to be methylated in RCC is consistent with this observation. These findings 
should be followed up to determine T-plastin protein expression in female right sided CRC, 
and it remains possible that PLS3 methylation status could be useful as part of the CIMP 
biomarker panel in this cohort. As the number of samples within each category is small, 
further sampling and analysis is important to validate these findings. It would also be 
necessary to include information about smoking, alcohol consumption and obesity in any 
subsequent analysis since these risk factors may have independent associations with either 
LCC or RCC. 
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In summary, we have investigated PLS3 promoter methylation in a large CRC cohort, and 
whilst PLS3 promoter methylation cannot be used as an independent prognostic biomarker, 
our data suggests that PLS3 promoter methylation is an important mechanism of 
transcriptional silencing. Moreover, demethylation of the PLS3 promoter may lead to 
aberrant expression of T-plastin in tumour tissue. Given that T-plastin functions as an actin-
bundling protein, once may hypothesise that increased expression of the protein, brought 
about by demethylation of the promoter, results in changes in the cytoskeletal architecture 
that favours growth and metastasis. 
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Chapter 4: Characterisation of polyclonal plastin 
antibodies 
 
4.1 Introduction 
The actin cytoskeleton is a dynamic meshwork that is an essential component of all 
eukaryotic cells and is involved in many biological phenomena such as cell division, 
organisation of cytoplasmic organelles and intracellular compartments, cellular motility, 
cellular adhesion, and control of cell shape (Pollard and Cooper, 1986). In cancer, many of 
these characteristics of normal cell behaviour are lost or perturbed. For example, in tumour 
metastasis, cancer cells acquire migratory and invasive capabilities in order to leave the 
primary tumour and disseminate through the body to a secondary site (Toyooka et al., 
2006). This process involves a dramatic reorganization and remodelling of the actin 
cytoskeleton and the concomitant formation of membrane protrusions required for invasive 
growth. Importantly, this overall organization of the actin cytoskeleton is tightly controlled 
by a plethora of actin-binding proteins including α-actinin and filamins, which are involved in 
cross-linking and anchoring glycoproteins to the cytoskeleton (Dos Remedios et al., 2003). 
Plastins also belong to this family of actin-binding proteins (known as actin-bundling 
proteins) which are conserved from lower eukaryotes to humans (Lin et al., 1999; Shinomiya 
et al., 1994). These polypeptides function to stabilize and rearrange the organization of the 
actin cytoskeleton in response to external stimuli (Bretscher, 1981; Delanote et al., 2005; 
Glenney et al., 1981; Namba et al., 1992). 
 
Members of the plastin family have a modular structure which consists of an amino terminal 
domain (10 kDa) with two EF-hand motifs, and two ABDs, each divided into two tandemly 
arranged CH domains. Each CH domain is composed of four α-helical segments, three of 
which form a loose bundle of helices, with the fourth α-helix sitting perpendicular to the 
main bundle. These segments are connected by extended and variable loops (Delanote et 
al., 2005). 
 
Plastins normally localise to various actin-rich membrane structures involved in locomotion, 
signalling, adhesion and immune defense, including focal adhesions, ruffling membranes, 
filopodia and the phagocytic cup. Moreover, plastins are also located in highly specialized 
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surface structures with ordered microfilament bundles such as stereocillia. This is of 
particular interest, as actin bundles formed by plastin may also have a mechanosensory 
function by sensing mechanical alterations in signals during chemosensory signal 
transduction (Daudet and Lebart, 2002).  
 
As previously mentioned, the different plastin isoforms have been implicated in a number of 
cancers (Ikeda et al., 2005; Leavitt, 1994; Otsuka et al., 2001; Sasaki et al., 2002a). The 
expression of L-plastin, for example, is induced in many types of malignant human cells of 
non-hematopoietic origin, suggesting that its expression accompanies tumourigenesis in 
solid tissues. Foran and co-workers (2006) found that overexpression of L-plastin in SW480 
cells leads to the loss of E-cadherin and hence increased proliferation and invasiveness. T-
plastin has been associated with both drug and radiation resistance in cancer cells; increased 
expression of T-plastin has also been reported in cisplatin-resistant human cancers (Hisano 
et al., 1996). In our laboratory, we have shown that RNAi knockdown of T-plastin results in 
decreased motility in CRC cells (Willis et al., 2008). Moreover, qPCR analysis demonstrated 
that T-plastin mRNA expression is elevated in tumour tissue compared to matching normal 
colonic mucosa (Chapter 3, Figure 3.11). Given that both increased T and L-plastin 
expression may be important in the progression of CRC, plastin isoform-specific antibodies 
might be useful as tools for biomarker studies. Antibodies can be used in a wide range of 
situations where characterisation, quantification, and localisation of proteins are required 
(Brehm-Stecher and Johnson, 2004; Norman E, 1999). Importantly, the use of antibodies has 
proved invaluable in diagnostic and therapeutic applications. The aim of this chapter was to 
characterise six commercially produced rabbit polyclonal antibodies raised against three 
immunising peptides and to examine their plastin isoform specificity (Figure 4.1).  
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Figure 4.1: Schematic representations of human plastin isoforms 
Domain organisation in human plastin isoforms. A scale (in amino acids) is displayed at the top of the 
schematic. Each plastin contains two amino-terminal EF hands, and two actin binding (ABD) domains. 
Each ABD consists of two calponin (CH) domains. Human T-plastin contains an nuclear export signal 
(NES), and L-plastin contains a phosphorylation site. The locations of the immunising peptides used 
to produce the antibodies are shown. The number in parenthesis corresponds to the amino acid 
residues. Dann1 is located in the N-terminus, Dann2 is located in ABD1, and Dann3 is located in ABD2 
(adapted from Delanote et al. 2005). 
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4.2 Results 
 
4.2.1 Sequence alignments of plastin isoforms 
As shown in Figure 4.2, T-, L- and I-plastin are homologous proteins. A sequence alignment 
of the human plastin isoforms using UniProt shows that they share approximately 70% 
homology in the amino acid sequence. T and L-plastin are 83% identical. Three human 
peptides to be used for immunisation were designed against exposed regions of the protein 
that were likely to be antigenic. For the Dann1 peptide, four out of 18 residues vary between 
T, L- and I-plastin. Only two of these residues vary between T and L-plastin. For the Dann2 
peptide, four of the 13 residues are different. The Dann3 peptide resides in a region that 
differs in five of the 16 residues.  
 
To verify whether antibodies against these peptides would be likely to recognise both 
human and rodent cells and tissues, an alignment of T-plastin in human, mouse and rat was 
performed (Figure 4.3). The alignment confirms that the sequences are highly similar 
(highlighted in grey). There are no differences in the human, mouse and rat T-plastin in the 
peptide sequence corresponding to Dann1 or Dann2. Just two out of 16 residues differ 
between rat and human in the Dann3 peptide, with this region being identical between 
human and mouse. The alignment suggests that T-plastin is not under rapid natural 
selection, and confirms that the antibodies have the potential to be used on human or 
mouse material. 
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Figure 4.2: Alignment of human T-plastin with L-plastin and I-plastin. 
The full-length protein sequences of T-plastin (PLST, P13797), L-plastin (PLSL, P13796) and I-plastin 
(PLSI, Q14651) were aligned using the Uniprot program. The peptides used for immunisation are 
indicated by lines above the sequence: Dann1 (red), Dann2 (purple) and Dann3 (green).  
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Figure 4.3: Alignment of human T-plastin with mouse and rat T-plastin 
The full-length protein sequences of human T-plastin (PLST, P13797), mouse T-plastin (PLST, Q99K51) 
and rat T-plastin (PLST, Q63598) were aligned using the Uniprot program. Regions of identity are 
shaded dark grey. The sequences corresponding to the Dann1 peptide (red) and Dann2 peptide are 
identical in human, mouse and rat T-plastin. The sequences corresponding to the Dann3 peptide 
(green) are identical between human and mouse, but not rat.  
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4.2.2 Characterisation of the polyclonal Dann antibodies  
 
4.2.2.1 Producing recombinant plastins to test reference antibodies 
To assess the reactivity and specificity of the Dann antibodies, recombinant proteins against 
T-, L- and I-plastin were expressed in E. coli. The plastin-expressing bacteria were obtained as 
a kind gift from Dr Francisco Rivero (University of Hull). Bacterial protein expression was 
induced by adding IPTG to the cultures, and samples were taken at 0 hr, 1 hr, 2 hr and 3 hr 
post-induction. After lysis, the bacterial proteins were analysed by SDS-PAGE and Coomassie 
stained to verify the expression of the fusion proteins. Figure 4.5 shows that each 
recombinant plastin and the GST-fusion control had been expressed. Note that expression 
was detected prior to induction in all four cases (Figure 4.4 A-D), since recombinant protein 
was visible at the 0 hr time points. Each fusion protein was expressed at the predicted 
molecular weight, and they were the most abundant proteins in the lysates. The GST-control 
was expressed at 25 kDa, GST-T-plastin at 96 kDa, GST-L-plastin (only N-terminal) at 40 kDa, 
and GST-I-plastin at 96 kDa.  
 
The protein lysates from the 3-hour time point were tested using antisera against T-plastin, 
L-plastin, and an affinity-purified antibody against I-plastin, kindly provided by Dr. Francisco 
Rivero (Figure 4.5 A-C) and commercially available antibodies from Abcam (Figure 4.5 D-E). 
The T-plastin antisera strongly recognised T-plastin as expected, resulting in an intense 
smear on Western blot (Figure 4.5 A, lane 2). This antibody also detected recombinant L-
plastin. Surprisingly, more background was detected in the GST-only lane than in the I-
plastin lane (Figure 4.5 A, lanes 1 and 4). In contrast, the L-plastin antisera did not specifically 
detect L-plastin at the 1:1000 dilution used in these experiments (Figure 4.5 B). This antibody 
did recognise a background band present in all bacterial lysates; hence this antibody was 
used as a control for protein loading in subsequent peptide inhibition experiments. The I-
plastin antibody did specifically recognise the recombinant I-plastin at ~96 kDa (Figure 4.5 C, 
lane 4), consistent with the recombinant protein band seen on Coomassie (Figure 4.4). The 
Abcam antibody against GST-T-plastin was specific (Figure 4.6 D), as was the Abcam antibody 
against GST-L-plastin, both producing a signal at ~96 kDa (Figure 4.5 E). Note that both 
Abcam antibodies recognised likely degradation products. 
     
 
124 
 
 
 
Figure 4.4: Coomassie staining of recombinant plastin proteins  
Plastin expression was induced for 0 hr, 1 hr, 2 hr or 3 hr with 1 mM IPTG. Protein lysates were 
resolved by 10% SDS-PAGE prior to staining with colloidal Coomassie. (A) GST-control (B) T-plastin (C) 
L-plastin (D) I-plastin. Arrows indicate specific GST-fusion expression. Molecular weight markers are 
given in kDa. The recombinant proteins are induced at each time point analysed. Each fusion protein 
was expressed at the predicted molecular weight; GST-control at 25 kDa, GST-T-plastin (human) at 96 
kDa, GST-L-plastin (mouse) at 40 kDa and GST-I-plastin (human) at 96 kDa. 
 
 
 
 
 
     
 
125 
 
 
Figure 4.5: Western blotting analysis of plastin GST-fusion proteins 
Lysates from bacteria three hours after induction with IPTG were analysed by 10% SDS PAGE, 
transferred to PVDF membrane and immunoblotted. GST-cntl, GST-T-plastin, GST-L-plastin, and GST-
I-plastin with probed with (A) crude T-plastin antisera. (B) L-plastin antisera (C) affinity purified I-
plastin antibody (D) a commercially available T-plastin antibody and (E) a commercially available L-
plastin antibody. Molecular weight markers are given in kDa. Arrow denotes specific band at 
predicted molecular weight. Asterisk denotes background band. Note that the T-plastin antisera gave 
a strong background; the L-plastin antisera  gave a signal in all lysates including the GST control. The 
I-plastin antibody gave a specific signal against the GST-fusion protein at the predicted molecular 
weight of 96 kDa. Both Abcam antibodies produced a signal at the predicted molecular weight of 96 
kDa. 
* 
* 
* 
* 
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4.2.2.2 Characterising the Dann1a antibody against recombinant plastins 
The recombinant proteins were used to test the specificity of the Dann antibodies, starting 
with Dann1a. Bacterial lysates containing each recombinant GST-fusion protein were run on 
10% SDS-PAGE as before, transferred to PVDF membranes and immunoblotted with Dann1a 
at 1:100, 1:500 and 1:1000 dilution (Figure 4.6). The 1:100 dilutions gave a strong signal for 
both L-plastin and T-plastin (Figure 4.6 A, lanes 2 and 3). No signal was detected against the 
GST-only lysate or the I-plastin lysate, demonstrating the specificity of the antibody for T- 
and L-plastin (Figure 4.6 A, lanes 1 and 4). At 1:100 dilution, four bands were seen in the T-
plastin lane, most likely corresponding to degradation products or truncated protein 
products. Titrating the antibody out to 1:1000 gave a clear single band for both T and L-
plastin, at the expected molecular weights for the fusion proteins (~96 kDa and ~40 kDa, 
respectively). This experiment demonstrates that the Dann1a antibody detects both T-
plastin and L-plastin, as expected from the sequence alignment (Figure 4.2). The antibody 
did not detect any non-specific bacterial proteins, since no signal was observed in the GST-
control lysate.  
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Figure 4.6: Characterisation of Dann1a antibodies by Western blot analysis 
Lysates from bacteria expressing GST-fusion proteins were analysed by 10% SDS-PAGE, transferred to 
PVDF membrane and immunoblotted. GST-cntl, GST-T-plastin, GST-L-plastin, and GST-I-plastin were 
probed with (A) Dann1a at 1:100 dilution (B) Dann1a at 1:500 dilution and (C) Dann1a antibody at 
1:1000 dilution. Molecular weight markers are given in kDa. Arrow denotes specific band at predicted 
molecular weight. Asterisk denotes background band. Dann1a specifically recognised both GST-T-
plastin at a predicted molecular weight of 96 kDa and GST-L-plastin at a predicted molecular weight 
of 40 kDa. The optimal dilution was 1:1000. 
 
 
 
 
 
 
 
 
 
 
 
* * 
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4.2.2.3 Characterising the Dann1b, Dann2a, Dann2b, Dann3a and Dann3b 
antibodies against recombinant plastins 
Having demonstrated that the Dann1a antibody recognises T-plastin and L-plastin, Dann1b, 
Dann2a, Dann2b and Dann3a were taken for analysis (Figure 4.7 A-D). At 1:500 dilution, the 
Dann1b antibody recognised T-plastin and L-plastin as expected (Figure 4.7 A, lanes 2 and 3). 
Multiple bands were observed in this experiment and some signal was detected in the I-
plastin lane (Figure 4.7 A, lane 4). The Dann3b antibody at 1:500 recognised T-plastin at the 
predicted molecular weight. However, this antibody also produced multiple background 
bands (Figure 4.7 E, lane 2). In contrast, the Dann2a and Dann3a antibodies did not 
recognise the recombinant plastins at all (Figure 4.7 B and D). The most promising result was 
obtained with the Dann2b antibody, which recognised a single band at the expected 
molecular mass for T-plastin (Figure 4.7 C). The Dann2 and Dann3 antibodies were not 
expected to recognise the GST-L-plastin fusion protein, because only the N-terminus of L-
plastin was encoded in the fusion protein. 
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Figure 4.7: Characterisation of Dann1b-3b antibodies by Western blot analysis 
Lysates from bacteria expressing GST-fusion proteins were analysed by 10% SDS-PAGE, transferred to 
PVDF membrane and immunoblotted. GST-cntl, GST-T-plastin, GST-L-plastin and GST-I-plastin were 
probed with (A) Dann1b at 1:500 dilution (B) Dann2a at 1:100 dilution (C) Dann2b antibody at 1:100 
dilution (D) Dann3a antibody at 1:100 dilution and (E) Dann3b antibody at 1:500 dilution. Molecular 
weight markers are given in kDa. Arrow denotes specific band at predicted molecular weight. 
Asterisk denotes background band. Dann1b was unspecific as a signal was detected in all three 
lysates. Dann2a and Dann3a produced no signal against the lysates. Dann2b was specific against GST-
T-plastin at a predicted molecular weight of 96 kDa. Dann3b detected multiple bands against GST-T-
plastin. Note that the GST-L-plastin construct only encodes the N-terminal half of the protein and the 
Dann2 peptide is located in the ABD1. 
* 
* 
* 
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4.2.2.4 Confirming the specificity of Dann antibodies by peptide inhibition 
assay 
Having demonstrated that Dann1a, Dann2b and Dann3b recognise recombinant T-plastin 
and/or L-plastin, peptide inhibition assays using the immunogenic peptides were performed 
to determine the specificity of each antibody. For Dann1a, the antibody was pre-incubated 
with 2-fold and 10-fold Dann1a peptide for 1hr prior to immunoblotting. E.Coli lysates 
expressing the GST-fusion proteins were used as the source of the plastin antigens. In the 
absence of peptide, Dann1a recognised proteins in both the T-plastin and L-plastin lysates, 
as seen before (Figure 4.8 A). In the presence of 2-fold (Figure 4.8 B) or 10-fold (Figure 4.8 C) 
SELSSEGTQHSYSEEEKY, the Dann1a antigen, the antibody signal was completely blocked. Re-
probing the membranes with the L-plastin antibody first shown in Figure 4.5 B gave a 
background signal in all lysates, confirming that proteins were present on the PVDF 
membranes (data not shown). When the Dann3 antigen SGNLTEDDKHNNAKYA was used, 
there was no reduction in the Dann1a antibody signal, demonstrating the specificity of the 
antibody for its antigen (Figure 4.8 D). The same assay was performed for the Dann2b 
antibody. In the absence of any peptide, Dann2b recognised T-plastin and not L-plastin or I-
plastin (Figure 4.9 A) as expected from previous experiments (Figure 4.7 C). When the 
Dann2b antibody was pre-incubated with the Dann2b peptide APKGQKEGEPRID prior to 
Western blotting, the antibody signal was only partially blocked (Figure 4.9 B and C). This is 
consistent with the high titre of Dann2b found in the ELISA experiments (Supplementary 
Figure S2). The specificity of Dann2b for its antigen was demonstrated by incubating the 
antibody with the non-specific Dann3 antigen, SGNLTEDDKHNNAKYA. No inhibition of 
binding to the recombinant protein occurred in the presence of this control peptide (Figure 
4.9 D). A third peptide inhibition experiment was conducted using the Dann3b antibody. In 
the absence of any peptide, a strong signal with multiple bands was seen for T-plastin, but 
not for L-plastin or I-plastin (Figure 4.10 A). In the presence of the Dann3 antigen 
SGNLTEDDKHNNAKYA, the major T-plastin band at 96 kDa disappeared, but a band at ~55 
kDa remained. This suggested that the 55 kDa band was a non-specific protein rather than a 
degradation product of T-plastin. To confirm the specificity, incubating the Dann3b antibody 
with the control Dann1 peptide SELSSEGTQHSYSEEEKY had no effect on the detection of T-
plastin from the bacterial lysate. Taken together, the results confirm Dann1a and Dann2b 
are specific antibodies, whereas Dann3b might also recognise a non-specific bacterial 
protein. 
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Figure 4.8: Confirmation of the specificity of Dann1a antibody by peptide inhibition assay 
Lysates from bacteria expressing GST-fusion proteins were analysed by 10% SDS-PAGE, transferred to 
PVDF membrane and immunoblotted. GST-cntl, GST-T-plastin, GST-L-plastin and GST-I-plastin were 
incubated with (A) Dann1a antibody and no peptide (B) Dann1a antibody and 2x concentration of 
Dann1 peptide (C) Dann1a antibody and 10x concentration of Dann1 peptide and (D) Dann1a 
antibody and Dann3 peptide as a control. Molecular weight markers are given in kDa. Arrow denotes 
specific band at predicted molecular weight. Asterisk denotes background band. Dann1a was specific 
for the Dann1 peptide as no signal was detected in either the 2x or 10x concentration of Dann1 
peptide. Moreover, it had no affinity for the Dann3 peptide (control) as a signal in the GST-T-plastin 
and GST-L-plastin lanes was detected. 
 
* 
* 
     
 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Confirmation of the specificity of Dann2b antibody by peptide inhibition assay 
Lysates from bacteria expressing GST-fusion proteins were analysed by 10% SDS-PAGE, transferred to 
PVDF membrane and immunoblotted. GST-cntl, GST-T-plastin, GST-L-plastin and GST-I-plastin were 
incubated with (A) Dann2b and no peptide (B) Dann2b antibody and 2x concentration of Dann2 
peptide (C) Dann2b antibody and 10x concentration of Dann2 peptide and (D) Dann2b antibody and 
Dann1 peptide as a control. Molecular weight markers are given in kDa. Arrow denotes specific band 
at predicted molecular weight. Asterisk denotes background band. Dann2b antibody binding was not 
completely inhibited by the peptide as there was a signal detected in both the 2x and 10x 
concentration panels. The control peptide gave no inhibition of Dann2b binding to T-plastin. 
 
 
* 
* 
* 
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Figure 4.10: Confirmation of the specificity of Dann3b antibody by peptide inhibition assay 
Lysates from bacteria expressing GST-fusion proteins were analysed by 10% SDS-PAGE, transferred to 
PVDF membrane and immunoblotted.  GST-cntl, GST-T-plastin, GST-L-plastin and GST-I-plastin were 
incubated with (A) Dann3b antibody and no peptide (B) Dann3b antibody and 2x concentration of 
Dann3 peptide (C) Dann1a antibody and 10x concentration of Dann3 peptide and (D) Dann3b 
antibody and Dann1 peptide as a control. Molecular weight markers are given in kDa. Arrow denotes 
specific band at predicted molecular weight. Asterisk denotes background band. Dann3b antibody 
binding was partially inhibited by the peptide as there was a signal detected in both the 2x and 10x 
concentration panels. The control peptide gave no inhibition of Dann3b binding to T-plastin. 
 
 
 
* 
* 
* 
* 
* 
* 
* 
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4.2.2.5 Detection of plastins in mouse tissue using the Dann antibodies 
Having shown that the Dann1a antibody recognised its target antigens, and was largely 
specific in the context of a bacterial lysate, the next step was to test them against mouse 
tissue. Muscle, spleen, kidney and liver were selected as the tissues to test because T-plastin 
is expressed in normal muscle, L-plastin is expressed in normal spleen and I-plastin is 
expressed in normal kidney (Shinomiya, 2012). Liver was taken as an additional tissue since 
T-plastin is expressed in immortalised (cancer) liver cell lines (Ikeda et al., 2005). 
 
Mouse tissue samples were analysed by SDS-PAGE and stained by coomassie to confirm that 
protein had been recovered post-lysis (Figure 4.11 A). Equivalent samples were run on SDS-
PAGE, transferred to PVDF membranes and immunoblotted using the Abcam T-plastin 
antibody (Figure 4.12 B), the I-plastin antibody from Dr. Francisco Rivero (Figure 4.11 C) and 
the Dann1a antibody (Figure 4.11 D). The Abcam antibody recognised a ~70 kDa band in 
muscle, spleen and kidney, but not in liver. Additional bands were also seen in spleen and 
kidney (Figure 4.11 B). Thus, the Abcam antibody did not appear to be very specific. The I-
plastin antibody detected a single band in kidney, as expected, and a weak band in spleen 
(Figure 4.11 C). The Dann1a antibody detected the same ~70 kDa band in spleen, confirming 
that it detected L-plastin cleanly. The Dann1a antibody also decorated a single band in 
mouse muscle, but this protein ran at ~50 kDa rather than the expected molecular mass of T-
plastin which is ~70 kDa (Figure 4.11 D). Although it is possible that some degradation of the 
muscle plastin occurred during lysis, the Abcam antibody did detect a ~70 kDa protein in 
muscle. It should also be noted that no signal was detected in liver for T, L or I-plastin. The 
overall con  
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Figure 4.11: Confirmation of the specificity of Dann1a using mouse tissue 
(A) Lysates from mouse muscle, spleen, kidney and liver tissue were analysed by 10% SDS PAGE prior 
to staining with colloidal coomassie. Lysates from mouse muscle, spleen, kidney and liver tissue were 
analysed by 10% SDS PAGE, transferred to PVDF membrane and probed with (B) T-plastin antibody 
(Abcam) (C) I-plastin antibody as used in Figure 4.6 and (D) Dann1a 1:500 dilution. Molecular weight 
markers are given in kDa. Arrow denotes specific band at predicted molecular weight. Dann1a 
recognised a ~50 kDa in muscle and a ~70 kDa band in spleen. 
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4.2.2.6 Detection of plastins in cell lines 
The Dann1a antibody gave a signal at the expected molecular weight against spleen tissue, 
but an unexpected specific signal against a protein of ~55 kDa from muscle. To investigate 
the size of the plastin protein being detected by Dann1a, the antibody was tested against 
immortalised cell lines (Figure 4.12). The CRC cell lines SW480/lamA, SW480/cntl and SW620 
were used for this analysis. Willis et al. previously showed that T-plastin was upregulated in 
the SW480/lamA compared SW480/cntl cells, as determined by RT-PCR (Willis et al., 2008). 
In addition, Foran and colleagues have shown that L-plastin is absent in the SW480 cell line 
but elevated in its metastatic counterpart SW620. Cell lysates were generated and equal 
amounts were taken for Coomassie staining (Figure 4.12 A) and for Western blotting (Figure 
4.12 B and C). As expected, no Dann1a signal could be detected in the SW480/cntl cell line, 
whereas a doublet at ~70 kDa could be detected in the SW620 cells, most likely 
corresponding to T-plastin and L-plastin. A single band was seen in the SW480/lamA cell line, 
consistent with the induction of T-plastin but not L-plastin by lamin A expression. 
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Figure 4.12: Confirmation of the specificity of Dann1a using CRC cell lines 
(A) Lysates from SW480/cntl SW480/lamA and SW620 were analysed by 10% SDS PAGE prior to 
staining with colloidal coomassie. Lysates from SW480/cntl SW480-lamA and SW620 were analysed 
by 10% SDS PAGE, transferred to PVDF membrane and probed with (B) Dann1a 1:100 dilution and (C) 
β-actin as a control. Molecular weight markers are given in kDa. Arrow denotes specific band at 
predicted molecular weight. Dann1a recognised a single band of ~70 kDa  in the SW480/lamA and a 
doublet at a similar molecular weight in the SW620 cells. 
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4.3 Discussion 
In this chapter, we characterised polyclonal plastin antibodies raised against three 
immunising peptides and demonstrated their specificity by a combination of Western 
blotting and peptide inhibition assays. The antibodies were tested against recombinant 
proteins in an E. coli lysate, murine tissues and CRC cancer lines. Sequence analysis of the 
plastins showed that they are well conserved, both within the plastin family and between 
species (Figures 4.2 and 4.3). This makes designing isoform-specific antibodies challenging. 
The central region of T-plastin is the most divergent, and the Dann2 peptide designed in this 
region was only 54% identical to the equivalent peptide sequence in L-plastin. The Dann2b 
antibody raised against this peptide showed high affinity by ELISA (Supplementary Figure S2) 
and gave a specific signal when used for Western blotting against recombinant GST-T-plastin 
(Figure 4.7). The interaction between Dann2b and its antigen could be partly inhibited by 
pre-incubating the antibody with the immunising peptide (Figure 4.9), providing further 
evidence of a high affinity interaction with the GST-T-plastin protein. To explore this further, 
experiments could be performed to titrate the antibody with even higher concentrations of 
peptide, if desired, or by using higher dilutions of the antibody. Unfortunately, although the 
Dann2b antibody looked the most promising in the fusion protein analysis, it did not work in 
immunoblotting on cell lysates, despite numerous attempts using different extraction 
protocols (data not shown). This finding highlights the fact that while antibody reactivity may 
be excellent in the context of a bacterial lysates, this does not necessarily mean that there 
will be a positive result when the antibody is tested on mammalian cells.  
 
In contrast to the Dann2b antibody, the Dann2a antibody did not recognise GST-T-plastin 
(Figure 4.7), despite having a high titre when measured against the peptide in ELISA (Figure 
S2). This finding demonstrates that the context of an epitope within a protein sequence is 
important for its antigenicity. It may be that some secondary structure is lost in the SDS-
denatured protein, since although the Dann2 peptide is only 13 residues in length, it does 
have 2 proline residues and a glycine that may introduce kinks in its secondary structure. The 
difference between the Dann2a and Dann2b antisera also demonstrate that individual 
animals can raise very different antibody responses to the same peptide. The B cell 
repertoires of the two animals used to raise these antibodies will not be the same, due to B 
cell specific antibody gene rearrangement and somatic hypermutation in the germinal 
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centres (Manz et al., 2005). The different antibody responses made by individual rabbits also 
highlight the potential problem in using polyclonal antisera as potential biomarkers. Each 
time a new antibody is raised against the same peptide, an equivalent antibody response 
cannot be guaranteed. Therefore, the preferred choice is to raise a monoclonal antibody 
through hybridoma technology. Although this is more time consuming, the immortalised B 
cell hybridoma produced will continue to secrete the same antibody throughout the cells 
lifetime, ensuring a consistent antibody product. Alternatively, phage display or yeast 
surface display technologies could be used to try and develop specific antibodies to closely 
related sequences such as those found in the plastins (Baird et al., 2009).  
 
The Dann3 peptide did not produce a useful antibody. Dann3a gave no signal, whereas 
Dann3b gave a background band that could not be blocked by the immunogen (Figure 4.10). 
Interestingly, the antibody response to Dann3 did seem to be specific to T-plastin and 
Dann3b did not bind to GST-L-plastin or GST-I-plastin despite the peptide sequences being 
~75% identical in this C-terminal region. To probe the nature of the Dann3b epitope (or any 
of the Dann antibodies) further, one could synthesise a nested series of truncated peptides 
to see at what point the antibodies ceased to recognise the antigens. Similarly, alanine 
mutations in the immunising peptide could be introduced at different positions to determine 
which amino acids were specifically required for antibody binding, either by ELISA or by 
western blotting. 
 
The most promising antibody arising out of the work in this Chapter was Dann1a. Although 
this antibody recognised both T-plastin and L-plastin, it did not cross-react with any bacterial 
or mammalian proteins, and it could be specifically inhibited by the immunising peptide 
(Figures 4.6-4.8). Dann1a also detected plastins in muscle and spleen (Figure 4.12). The role 
of T-plastin in muscle is worthy of further investigation. Dann1a recognised a ~55 kDa 
species in bacterial lysates and in muscle (Figure 4.8 and Figure 4.11). This band looked 
specific, at least in the recombinant protein blots, because it was inhibited by the peptide. 
Since lamin A/C mutations often give rise to muscle phenotypes (Benedetti and Merlini, 
2004) and lamin A/C expression may be linked to that of T-plastin, it might be worth 
studying T-plastin function in the muscle to determine whether or not unusual alternative 
splicing or protein processing of T-plastin is occurring in this tissue. T-plastin has been shown 
to be upregulated in failing hearts compared with non-failing hearts, in patients with end-
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stage dilated cardiomyopathy (Tan et al., 2002). Since proteolytic stress responses are 
induced during heart failure by mechanical injury and neurohormonal perturbations (Vatner 
and Vatner, 1998), one explanation for the 55 kDa band in muscle might be that T-plastin is 
regulated by proteolysis. Further experiments to study the half-life and post-translational 
modification of T-plastin in heart muscle could be performed by taking cardiomyocytes in 
culture and subjecting them to pulse-chase metabolic labeling experiments. It might also be 
possible to compare T-plastin protein expression and regulation in skeletal and heart muscle 
in animals, for example by performing muscle ‘work rate’ experiments in mice. Another 
possible explanation for the 55 kDa T-plastin band in muscle is that the protein is regulated 
by alternative splicing, and that muscle expresses a different form to spleen. Consultation 
with the human protein atlas (www.proteinatlas.org) shows that at least nine PLS3 
alternative splice variants have been annotated, potentially giving rise to a range of protein 
species in addition to the regular 71 kDa form (PLS3-001). However, whether these 
additional splice variants are functionally expressed in muscle or other tissues is not clear. T-
plastin is also subject to post-transcriptional regulation by the mRNA decay pathway and this 
process could have a degree of transcript or tissue specificity (Brazao et al., 2012). The 
expression of plastins in normal liver is also worthy of further investigation, since no signal 
was detected in liver with any of our antibodies (Figure 4.11). The absence or presence of 
plastins in this organ could be tested by RT-PCR. If no mRNA were to be detected, liver could 
be investigated as a model for how the cytoskeleton is organised in the absence of plastin 
expression. If mRNA is detected, it would be interesting to investigate why the Dann1a and 
the Abcam antibody do not detect it. Perhaps T-plastin is alternatively spliced or rapidly 
turned over in this tissue.  
 
The induction of T-plastin expression by GFP-lamin A was also confirmed by immunoblotting, 
using the Dann1a antibody, and the result suggested that T-plastin but not L-plastin was 
upregulated (Figure 4.12). Why lamin A expression should selectively induce only one of the 
plastin genes is not known, and is worthy of further exploration. The fact that Dann1a 
detects a doublet in the SW620 cells suggests that it could be a good tool to probe the 
relative levels of T-plastin and L-plastin in various cell types. Taken together, the data in this 
Chapter suggest that Dann1a is specific to both T and L-plastin isoforms and this antibody 
can now be used for the further study of plastin in CRC cell lines and tumour tissues. 
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Chapter 5: Immunohistochemical analysis of 
plastin expression in colorectal cancer 
 
5.1 Introduction 
Plastins belong to a family of actin bundling proteins, which function to cross-link actin 
filaments in networks (Delanote et al., 2005). This is essential for the formation of 
specialised cell structures and remodelling of the actin cytoskeleton (Stevenson et al., 2012). 
Three plastin isoforms exist, sharing approximately 70% similarity in their amino acid 
sequence, each of which is expressed in a tissue specific manner. Importantly, the different 
plastin isoforms have been implicated in a number of cancers (Lin et al., 1993; Shinomiya et 
al., 2012). The expression of L-plastin, for example, is induced in many types of cancerous 
human cells of non-haematopoetic origin (Lin et al., 1993). In addition, Osuka and colleagues 
identified L-plastin as a metastatic marker for CRC progression in a tissue microarray 
consisting of 58 clinically stratified specimens (Otsuka et al. 2001). This group showed that L-
plastin gene expression correlated with cancer stage, and suggested that L-plastin is a 
potential metastatic marker. However, the antibody stainings in this paper are not entirely 
clear.  
 
It has been shown previously that T-plastin mRNA expression is increased upon stable 
transfection of GFP-lamin in the SW480 CRC line (Willis et al., 2008). Moreover, we have 
observed that T-plastin mRNA expression is significantly upregulated in human colorectal 
tumours, compared to the corresponding normal colonic mucosa (Chapter 3, Figure 3.11 B 
and C). Given the potential importance of plastin in cancer, we sought to examine T/L-plastin 
expression in the NLCS cohort (Figure 5.1), using the Dann1a antibody characterised in 
Chapter 4. The overall aims of this chapter were to examine the expression pattern of T/L-
plastin in human CRC tumours, investigate the relationship between expression and tumour 
progression and explore the potential of T/L-plastin as a prognostic biomarker in CRC. 
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Figure 5.1: Study design of the Netherlands Cohort Study on Diet and Cancer (NLCS) 
(adapted from Hughes, 2011) 
 
 
                                Total cohort (n = 120,852)          
  Baseline 1986 
                                            Sub-cohort (n = 5,000) 
n cases = 737 
7.3 years 
follow-up 
(excluding first 
2.3 years) 
CRC cases determined 
from annual record 
linkage to the 
Netherlands cancer 
Registry and PALGA 
Collection of paraffin 
embedded tumour 
Molecular pathological 
analysis of CRC tumours 
16 years follow-up 
n cases = 3360 
Biennial follow-up of 
the sub-cohort for 
estimation of person 
years at risk in the 
whole cohort 
656 CRC cases were 
scored for lamin A/C 
expression (IHC) 
Genomic DNA from 
161 patients analysed 
for T-plastin promoter 
methylation 
70 CRC cases 
investigated for plastin 
expression by IHC 
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5.2 Results 
 
5.2.1 Characterisation of plastin antibodies in normal human skin 
and colon  
In the previous chapter, we successfully characterised the Dann1a antibody by 
Immunoblotting. Here, we wanted to establish whether this antibody could recognise plastin 
in human tissues. Prior to assessing the plastin expression status in human colorectal 
carcinomas from the NLCS archive, normal human skin was used to further characterise the 
Dann1a antibody, as T and L-plastin plastin were known to be expressed in the epidermis 
and infiltrating leukocytes, respectively (Shinomiya, 2012). Initially, tissues were subjected to 
different antigen retrieval techniques. Skin sections exposed to primary antibody Dann1a 
produced highly specific staining after microwave digestion with Tris-EDTA buffer pH 8.0, 
and a specific but weaker stain with citrate buffer pH 6.0. Thus, it was deduced that antigen 
retrieval using Tris-EDTA pH 8.0 was optimal and would be used in further experiments (data 
not shown). 
 
Once an optimal antigen retrieval technique had been established, skin sections were then 
subjected to different antibody dilutions. Figure 5.2 shows that 1:100 antibody dilution was 
optimal. Omitting the primary antibody produced negative staining. In the skin sections, 
Dann1a decorated the epidermal cells and was present in leukocytes, as expected. 
Interestingly, T/L-plastin appeared to be strongly expressed in the nucleus, as well as the 
cytoplasm of skin epithelial cells (Figure 5.2 A-C). Having optimised the antibody dilution for 
Dann1a, we then wanted to examine the expression pattern in normal human colonic 
epithelia. The data showed that T/L-plastin expression was absent in normal colon (Figure 
5.3). 
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Figure 5.2: Optimisation of Dann1a antibody in normal human skin 
Formalin-fixed, paraffin-embedded human skin sections were deparaffinised by xylene, followed by 
100% ethanol and endogenous peroxidise activity was quenched in 0.3% hydrogen peroxide. Antigen 
retrieval was performed by microwave with Tris-EDTA buffer pH 8.0. Sections were incubated with 
Dann1a antibody at (A-C) 1:50 dilution and (D-E) 1:100 dilution and (F) with no primary antibody, 
before detection with DAB and photography at x20 magnification. Blue (hematoxylin) staining 
represents the nuclear staining and brown (DAB) staining represents the antibody (Dann1a). E = skin 
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epidermis, L = leukocytes. Data shows that Dann1a at 1:100 produced optimal staining. Scale bar = 50 
μm. 
 
 
Figure 5.3: T/L-plastin is absent in normal colonic epithelia 
Formalin-fixed, paraffin-embedded human colon and skin sections were deparaffinised by xylene, 
followed by 100% ethanol and endogenous peroxidise activity was quenched in 0.3% hydrogen 
peroxide. Antigen retrieval was performed by microwave with Tris-EDTA buffer pH 8.0. Sections were 
incubated with Dann1a antibody at (A-C) 1:100 dilution (normal colon). (D) skin section incubated 
with Dann1a at 1:100 dilution as a positive control. Images were photographed at x20 magnification. 
Blue (hematoxylin) staining represents the nuclear staining and brown (DAB) staining represents the 
antibody (Dann1a). E = skin epidermis, L = leukocytes, C = colonic crypts. Data shows that T/L-plastin 
is absent from normal colonic crypts. Scale bar = 50 μm. 
 
 
 
 
 
     
 
146 
 
5.2.2 Immunohistochemical analysis of T/L-plastin expression in 
CRC 
To investigate the pattern of plastin expression in CRC, immunohistochemical analysis was 
performed on tissues from 70 CRC patient samples from the NLCS archive that had 
previously been stained for lamin A/C (Figure 5.1). After quenching of endogenous 
peroxidise activity followed by antigen retrieval, slides were stained for T/L-plastin with 
Dann1a antibody, exactly as described in Chapter 2, section 8. An example of the staining 
pattern is shown in Figure 5.4. Muscle always stained strongly and thus was used as a 
positive control. The availability of an internal positive control demonstrated that a negative 
stain in tumour tissue corresponded to an absence of antigen rather than poor staining 
(Figure 5.4 C and D). Normal colonic epithelial cells within the section always stained 
negatively and hence were used as an internal negative control. Adjacent stromal nuclei 
stained positively or negatively, depending on the expression pattern of the surrounding 
tumour tissue. Leukocytes sometimes stained positively (possibly indicating the presence of 
L-plastin). Out of the 70 slides processed, not all specimens were available for analysis. This 
was due to either insufficient tumour material, or the lack of an internal control. In addition, 
the subsequent retrieval of information from the NLCS archive and PALGA databases led to a 
further reduction to 58 due to incomplete information or the duplication of administrative 
codes. Slides were scored blind on two separate occasions, in consultation with senior 
pathologist Dr Robert Reidl (University Hospital Maastricht, Netherlands). A scoring criterion 
was established, based on the following descriptors; absent, weak, positive, and 
heterogeneous (Figure 5.5). Tumour cells can be clearly recognised due to the dense staining 
of haematoxylin (denoted by T, Figure 5.5). However, there were clearly some tissues where 
tumour cells were present that did not express plastin (Figure 5.5 A-B). Antigen retrieval had 
occurred in these cases because staining of muscle was seen in the sample. In other 
examples, tumour tissue stained very strongly for T/L-plastin, when the antibody was used at 
the same dilution (Figure 5.5 E-F). Of the available 58 specimens immunohistochemically 
assessed, plastin was found to be positive in 47 (81%) and negative in 11 (19%) patients. This 
is a remarkable result given that T/L-plastin is not seen in normal colonic tissue.  
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Figure 5.4: Positive plastin expression in muscle and negative plastin expression in normal colonic 
epithelia within CRC tissue  
Four µm thick, formalin-fixed paraffin embedded tissue sections were deparaffinised using xylene, 
followed by 100% ethanol and endogenous peroxidise activity was blocked in 0.3% hydrogen 
peroxide. Antigen retrieval was performed by microwave with Tris-EDTA buffer pH 8.0. Sections were 
incubated with Dann1a primary antibody at 1:100, prior to detection with DAB and photography at 
x10/20 magnification. B = blood vessel, C = colonic crypts, L = lymphocytes, M = muscle of arterial 
wall, MP = Muscularis propria, R = red blood cells, S = stromal cells. (A & B) Plastin is strongly 
expressed in red blood cells, weakly in surrounding stromal tissue and is absent from leukocytes and 
normal colonic crypts. (C and D) Plastin is expressed in muscle cells. Blue (hematoxylin) staining 
represents the nuclear staining and brown (DAB) staining represents the antibody (Dann1a). Each 
image is from a different patient. (A & D: x10 magnification; scale bar = 200 μM; B & C: x20 
magnification; scale bar = 50 μm. 
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Figure 5.5: T/L-plastin expression in CRC 
Four µm thick, formalin-fixed paraffin embedded tissue sections were deparaffinised using xylene, 
followed by 100% ethanol and endogenous peroxidise activity was blocked in 0.3% hydrogen 
peroxide. Antigen retrieval was performed by microwave with Tris-EDTA buffer pH 8.0. Sections were 
incubated with Dann1a primary antibody at 1:100, prior to detection with DAB and photography at 
x5/10/20 magnification. (A-B) Negative: plastin expression is absent in the tumour and surrounding 
stromal cells. (C-D) Weak: plastin expression is weak in the tumour and surrounding stromal tissue 
and (E-G) Positive: plastin is strongly expressed in the adenocarcinoma (D) Heterogeneous:  plastin 
expression is strong in some tumour cells, and weaker in others within the same tissue. T = tumour 
cells, S = stromal cells. Blue (hematoxylin) staining represents the nuclear staining and brown (DAB) 
staining represents the antibody (Dann1a). Each image is from a different patient. A-B: x20 
magnification; scale bar = 50 μm; C-G: x10 magnification; scale bar = 200 μm; H: x5 magnification; 
scale bar = 400 μm). 
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5.2.3 T/L-plastin is strongly expressed at the invasive front of 
colorectal tumours 
Having demonstrated that 81% of colon cancers were positive for plastin (including weak, 
positive and heterogeneous), we went on to examine more closely the expression pattern of 
plastin in the tumours. Strikingly, we observed in a number samples that plastin was strongly 
expressed at the invasive front and comparatively weak at the luminal side of the tumour 
(Figures 5.6 and 5.7). These observations suggest that plastin expression might play a role in 
invasiveness or metastasis, since the leading edge of the tumour is the most motile.  
 
5.2.4 T/L-plastin expression in signet ring carcinoma 
During our immunohistochemical analysis, we examined one case of signet ring carcinoma 
(SCC) (Figure 5.8). This is a very rare type of epithelial malignancy that account for less than 
1% of all CRC cases. SCC is characterised by the histological appearance of individual 
neoplastic cells containing intracytoplasmic vacuoles with pleomorphic nuclei (Verhulst et 
al., 2012). Although SCC is rare, data from immunohistochemical studies may provide 
important information that can aid in the development of better prognostic biomarkers and 
therapeutic interventions. In the one sample analysed, it was observed that T/L-plastin 
expression was elevated in this type of cancer, suggesting that plastin could be investigated 
further as a biomarker for SCC (Figure 5.8). Interestingly, SCCs have mutations in the E-
cadherin gene suggesting that there may be a relationship between T/L-plastin and E-
cadherin function (Darwanto et al., 2003). 
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Figure 5.6: T/L-plastin expression at the invasive front of a tumour (patient 1) 
Four µm thick, formalin-fixed paraffin embedded tissue sections were deparaffinised using xylene, 
followed by 100% ethanol and endogenous peroxidise activity was blocked in 0.3% hydrogen 
peroxide. Antigen retrieval was performed by microwave with Tris-EDTA buffer pH 8.0. Sections were 
incubated with Dann1a primary antibody, prior to detection with DAB and photography at 
x5/10/20/40 magnification. All images were taken from the same patient. (A) weak plastin 
expression at the luminal side of the tissue (x5 magnification) and (B) at x10 magnification. (C) Strong 
plastin expression at the invasive front of the tumour (x10 magnification) (D) at x10 magnification (E) 
at x20 magnification and (F) at x40 magnification. Data shows that plastin was strongly expressed at 
the leading edge of the tumour compared to the luminal counterpart. T = tumour cells, S = stromal 
cells. Blue (haematoxylin) staining represents the nuclear staining and brown (DAB) staining 
represents the antibody (Dann1a). Scale bar = 400 µm (x5 magnification); 200 µm (x10 
magnification); 50 µm (x20 magnification); 25 µm (x40 magnification). 
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Figure 5.7: T/L-plastin expression at the invasive front of a tumour (patient 2) 
Four µm thick, formalin-fixed paraffin embedded tissue sections were deparaffinised using xylene, 
followed by 100% ethanol and endogenous peroxidise activity was blocked in 0.3% hydrogen 
peroxide. Antigen retrieval was performed by microwave with Tris-EDTA buffer pH 8.0. Sections were 
incubated with Dann1a primary antibody, prior to detection with DAB and photography at 
x5/10/20/40 magnification.  All images are taken from the same patient. (A) weak plastin expression 
at the luminal side of the tissue (x5 magnification) (B) at x10 magnification (C) at x20 magnification. 
(D) Strong plastin expression at the leading edge of the tumour (x10 magnification) (E) at x20 
magnification (F) at x40 magnification. Data shows that plastin was strongly expressed at the leading 
edge of the tumour compared to the luminal counterpart. T = tumour cells, S = stromal cells. Blue 
(hematoxylin) staining represents the nuclear staining and brown (DAB) staining represents the 
antibody (Dann1a). Scale bar = 400 µm (x5 magnification); 200 µm (x10 magnification); 50 µm (x20 
magnification); 25 µm (x40 magnification). 
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Figure 5.8: T/L-plastin expression in signet cell carcinoma 
Four µm thick, formalin-fixed paraffin embedded tissue sections were deparaffinised using xylene, 
followed by 100% ethanol and endogenous peroxidise activity was blocked in 0.3% hydrogen 
peroxide. Antigen retrieval was performed by microwave with Tris-EDTA buffer pH 8.0. Sections were 
incubated with Dann1a primary antibody, prior to detection with DAB and photography at x20 
magnification. (A-B) Elevated plastin expression in signet cell carcinomas. T = tumour cells, S = 
stromal cells. Blue (hematoxylin) staining represents the nuclear staining and brown (DAB) staining 
represents the antibody (Dann1a). Scale bar = 50µm. 
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5.2.5 Patient analysis 
The patients included in this study developed cancer between 1989 and 1994. Information 
on mortality from 1
st
 January 1989 until 1996 (7 years) was retrieved through linkage with 
the Central Bureau for Statistics. CRC related death was concluded if CRC was determined to 
be either the primary cause of death or as a primary, secondary or tertiary complication, 
using the ICD system. Differences in patient, tumour and follow-up characteristics were 
analysed using the Chi-square (χ²) test. Kaplan-Meier analysis was selected to investigate 
survival. Hazard ratios (HR) (an estimate of the relative effect of a variable [e.g. plastin 
expression status] on an event [e.g. CRC mortality]) and corresponding 95% confidence 
intervals (CI) for CRC-related mortality according to plastin status were estimated using Cox 
regression analysis. All analysis was performed using SPSS. This work was carried out in 
collaboration with senior epidemiologist Dr Kim Smits (University Hospital, Maastricht). 
 
5.2.5.1 Plastin expression versus tumour progression and location  
Initial baseline analysis was performed on all patient and tumour characteristics in relation 
to CRC related mortality (outlined in Table 5.1). The study population characteristics 
appeared to be normal with 50% (n = 29) of patients being male and 50% (n = 29) of patients 
being female. There was no statistically significant difference between CRC-related mortality 
and sex (p = 0.311). There was no difference in age at diagnosis and CRC-related mortality (p 
= 0.323). Classification using Dukes’ staging system were as follows: Dukes’ A, 24% (n = 14), 
Dukes’ B, 24% (n = 14), Dukes’ C, 36% (n = 21) and Dukes’ D, 16% (n = 9). Furthermore, there 
was no association between plastin expression status and Dukes stage (p = 0.658) (Figure 5.9 
A). Thus plastin expression is present throughout the Dukes stages, indicating that the 
plastin gene must be activated early on during cancer initiation. Although no statistical 
significance could be attributed to the level of plastin expression versus Dukes’ stage, there 
was a trend towards a higher proportion of negatively staining tumours at Dukes’ stage B, 
when the cancer cells are penetrating through the muscle layer. The explanation for this is 
not known. It would be necessary to follow individual cancers from Dukes’ stage A through 
to Dukes’ stage B to establish whether plastin can become downregulated upon contact with 
the muscle cells. The percentage of ‘positive’ plastin expressing tumours does rise from 
~70% in Dukes’ C to ~90% in Dukes’ D, indicating that the more advanced the cancer is, the 
more likely it is that plastin will be expressed. This observation also suggests that plastin 
     
 
157 
 
expression is not switched off once the tumour cell has acquired the necessary changes to 
invade and metastasize. Similarly, no association was found between plastin expression and 
tumour location within the colon (p= 0.372) (Figure 5.9 B). However, examination of 
rectosigmoid tumours showed that the ratio between positive and absent expression was 
lower than that found in proximal distal and rectal cancers. Further analysis of more 
rectosigmoid tumour samples will be required to investigate this trend further. 
 
Table 5.1: Follow-up analysis 
 Plastin 
absent 
Plastin 
weak 
Plastin 
positive 
Plastin 
heterogeneous 
p-value 
Total population, N 11 4 38 5  
Dukes’ A, N 2 1 9 2  
Dukes’ B, N 5 1 6 2  
Dukes’ C, N 3 2 15 1  
Dukes’ D, N 1 0 8 0 0.658 
Proximal 2 1 12 3  
Distal 4 1 13 0  
Rectosigmoid 3 0 5 2  
Rectum 2 2 8 0 0.372 
Male patients, N 8 1 18 2  
Female patients, N 3 3 20 3 0.311 
Age at diagnosis, 
mean (SD) 
69.7  
(4.41) 
70.8  
(5.50) 
67.6 
(3.83) 
68.8  
(6.14) 
0.323 
 
 
5.2.5.2 T/L-plastin expression versus lamin A/C expression 
We previously reported that lamin A/C is a prognostic biomarker for CRC, and that ectopic 
expression of lamin A/C in CRC cell line SW480 increases the level of T-plastin (Willis et al., 
2008). Moreover, it has been shown that L-plastin is elevated in its metastatic counterpart in 
SW620 (Foran et al., 2005). Here, we have asked whether there was an association between 
lamin A/C expression (staining previously carried out on the NLCS by Willis et al. 2008) and 
T/L-plastin expression by χ² analysis. This statistical analysis shows that although plastin is 
expressed in CRC, there is no association between T/L-plastin expression and lamin A/C 
expression in the samples analysed (Figure 5.10).  
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5.2.5.3 T/L-plastin expression and patient survival analysis 
In order to investigate whether plastin expression was linked to patient survival, two 
statistical analyses were carried out. Firstly, Kaplan-Meier curves were produced to estimate 
survival probability (Figure 5.11). Secondly, Cox regression analysis using the Breslow 
method for ties was performed to estimate the cumulative hazard. The cumulative hazard 
refers to death as a result of CRC. Co-efficients or hazard ratios > 1 indicate a worse 
prognosis and a coefficient of < 1 indicates a protective effect. Analysis suggests that plastin 
expression may be an indicator of worse prognosis (HR = 2.27). However, this observation is 
not statistically significant in a population in which lamin A/C shows a positive correlation 
with poor survival (Figure 5.11 A). Moreover, stratified analysis of expression status also 
confirms that there is no association between plastin and lamin A/C expression (Willis et al., 
2008). There does appear to be a trend for patients exhibiting heterogeneous expression to 
have poor survival, but given that n = 5, no reliable conclusions can be drawn. 
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Figure 5.9: T/ L-plastin expression in relation to Dukes’ stage and tumour location 
(A) Histogram of T/L-plastin expression by stage assessed using 58 tumour samples. Plastin is 
expressed in all Dukes stages, with highest expression in Dukes’ D. There is no association between 
T/L-plastin expression status and tumour progression (p = 0.658). (B) Histogram of T/L-plastin 
expression by tumour location. There is no association between the frequency of plastin expression 
and tumour location (p= 0.372). Statistical analysis was performed using the Chi (χ²) test. All p values 
are two-sided. 
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Figure 5.10: T/L-plastin expression versus lamin A/C expression in NLCS tumours 
Histograms of T/L-plastin expression status by lamin A/C expression (staining previously carried out 
by Willis et al. 2008) assessed using 58 tumour samples. (A) There is no association between the 
presence or absence of T/L-plastin and lamin A/C expression (p= 0.531). (B) There is no association 
between the frequency of T/L-plastin expression and lamin A/C expression in either absent, weak, 
positive or heterogeneous categories (p = 0.703). Statistical analysis was performed using the Chi (χ²) 
test. All p values are two-sided.  
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Figure 5.11: T/L-plastin expression in CRC and survival 
(A) Kaplan-Meier plots of cumulative survival for CRC patients in relation to T/L-plastin expression. 
Data shows that there is no statistically significant correlation between presence or absence of T/L-
plastin expression and survival. Relative hazard ratio (HR) = 2.27 (95% C.I. = 0.50 – 10.18), p = 0.31 
(adjusted for gender and age at diagnosis). (B) Kaplan-Meier plot of cumulative survival for CRC 
patients in relation to differential plastin expression. Data shows that there is no statistically 
significant correlation between expression pattern and survival. Relative hazard ratio (HR) = 1.65 
(95% C.I. = 0.87 – 3.15), p = 0.32 (adjusted for gender and age at diagnosis). 
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5.3 Discussion 
The availability of the NLCS archive material (University Hospital Maastricht, Netherlands) 
allowed the expression pattern of T/L-plastin to be investigated in a population in which 
positive lamin A/C expression is predictive of poor prognosis in CRC. Following successful 
optimisation of previously established protocols, this study showed that plastin protein 
epitopes can be successfully re-exposed in formalin-fixed paraffin-embedded tissue 
specimens and immunohistochemically stained using the Dann1a antibody. This technical 
approach was both reliable and reproducible (Figure 5.2-5.4). 
 
Plastin expression has previously been implicated in cancer (Lin et al., 1993; Park et al., 1994; 
Delanote et al., 2005; Ikeda et al., 2005; Sasaki et al., 2002). However, the relationship 
between its expression and tumourigenesis and prognosis is unknown. Here, we attempted 
to link T/L-plastin expression to CRC progression and patient survival. Analysis of 
clinicopathological features in relation to T/L-plastin did not reveal any dramatic findings. In 
the 58 patient samples analysed, T/L-plastin expression was not associated with gender, age, 
tumour location or tumour stage (Table 5.1. and Figure 5.9). Moreover, T/L-plastin 
expression is not associated with the expression of lamin A/C (Figure 5.10), nor was it 
associated with patient survival (Figure 5.11). In short, T/L-plastin is not a prognostic 
biomarker for CRC. However, despite this, some interesting observations were made.  
 
Firstly, we demonstrated that T/L-plastin is absent in histologically normal colonic mucosa 
(Figures 5.3 and 5.4). This is in support of the literature, which states that human plastin 
isoforms are mutually exclusive and exhibit a tightly controlled tissue-specific expression 
pattern. I-plastin is the only isoform usually present in the colon (Lin et al., 1993b; Delanote, 
et al. 2005). Given the absence of T/L-plastin in normal colon, finding that at least one of 
these plastin isoforms is switched on in CRC is quite remarkable (Figure 5.5). Over 80% of the 
tumour samples that were analysed exhibited weak, positive or heterogeneous expression. 
Thus it is clear that the onset of T/L-plastin expression must be associated with a switch from 
a normal cell type to a dysregulated cancer cell type. During the preparation of this thesis, a 
recent publication reported that L-plastin is expressed in 82.5% of CRC, independently 
validating our results. These investigators also showed that L-plastin is associated with 
tumour stage, size and lymph node metastasis (Li and Zhao, 2011). Given that our study 
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showed highest expression of plastin in Dukes’ stage D, it would be interesting to examine 
the expression of plastin in the lymph nodes and other organs of Dukes’ D patients, to assess 
whether plastin levels remain high in cells that have metastasized. One limitation of our 
study was that the Dann1a antibody used could not differentiate between T/L-plastin. Thus 
it is possible that either T or L-plastin may have independent prognostic value and may 
become correlated with lamin A/C expression. To explore this further, it would be useful to 
have specific antibodies, preferably of monoclonal origin, to differentially detect the plastin 
isoforms.  
 
Within our cohort of 58 tumour samples, one was classified as a signet ring carcinoma 
(Figure 5.8). Although this type of cancer is less prevalent than adenocarcinomas, it was 
interesting to observe that this specimen showed elevated levels of T/L-plastin. Signet ring 
tumours are characterised by loss of E-cadherin, a hallmark of metastasis (Gopalan et al., 
2011). E-cadherin plays a crucial role in epithelial cell-cell adhesion and in the maintenance 
of tissue architecture. It has been extensively documented that downregulation of E-
cadherin correlates with a loss of cell adhesion and a strong invasive potential (Tsanou et al., 
2008). Moreover, Foran and co-workers have shown that ectopic expression of L-plastin in 
the SW480 CRC cell line caused a downregulation of E-cadherin and increased invasiveness 
of the cells (Foran et al., 2006). Taken together, this suggests that E-cadherin and T/L-plastin 
are dysregulated as part of the cytoskeletal signalling network that leads to changes in a cells 
capacity to migrate. The effect of A-type lamin expression on E-cadherin levels will be 
explored in Chapter 6. 
 
Another interesting observation was the presence of strong plastin expression at the 
invasive front of the tumour compared to the luminal counterpart (Figure 5.6 and 5.7). What 
this represents functionally within the tumour remains unclear. However, two potential 
scenarios can be imagined. In the first scenario, upregulation of plastin could promote 
invasion and metastasis through the increased formation of actin-rich protrusions. In cancer, 
cytoskeletal remodelling is essential for a cell to acquire invasive and metastatic abilities 
(Stevenson et al., 2012). Metastatic cancer cells use specialised cell structures such as 
filopodium and invadopodium which allow the cancerous cell to escape from the primary 
tumour and pervade the surrounding tissue (Mattila and Lappalainen, 2008; Stevenson et al., 
2012; Weaver, 2006). Upon reaching the vasculature or lymphatic system, the cancer cell 
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can establish a new niche and seed a new tumour (Hanahan and Weinberg, 2011). Since 
recent evidence shows that that T-plastin may be involved in filopodia formation, it is 
conceivable that plastin(s) help to increase force generation and mechanical stiffness 
through the generation of these specialized cell structures. For example, Xue et al. have used 
mouse melanoma cells transfected with mCherry-T-plastin and shown that T-plastin is 
enriched in filopodia (Xue et al., 2010). When cell movement was studied using time-lapse 
confocal microscopy, the lateral motion of these structures was related to the direction in 
which cancer cells migrate. Interestingly, the lateral filopodia decorated with T-plastin 
appeared at the ‘leading edge’ of the cell and moved in the opposite direction to that of the 
cell with time, implying that a force generating system was at work. 
 
Increased mechanical stiffness is frequently observed in cancer and is often associated with 
metastasis and poor prognosis (Evans et al., 2012; Fung et al., 2011; Narumiya et al., 2009). 
So in a second scenario, aberrant expression of plastin may lead may alter the mechanical 
stiffness of a cell and disrupt its normal contextual behaviour. Cells sense mechanical cues 
from the ECM using an interconnected mechanochemical system that links adhesion 
receptors to the cytoskeletal network (Butcher et al., 2009; Erler and Weaver, 2009). 
Alterations in this mechanical interaction between the cell and the environment may 
compromise tissue integrity, potentially contributing to cancer formation. For example, 
numerous members of the cell survival MAPK/ERK signalling pathway are 
increased/activated when osteoblasts are subjected to a mechanical stress of 0.5 Hz for one 
hour per day (Yan et al., 2012) and notably a similar set of genes are also associated with a 
lamin A related cancer gene network which will be discussed in Chapter 6. Increased 
‘stiffness’ and increased matrix remodelling is frequently observed at the tumour invasive 
front where we found T-plastin to be highly expressed. To test the hypothesis that T-plastin 
contribute to mechanical stiffness, mechanical stress experiments could be performed 
(perhaps in association with scratch-wound migration studies) in colon cancer cells that 
either overexpress T-plastin, or are downregulated for T-plastin using optical tweezers 
positioned at filopodial locations (Bordeleau et al., 2011). This approach could also be used 
to establish whether direct binding of T-plastin to F-actin resulted in the acquisition of 
stiffness through combined confocal, co-immunoprecipitation and co-localisation studies. 
Experiments could also be performed to compare the mechanical response of T-plastin 
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expressing cells grown in conventional culture conditions with those grown in 3D in gels or 
on a support matrix (Gjorevski and Nelson, 2012).  
 
In conclusion, further study of plastin is merited because its role in microfilament 
organisation may help us to understand neoplastic transformation events in cancer. T/L-
plastin is not a prognostic biomarker for CRC. However, T/L-plastin is strongly expressed in 
CRC and most strikingly, at the leading edge of tumours. Although these results are 
encouraging, the mechanism that determines its expression pattern is unknown, and 
molecular data is required to explain how increased or ectopic plastin expression contributes 
to tumour formation. These approaches may help resolve whether individual plastins could 
indeed serve as part of a multi-panel cancer biomarker, or whether plastins could be 
valuable targets for cancer drug development.  
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Chapter 6: Identification and validation of a 
candidate colorectal cancer gene network  
 
6.1 Introduction 
CRCs arise from benign neoplasms and evolve into adenocarcinomas through a stepwise 
histological progression sequence, characterised by the sequential accumulation of both 
genetic and epigenetic alterations (Fearon, 2011; van Engeland et al., 2011). CRC is a truly 
heterogeneous disease, encompassing several histological and clinical behaviours. Current 
histopathological classification systems are based on descriptive entries such as tumour 
location and size (Compton and Greene, 2004). In the UK, the implementation of the Dukes’ 
staging system has made an enormous contribution to the diagnosis, prognosis and 
treatment of CRC (Graziano and Cascinu, 2003). However, tumours with similar histological 
features may display disparate clinical behaviours due to the innate biological and genetic 
variability of CRC (Draht et al., 2012; Newton et al., 2010). The quest for robust and reliable 
immunohistochemical biomarkers that can predict patient prognosis or treatment response 
has gone some way to addressing this problem. Nevertheless, the information gained from a 
subjective antibody assessment cannot reveal the underlying molecular mechanisms 
involved in carcinogenesis. 
 
The development of innovative high-throughput molecular technologies has revolutionized 
our understanding of the cancer genome, of which microarray-based gene expression has 
received most attention (Nanini et al., 2009). In comparison with traditional methods such as 
Northern blotting and Southern blotting, microarray technologies have a higher density of 
probes that enable the precise quantification of hundreds to thousands of gene transcripts 
in a single sample, providing a measurement of gene expression patterns (Duftner et al., 
2008; Jung et al., 2011; Nannini et al., 2009). Briefly, microarrays are slides dotted with a 
panel of gene probes used to quantify the relative amount of RNA transcripts present in a 
cell or tissue. A fluorescent signal is produced when labelled cDNA is bound to the 
complementary sequence on the microarray. Changes in gene expression can be compared 
between samples by using two different fluorescent probe colours.  
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By enabling simultaneous expression analysis of thousands of genes, microarray technology 
has shed light on the molecular changes associated with tumour progression, and enabled 
the subsequent discovery of novel prognostic biomarkers and therapeutic targets (Colombo 
et al., 2011). Breast cancer has been the most studied with respect to gene expression 
profiling and clinical outcomes. One group were able to find a distinct gene expression 
signature that was indicative of poor prognosis (van 't Veer et al., 2002). 
 
The data in Chapter 5 shows that T/L-plastin expression status cannot be used a prognostic 
biomarker in a population where lamin A/C can predict CRC patient prognosis.  Nevertheless, 
we demonstrated that T/L-plastin is elevated in tumour tissue compared to normal colonic 
mucosa and thus plastin may be downstream of key genes that do have prognostic potential. 
A comprehensive knowledge of plastin signalling networks with respect to lamin A may assist 
in the discovery of novel biomarkers and the development of new drugs.  
 
It has been shown that increased expression of lamin A causes the SW480 cells to adopt a 
more motile phenotype, as determined by wound-healing assays (Willis et al., 2008). In an 
attempt to elucidate the potential mechanisms responsible for this observation, our lab 
carried out quantitative genome-wide DNA pair wise screening on the SW480/lamin A and 
SW480/control CRC cell lines using the Human Genome U133 Plus 2.0 high density 
oligonucleotide Affymetrix GeneChip® Array. The overarching aim of this work was to 
identify candidate genes for future analysis using a bioinformatics approach. Here, we 
describe the generation of a cancer gene network, and validation of the microarray data by 
quantitative real-time PCR (qPCR) and immunoblotting. 
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6.2 Results 
 
6.2.1 Generation of interaction network 
Genome-wide DNA microarray analysis was previously carried out on SW480/lamA and 
SW480/cntl CRC cell lines by Dr N. Willis (Durham University) and Dr H. Peters (Newcastle 
University). A two-fold change or more between genes from the SW480/cntl cells and the 
SW480/lamA cells was considered to be indicative of differential expression. Changes in 
gene expression were observed in a total of 1,211 genes when expression patterns were 
compared between the two cells lines. In order to extract the most relevant biological 
information from the microarray data and to identify a network based on known 
interactions, we used Ingenuity Pathway Analysis (IPA®). The microarray dataset analysis was 
performed in collaboration with Dr Dan Swan (Newcastle University) and Dr Clare Foster 
(Durham University). IPA® is a professionally curated, web-based application containing an 
extensive database of biological interactions between genes, proteins, cells, drugs and 
diseases based on information from over 200,000 peer-reviewed publications (Calvano et al., 
2005). Functional analysis of probesets showing greater than 2.5-fold differential expression 
between genes from SW480/lamA and SW480/cntl cells was performed by IPA®. The outputs 
that met this criterion were integrated into a molecular network or ‘interactome’ based on 
the connectivity of the inputted genes. IPA® was run using standard settings to check for 
significance against biological functions and disease and canonical pathways (significance 
indicated by Fischer Exact Test p < 0.05).  
 
The interaction networks that were obtained represent biological processes that are over-
represented in the microarray data and identify candidate genes for further analysis. The 
algorithm that creates the networks ensures that as many genes from the dataset are 
included as possible. The program also identifies genes that are likely to be part of a network 
but were not part of the experimental dataset. These genes were added to the networks 
obtained by IPA®. Approximately 35 molecules were represented in each network, with the 
most highly significant network clustering together proteins linked to cancer, cellular 
movement, cellular growth and proliferation. Genes within the network that were up- or 
downregulated in the SW480/lamA cells compared to SW480/cntl cells are shown in Table 
6.1. The Cancer, Cellular Movement, Cellular Growth and Proliferation Network is shown in 
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Figure 6.1. The nodes represent the molecules or genes within the network and the lines 
between the nodes indicate a functional relationship. The genes that were upregulated in 
the SW480/lamA cells are circled in blue and genes downregulated in the SW840/lamA cells 
compared to SW480/cntl cells are circled in red. Interestingly, PLS3 was not identified in this 
network analysis, even though the microarray analysis revealed that PLS3 was upregulated 
13-fold in the SW480/lamA compared to the SW480/cntl. This observation indicates that in 
silico analysis has some limitations in identifying novel interactions, for example between 
intracellular compartments, previously unrelated pathways or novel protein products.  
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Gene ID Gene name Fold Change Gene Function(s) 
EMP1 epithelial membrane protein 1 6.40 up Cell growth/cell proliferation 
DKK1 dickkopf homolog 1 (Xenopus laevis) 6.30 up Antagonises canonical Wnt signalling 
EREG Epiregulin 5.73 up Mediator of cell proliferation/angiogenesis 
AREG Amphiregulin  5.22 up Carcinoma growth inhibitor 
SNAI2 snail homolog 2 (Drosophila) 4.05 up Transcriptional repressor 
FOSL1 FOS-like antigen 1 4.04 up Positive regulator of cell proliferation 
IL6R interleukin 6 receptor 3.97 up Receptor for Interleukin 6/immune response 
SERPINE1 serpin peptidase inhibitor (plasminogen activator inhibitor type 1) 3.81 up Regulator of mRNA stability 
ETS1 erythroblastosis virus E26 oncogene homolog 1 (avian) 3.61 up Transcription factor/regulation 
MSX1 msh homeobox 1 3.54 up Acts as a transcriptional repressor 
CDC42EP5 CDC42 effector protein (Rho GTPase binding) 5 3.43 up Organisation of actin cytoskeleton 
FN1 fibronectin 1 3.31 up Cell adhesion/cell motility/cell shape  
AKAP11 A kinase (PRKA) anchor protein 11 3.18  up Protein kinase A regulator 
EIF4E eukaryotic translation initiation factor 4E 3.15 up  Facilitates ribosome binding 
EGFR epidermal growth factor receptor  2.99 up Cell surface receptor/ tyrosine kinase signalling 
BRCA2 breast cancer 2, early onset 2.93 up DNA repair/homologous recombination 
CKAP2 cytoskeleton associated protein 2 2.78 up Microtubule stabilizing properties/cell cycle 
NRP1 neuropilin 1 2.75 up Receptor involved in development/angiogenesis 
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 2.68 up RNA-binding protein/regulates RNA stability 
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 2.37 up RNA-binding protein/regulates RNA translation 
IGF2 insulin-like growth factor 2  8.61 down Growth-promoting activites 
BMP4 bone morphogenetic protein 4 7.19 down Inducer of bone/cartilage formation 
CHGA chromogranin A (parathyroid secretory protein 1) 4.80 down Inhibits glucose-induced insulin 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 3.43 down Cell adhesion molecule/motility 
MSX2 msh homeobox 2 2.89 down Transcriptional regulator in bone development 
COL18A1 collagen, type XVIII, alpha 1 2.70 down Inhibits proliferation and angiogenesis 
INSIG1 insulin induced gene 1 2.41 down Mediates control of cholesterol synthesis 
Table 6.1: List of genes identified in a cancer network by Ingenuity Pathway Analysis  
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Figure 6.1: Biological network linked to Cancer, Cellular movement, Cellular growth and Proliferation  
Up-regulated in  
SW480/lamA 
 
Down-regulated in 
SW480/lamA 
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Figure 6.2: Interactions and molecules used in Ingenuity Pathway Analysis network  
The shape surrounding the gene name represents the type of molecule encoded by the gene. The 
lines that link the genes together refer to known interactions dotted lines represents an indirect 
interaction. The arrowheads indicate directionality. Curved arrows designate self-regulation. Lines 
without an arrowhead refer to a binding interaction.  
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6.2.2 Confirmation of microarray data by real-time PCR 
Once an interaction network has been generated from the microarray data, the gene 
expression profiles and linkages must be validated using a biological assay. Quantitative real-
time PCR (qPCR) is the gold standard for the precise quantification of mRNA expression and 
is predominantly used to validate microarray data. Before confirming the data by qPCR, 
primers for the genes of interest were optimised as described in (Chapter 2, Section 2.6). 
From the cancer network, 11 nodes were chosen for analysis by qPCR. The selection was 
based on genes that were connected to at least two other genes in the network shown in 
Figure 6.1. Q-PCR was performed for AREG, BMP4, CDH1, COL18A1, EGFR, EIF4E, EREG, FN1, 
IGF2, SERPINE1 and SNAI2 in the SW480/lamA and SW480/cntl cells. The mRNA expression 
between SW480/cntl and SW480/lamA was calculated using the 2
-∆∆CT
 method (Livak and 
Schmittgen, 2001b). The 2
-∆∆CT
 method was chosen as it is a convenient way to perform 
relative quantification of mRNA expression between two samples. Normalisation was against 
housekeeping gene GAPDH. Statistical significance was determined by student t-tests (two-
sided). Of the eleven genes analysed, eight genes showed statistically significant changes in 
gene expression between the two cell types; BMP4, CDH1, COL18A1, EGFR, EIF4E, FN1, IGF2, 
and SERPINE1 (Figure 6.3). AREG and EREG were identified as differentially expressed by 
microarray analysis (Table 6.1), but this was not confirmed by qPCR (Figure 6.4). Moreover, 
SNAIL, which was shown to be upregulated ~4-fold in the SW480/lamA cells compared to the 
SW480/cntl cells by microarray analysis was actually statistically significantly down regulated 
in the SW480/lamA cells as determined by qPCR (Figure 6.4). However, since ~70% of the 
genes investigated by qPCR were consistent with the microarray analysis, the microarray as a 
whole was considered to be valid. 
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* p = <0.05, ** p = <0.01, *** p = <0.005 
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Figure 6.3: Confirmation of microarray data by quantitative real-time PCR 
Gene mRNA levels measured by real-time PCR in CRC cell lines SW480/lamA and SW480/cntl. 
Normalisation was against the housekeeping gene GAPDH. For each gene, the level of mRNA 
expression in SW480/cntl was set to equal 1. Data are presented as the relative changes in gene 
expression using the 2-∆∆CT method, from three to five biological replicates. The upper error bar 
corresponds to 2-(mean ∆∆CT – SE) and the lower error bar corresponds to 2-(mean ∆∆CT + SE). Statistical analysis 
was performed using the student t-test (two-sided) to compare the changes in gene expression 
between SW480/lamA and SW480/cntl. * = statistical significance. BMP4: p = 0.02, CDH1: p = 0.03, 
COL18A1: p = <0.01, EGFR: p = <0.01, FN1: p = 0.04, IGF2: p = <0.01, SERPINE1: p = 0.01, SNAI2: p = 
0.04.  
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Figure 6.4: Microarray versus quantitative real-time PCR: fold change in gene expression 
The relative fold change in gene expression in SW480/lamA cells compared to SW480/cntl cells is 
shown for the real time qPCR data (light purple bars), and the microarray data (dark purple bars). Of 
the eleven genes investigated, eight showed a similar trend, whereas AREG and SNAI2 were slightly 
downregulated in the qPCR and EREG was not significantly upregulated. 
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6.2.3 Confirmation of microarray data by Western blotting 
Although the microarray data were mostly confirmed at the mRNA level by qPCR this did not 
necessarily mean that there was a difference in the level of protein expression. This is 
because proteins may have long half-lives, may be highly abundant, could be subject to post-
translational regulatory mechanisms or there may be compensatory mechanisms that 
counter changes at the transcript level. To investigate whether changes in gene expression in 
the SW480/lamA cells were reflected at the protein level, immunobloting was performed 
(Figure 6.5). Lysates from the SW480/lamA cells were compared with those from 
SW480/cntl cells. A Bradford assay was used to calculate the protein levels in the lysates and 
SDS-PAGE followed by Coomassie staining was used to verify protein loading (Chapter 2, 
Section 2.9.4). GFP-lamin A was clearly expressed in the SW480/lamA cells only. The calcium 
dependent cell adhesion protein E-cadherin was downregulated in the SW480/lamA cell line 
as expected from the microarray data and from previous studies (Willis et al., 2008). The 
tyrosine kinase growth receptor EGFR was upregulated in the SW480/lamA cells, consistent 
with the microarray results. In addition, plasminogen activator inhibitor 1 (PAI-1) is a serine 
proteinase inhibitor protein encoded by the SERPINE1 gene. Predominantly synthesised by 
the vascular endothelial cells, it functions as fibrinolytic inhibitor by controlling the 
urokinase-type plasminogen activity (Sakakibara et al., 2005). Importantly, PAI-1 has been 
linked to tumour metastasis and has been associated with poor prognosis in several cancers 
(Cantero et al., 1997; Chambers et al., 1998; Konecny et al., 2001). In the Western blotting 
analysis shown, the level PAI-1 looked very similar between the two cell lines, suggesting 
that a two-fold change in the level of mRNA was not sufficient to make a difference to the 
steady-state level of this protein (Figure 6.5).  
 
Examination of SNAI2 (which encodes a zinc finger transcriptional repressor protein also 
known as Slug), gave conflicting results. In the microarray experiment SNAI2 levels were 
elevated in the SW480/lamA cells, whereas in the qPCR and Western blot there was a 
decrease in SNAI2 expression. In addition to these proteins, the expression of cofilin and 
MHC class I molecules was examined. Given that plastins are involved in binding and 
regulating the actin cytoskeleton, cofilin was chosen because it binds to both monomeric 
actin and F-actin. Cofilin is a small ~19 kDa protein that plays an important role in severing 
actin filament assembly and is upregulated in many cancers including renal cell carcinoma 
and ovarian cancer (Unwin et al., 2003; Martoglio et al., 2000). Moreover, cofilin has been 
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implicated with tumour invasion and metastasis (Wang et al., 2007). MHC class I levels were 
examined because MHC class I molecules are key determinants of the adaptive immune 
system and present viral and tumour peptides to cytotoxic CD8+ T cells. Expression of MHC 
class I molecules is thus required for tumour surveillance by cytotoxic T cells and for 
recognition of altered self by NK cells (Bubenik, 2003). Interestingly, MHC class I expression 
was strongly decreased in the SW480/lamA cells (Figure 6.5), suggesting that this may be a 
mechanism to allow the cancer cell to escape from immune surveillance. Unlike the result 
for MHC class 1, the actin binding protein cofilin was unchanged in the SW480/lamA cells, 
suggesting that lamin A expression does not effect cofilin expression (Chapter 4, Section 
4.2.3.6).   
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Figure 6.5: Coomassie and immunoblotting of selected proteins identified by microarray 
Lysates from SW480/lamA and SW480/cntl cells were analysed by SDS-PAGE, and stained with (A) 
colloidal Coomassie or (B) probed with a panel of antibodies. Molecular weight markers are given in 
kDa. β-actin was used a loading control. Data shows that E-cadherin, MHC 1 and Snail are 
downregulated in the SW480/lamA cells compared to SW480/cntl cells. EGFR was upregulated in the 
SW480/lamA cells compared to SW480/cntl cells. There was no change in protein expression 
between the cell lines for cofilin and plasminogen activator inhibitor 1 (PAI-1).  
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6.3 Discussion 
By sampling the expression of thousands of genes, microarray technology has revolutionised 
how we assess the molecular changes associated with tumour progression and biological 
responses in general. In this thesis, we have shown that T/L-plastin may be important in 
colorectal tumour formation, using diverse experimental approaches ranging from 
epigenetic studies to immunohistochemistry and western blotting. Having established that 
T-plastin is elevated when lamin A is overexpresed in CRC cell lines, we extended the analysis 
to seek other genes that responded to changes in lamin A expression in CRC and that might 
be linked to a functional network. A quantitative genome-wide DNA pair wise screening on 
the SW480/lamA and SW480/cntl cell lines was previously carried out. In order to identify 
other candidate genes that could be investigated for prognostic value (to be used in 
combination with lamin A/C), and to shed light on the molecular mechanisms involved in the 
lamin cancer pathway, we took a bioinformatic stance. IPA® analysis generated a highly 
significant cancer network (Figures 6.1 and 6.2), drawing on literature-curated interactions 
that allowed us to focus on the most promising genes from the microarray experiment 
(Figure 6.3). The most statistically significant network to arise out of this work was linked to 
cancer, cell motility, cellular growth and proliferation.  
 
It was important to confirm the microarray data by other biological assays. This was 
achieved by performing qPCR (Figure 6.4). Results revealed that eight out of the eleven 
genes investigated showed a statistically significant change in gene expression in 
SW480/lamA compared to SW480/cntl cells. However, AREG and EREG were identified as 
differentially expressed by microarray analysis, but this was not confirmed by qPCR. 
Moreover, SNAI2 was down regulated in the SW480/lamA cells according to the qPCR 
analysis (Figure 6.4). How can these discrepancies be explained? 
 
Firstly, it is possible that there are biological differences in the cells, as the RNA samples for 
the microarray and the RNA for the PCR experiments were isolated years apart, albeit from 
the same cell line. The SW480 cell line is genetically unstable (Camps et al., 2005; Lengauer 
et al., 1997; Ribas et al., 2003) and it is also possible that the expression of GFP-lamin A 
varies with time, or that passage number, confluency, stress or even batch to batch 
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variations in the composition of fetal calf serum influence the expression of a fraction of the 
lamin A target genes.  
 
Alternatively, differences in expression of SNAI2 may be due to changes in the way that 
transcription factors are expressed during cancer progression. Interestingly, gene expression 
can change during transition from one stage of the EMT to the next (Savagner et al., 1997; 
Vetter et al., 2009). Thus it is possible that SNAI2 is switched on and then off once the 
expression of its target genes has been initiated. Snail may initiate the repression of 
epithelial genes (Guaita et al., 2002; Peinado et al., 2007) and loss of E-cadherin, which 
occurs on expression of lamin A in the experiments shown in this chapter, could stabilise the 
mesenchymal state (Onder et al., 2008). This idea is backed up by data from the 
immunoblotting analysis, which showed that SNAI2 is downregulated at the protein level in 
the GFP-lamin A cells (Figure 6.5), with E-cadherin protein expression being markedly 
reduced. 
 
Another possible explanation for the differences observed between the microarray and 
qPCR data is the nature of the experimental setup. Some genes have more than one 
corresponding probeset on the microarray chip, including AREG and EREG. For these genes, 
only one of the two probesets showed up-regulation of the gene. For SNAI2 only one 
probeset was present on the microarray. It is possible that the results for these three genes 
were not reproducible because of variation in hybridisation efficiency, or in the 
amplification/detection steps of the microarray experiment. Comparison of the microarray 
and qPCR data shows why it is important to use different assays and approaches to 
reproduce and understand complex biological phenomena. 
 
Furthermore, the data in this chapter showed that a number of genes were downregulated 
in the SW480/lamA cells, as determined by qPCR analysis. One of the most striking genes 
that was downregulated was BMP4 which encodes BMP4, a protein usually involved in bone 
and cartilage formation but also involved in mesoderm induction and the inhibition of hair 
follicle induction (Wozney et al., 1988). BMP4 has been shown to be a downstream target of 
Ras in SW480, Hela, and 293 cells (Duerr et al., 2012). In this work, oncogenic KRAS 
downregulated RNA levels of BMP4 through the ERK pathway, fitting with the enchanced 
level of EGFR expression seen in our study. 
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An example of a gene that was upregulated in the SW480/lamA cells compared to the 
SW480/cntl cells was the fibronectin gene FN1. Fibronectin is a secreted protein that is well 
established as protein that can bind collagens and actin, and is important for cell adhesion, 
motility and the maintenance of cell shape. Studies in ovarian cancer cells suggest that 
fibronectin cleavage by matrix metalloprotease-2 (MMP2) is a key step in the initial stages of 
metastasis and allows the cell to break away from the tumour cell mass. Mutations in FN1 
have also been noted from DNA sequencing of breast and colon cancer tissue (Sjoeblom et 
al., 2006). Since a number of FN1 isoforms exist and fibronectin is subject to extensive post-
translational modification, it would be interesting to study the relationship between 
fibronectin and MMPs in the lamin A expressing cell line in future studies.  
 
The consequences of changes in transcript levels on the corresponding proteins were 
assessed by immunoblotting (Figure 6.5) and were largely in agreement with the qPCR data, 
with the exception of PAI-1. A possible explanation for this observation is that western 
blotting is not fully quantitative so that small differences in PAI-1 protein expression are not 
picked up. To address this, pulse chase experiments or semi-quantitative blotting using 
fluorescent probes could be used. Alternatively, changes in the transcript levels of SERPINE1 
could be buffered by post-translational feedback and regulatory mechanisms that maintain 
steady state levels of the protein. Although the influence of lamin A expression on SERPINE1 
remains unclear from our analysis, it has recently been shown that PAI-1 is expressed more 
strongly in SW480 cells than in CaCo-2 cells and that PAI-1 levels are increased in more 
aggressive colorectal tumors, from an analysis of 50 CRC specimens (Mazzoccoli et al., 2012).  
 
Notably, microarray, qPCR and immunblotting analysis all confirmed that EGFR was 
upregulated in the SW480/lamA compared to SW480/cntl cells. EGFR is frequently expressed 
in solid tumors including CRC, and promotes cancer cell growth and cell division (Harris and 
McCormick, 2010). In this chapter, it was noted that downregulation of E-cadherin was 
inversely correlated with the upregulation of EGFR in the lamin A overexpressing cells. It has 
recently been published that the same inverse correlation has been seen in head and neck 
squamous cancer cells (Wang et al., 2011) and EGFR has been reported to directly 
downregulate E-cadherin transcription. This suggests that the effect of lamin A on E-cadherin 
could be an indirect one in colon cancer cells and may proceed via EGFR. Further studies will 
be required to test this hypothesis, for example, by using an inducible lamin A construct to 
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evaluate the timing of E-cadherin downregulation and EGFR upregulation through pulse-
chase experiments. Two anti-EGFR monoclonal antibody therapies are currently prescribed 
for patients with metastatic colon cancer, namely Erbitux (cetuximab) and Vectibix 
(panitumumab), but these drugs are only prescribed to patients with wild-type KRAS genes, 
as ‘activating’ mutations in KRAS make patients unresponsive to anti-EGFR treatment 
(Sheridan, 2008). Therefore, lamin A, or a downstream target of lamin A, might be worth 
exploring as a drug target for CRC patients who are unresponsive to EGFR therapy. It would 
be interesting to revisit the NLCS tissue archive to examine the expression of EGFR and lamin 
A, and check the history of drug responsiveness in these patients. Given that an inverse 
relationship between EGFR and E-cadherin is also seen in head and neck cancer (Wang et al., 
2011), it would also be interesting to examine the expression of lamin A and T-plastin in this 
solid tumour type. It would also be important to explore whether EGFR signaling is activated 
in the SW480/lamA cell lines by using phosphorylation-specific antibodies and checking for 
activation through the ERK or JAK/STAT pathways, since EGFR signalling can lead to 
activation of genes involved in cell survival (through Ras/ERK or JAK/STAT), or the induction 
of protein synthesis (through the AKT pathway) (Figure 6.6). 
 
 
  
 
 
 
 
 
 
Figure 6.6: Overview of the EGF signaling pathway 
Activation of the EGF receptor results in tyrosine autophosphorylation. Phosphorylated EGFR binds 
proteins through the Src homology 2 (SH2) domain. Downstream signalling occurs through the 
RAS/extracellular signal regulated kinase (ERK) pathway, the phosphatidylinositol 3-kinase (PI3) AKT3 
pathway and the Janus kinase/Signal transducer and activator of transcription (JAK/ STAT) pathway. 
Together, these pathways co-ordinate cell survival. 
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A notable feature of the SW480/lamA cell line was the marked downregulation of MHC class 
I expression. MHC class I molecules are present on all nucleated cells (but not red blood 
cells), and have a central role in the immune system. They are chiefly involved in presenting 
antigenic peptides from intracellular sources, such as viruses, to CD8+ T cells. The CD8+ T 
cells are usually cytotoxic T cells that destroy an infected cell. However, MHC class I 
molecules are also involved in tumour surveillance. This is because mutations in the coding 
regions of genes can lead to a change in the amino acid sequence of the protein. This change 
can be detected by cytotoxic T cells in the context of the MHC class I molecule, enabling the 
killer T cells to destroy the tumour cell. There is a strong selection pressure on some 
tumours to escape detection by cytotoxic T cells, and hence MHC class I is downregulated in 
a number of cancer types, including CRC cell lines (Browning et al., 1996). Interestingly, a 
recent publication reported that positive MHC 1 expression is a biomarker of good prognosis 
in CRC patients (Simpson et al., 2010). However, the exact mechanisms underlying this 
aspect of tumour immunology are not well understood. It is therefore very exciting that 
simply overexpressing the lamin A gene has such a dramatic effect on MHC class I levels. The 
effect is not likely to be direct, given that lamin A is a nuclear protein and MHC class I 
molecules are trafficked to the cell surface through the ER-Golgi secretory pathway. 
However, lamins has been implicated in the global control of gene expression by influencing 
chromosome positioning and the organisation of heterochromatin close the nuclear 
periphery (Dechat et al., 2008). Therefore, one possibility is that lamin A may bring areas of 
Chromosome 6 to the nuclear periphery and shut down gene expression. Chromosome 
painting experiments in the SW480/lamA cells could be conducted to test this idea directly. 
Another possibility is that lamin A directly influences an intermediary protein, such as an 
MHC class I transcription factor, or a protease that increases the turnover of MHC class I 
molecules. This could be tested by performing pulse chase labelling studies and with cell 
surface biotinylation experiments to compare the synthesis and turnover of the MHC class I 
molecules in SW480/lamA and SW480/cntl cells.  
 
In summary, the work in this chapter has identified a candidate cancer network, with lamin A 
at the heart, influencing a number of genes involved in signalling and tumour metastasis. As 
a first step towards understanding the biological relationship with the genes identified in the 
microarray screen, qPCR and Western blotting were performed to confirm that EGFR was 
upregulated and that E-cadherin was downregulated. Taken together, the results suggest 
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that there is functional relationship between EGFR and lamin A, and how T-plastin fits in to 
this network merits further exploration as a biologically important hub and a clinically 
important therapeutic target. 
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Chapter 7: Discussion and future perspectives 
 
7.1 Background and aims of thesis 
CRC is the third most common form of malignancy in the Western world (Ferlay et al. 2010). 
Intimately linked with environment and lifestyle, the disease represents a huge challenge to 
global health organisations (Kolonel et al., 2004; Smits et al., 2008; Jemal et al., 2011). CRC 
starts as a benign polyp, which develops into an invasive carcinoma through a step-wise 
histological progression sequence spanning 10-15 years (Fearon et al., 2011). Current 
methods of clinicopathological staging used to predict patient prognosis are based on the 
Dukes’/TNM system (Compton and Greene, 2004). However, survival rates vary between 
90% - 10% with tumour progression (Fretwell et al, 2010). Since the discovery of the first 
oncogene in 1989, the central tenet has been that mutations in our genetic make-up drive 
the initiation and progression of carcinogenesis (Brower, 2011; Dawson and Kouzarides, 
2012). Whilst this theory remains irrefutable, we still lack a robust and reliable genetic 
biomarker that can accurately predict patient prognosis. This can be explained, at least in 
part, by two phenomena; firstly, the fact that CRC is a truly heterogeneous disease with 
thousands of abnormalities in the cancer genome and secondly, that ‘genetic’ events are not 
the sole contributors to neoplastic formation. Since 1994, when Baylin and Herman showed 
that the tumour suppressor gene von-Hippel Lindau (VHL) was silenced in renal cell 
carcinoma by DNA methylation, the appreciation that epigenetics plays a significant role in 
cancer formation has dawned on the scientific community (Herman et al., 1994). Until 
recently, epigenetic modifications have been thought of as a proxy for genetic changes in 
cancer. The argument for causality is confounded by a lack of mutations in epigenetic 
machinery (Feinberg, 2007; Dawson and Kouzarides, 2012). However, the idea that 
aberrations in the epigenome are a cause rather than a consequence of cancer has been 
strengthened by the finding that DNA methyltransferase DNMT3a is mutated in patients 
with acute myeloid leukemia (Ley et al., 2010).  
 
Understanding the molecular basis of this disease is crucial to help develop accurate 
biomarkers and treatments for CRC patients (Smits et al., 2008). As a step towards this aim, 
PLS3 promoter methylation and expression of the actin-bundling protein plastin has been 
studied in this thesis. This work arose from a study in our laboratory which identified lamin 
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A/C as a prognostic biomarker in CRC (Willis et al., 2008). When lamin A was overexpressed 
in the CRC cell line SW480, this caused the cancer cells to adopt a more motile phenotype. 
Strikingly, T-plastin expression was upregulated by GFP-lamin A expressing cells when 
compared with the GFP control counterparts (Willis et al., 2008). This finding stimulated the 
further study of plastins in CRC, in the hope that plastins may have some prognostic 
influence, perhaps together with lamin A as part of a biomarker panel. The overall objectives 
of this thesis were: to investigate PLS3 promoter methylation in CRC by N-MSP and explore 
whether there was an association between PLS3 methylation and clinicopathological 
characteristics; produce and characterise polyclonal plastin antibodies by immunoblotting; 
investigate the expression of plastin in CRC tissue archive by immunohistochemistry and 
determine the utility of plastin expression as a prognostic biomarker for CRC. The final 
objective of this thesis was to look at the global changes based on the expression on GFP-
lamin A in CRC SW480, generate a candidate gene network and validate this network by 
qPCR and immunoblotting. 
 
7.2 PLS3 promoter CpG island methylation is a mechanism 
for controlling T-plastin expression 
We began our investigation by assessing the methylation status of the PLS3 promoter in 
both CRC cell lines and DNA taken from the NLCS tissue archive. Whilst our data showed that 
PLS3 promoter methylation cannot be used as an independent prognostic biomarker, some 
interesting observations were made that warrant further research. Firstly, we found that the 
PLS3 promoter was unmethylated in SW620, SW480, LS and CaCo-2 cells and methylated in 
SW948 and HT29 CRC cell lines, as determined by N-MSP (Figure 3.3). The SW620 and 
SW948 cell lines were selected for bisulphite sequence analysis. Results confirmed that 
SW620 and SW948 are indeed unmethylated and methylated, respectively (Figure 3.5). In 
order to establish whether there was a relationship between PLS3 promoter methylation 
and T-plastin expression, we subjected the female methylated cell lines SW948 and HT29 to 
epigenetic drug treatment. We observed that upon DAC treatment, T-plastin mRNA 
expression was restored in a dose-dependent manner, suggesting that methylation at the 
PLS3 promoter regulates the T-plastin gene. This is supported by the current literature (Ikeda 
et al., 2005; Sasaki et al., 2002). However, the regulation of T-plastin expression is likely to 
involve additional factors (e.g. transcription factors and repressors) given that the T-plastin 
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protein is detected in ‘unmethylated’ SW620 cells but not in ‘unmethylated’ SW480 cells 
(Figure 4.1). This hypothesis is also based on the mixed results that were obtained from the 
methylation studies of normal and CRC colon tissue. In normal colon tissue, where T-plastin 
is never expressed, the frequency of methylation at the PLS3 promoter was only 65%, 
whereas in CRC patients, although the degree of methylation fell, ~50% of primary colorectal 
tumours analysed remained methylated. If methylation at the PLS3 promoter were the only 
mechanism that suppressed T-plastin expression, then 100% of normal colonic mucosa 
samples should be methylated. This idea is backed up by a growing body of literature that 
suggests that DNA methylation status does not always correlate with transcriptional activity 
(Suzuki and Bird, 2008). Future experiments to understand the consequences of PLS3 
methylation with respect to T-plastin protein expression could be conducted to clarify this 
issue. For example, it would be informative to know whether methylation at specific sites in 
the PLS3 promoter influences gene expression through the recruitment of transcription 
factors, and how lysine methylation of histone proteins relates to PLS3 gene expression. 
Very little is known about the control of plastin expression by transcriptional regulators, and 
perhaps CHiP experiments to compare PLS3 promoter occupancy from ‘methylated’ and 
‘unmethylated’ CRC cell lines would be informative in this regard. 
 
7.3 Does PLS3 promoter hypomethylation play a pivotal role 
in switching on T-plastin in CRC? 
Significantly, in the patient’s samples analysed (from frozen tissue), we noted a switch in the 
methylation status between normal colonic mucosa and corresponding tumour tissue. 
Quantitative real-time PCR analysis showed that T-plastin expression was suppressed in the 
‘methylated’ normal colonic tissue and upregulated in the ‘unmethylated’ tumour tissue. 
However, one limitation of this study is the small number of patients examined. In addition, 
we did not assess the same samples for T-plastin protein expression. Nevertheless, the 
increase of T-plastin mRNA observed in the patient colorectal tumor tissue, compared with 
their corresponding normal colonic mucosa (Figure 3.11), suggests that hypomethylation or 
demethylation of the PLS3 promoter may play a critical role in switching on T-plastin 
expression during neoplastic transformation. In the support of this theory, it has been 
recently reported by Jones and colleagues that the PLS3 promoter is hypomethylated 
causing an upregulation of T-plastin in Sezary syndrome patients (Jones et al., 2012). The 
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exact mechanisms involved and consequences of promoter methylation and demethylation 
in CRC are not fully understood. In general, it is well established that de novo methylation is 
initiated during embryogenesis by the DNMT3 family of methyltransferases and maintained 
by DNMT1 during DNA replication (Law and Jacobsen, 2010). DNMT1 is recruited to a 
position just downstream of the replication complex and associates with PCNA and UHRF1, a 
protein that specifically targets hemimethylated DNA in the post-replication phase. DNMT1 
can then restore the hemimethylated DNA to its fully methylated state (Bostick et al., 2007; 
Sharif et al., 2007). UHRF1 is only detectable in actively proliferating cells and its expression 
level is elevated in various cancers, including prostate, lung, breast, pancreatic, bladder and 
cervical cancer but not, until recently, CRC (Unoki et al., 2009). A difficulty in interpreting 
complex methylation patterns and predicting their effects in CRC is that proteins such as 
UHFR1 can both positively and negatively regulate gene expression. Therefore, further 
research is required to establish whether and how mutations in the DNMT1-associated 
methylation machinery contribute to CRC. 
 
7.4 Is there a role for active demethylation in CRC? 
In contrast to the active methylation of CpG dinucleotides, demethylation is usually thought 
of as a passive process in which the methylated cytosine is lost during replication in the 
absence of DNMT1 activity. However, evidence has accumulated to support a role for an 
active demethylation pathway, and although some findings remain controversial (Ooi and 
Bestor, 2008) investigating the dysregulation of demethylation in CRC and other cancers is 
likely to be an area of intensive research in the future. Active demethylation in plants is 
orchestrated by the DME1/ROS1 family of glycosylases, but orthologues of these proteins 
have not been identified in animals (Zhu, 2009). Instead it is thought that in animals, 
deamination of the methylated cytosine is catalysed by AID/APOBEC, resulting in a thymine 
base (mismatched to guanine). The mismatched A/T pair is probably recognized by the 
glycosidases Tdg and Mbd4, which cleave the N-glycosidic bond to leave an abasic site that is 
removed by an as yet unidentified apyrimidic lyase. The single nucleotide gap in the DNA 
sequence must then be repaired by as yet unknown DNA polymerase/ligase activities. 
Evidence for this pathway mainly comes from work in zebrafish embryos in which over-
expression of Aid, Apobec2a and Apobec2b resulted in loss of methylation in an Mbd4 
dependent manner (Rai et al., 2008). Knocking out Aid in mice also results in a genome-wide 
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reduction of demethylation in primordial germ cells (Popp et al., 2010). Given these recent 
discoveries, it would be very interesting to examine the expression and activities of 
Aid/Apobec and Tdg/Mbd4 in the CRC cell lines and patients that we have presented in this 
study, and to determine whether there is any relationship with T-plastin expression.  
 
T-plastin is expressed in the embryonic development of the intestinal system and then 
switched off, but is re-expressed during the initiation of colon cancer (Chapter 3). Of 
relevance to this finding is that loss of the APC tumour suppressor gene in zebrafish results 
in upregulation of the DNA demethylase machinery (Rai et al., 2010). The model proposed by 
Rai et al, in which APC controls intestinal cell fate by downregulating demethylation and 
promoting differentiation is consistent with the finding that T-plastin is expressed early 
during embryonic gut development, is switched off in adults and is re-expressed in CRC 
(Chapters 3 and 5). Since loss of APC is a key step in the initiation of CRC, one would predict 
that DNA demethylase activity is also enhanced in CRC patients. Demethylase activity is 
indirectly repressed by retinoic acid (Zhu, 2009), so it would be interesting to see whether 
treating T-plastin positive CRC cells with retinoids results in the re-establishment of PLS3 
promoter methylation and subsequent repression of T-plastin protein expression.  
 
An alternative mechanism to demethylation by AID/APOBEC is the conversion of 5-
methylcytosine (5-mc) to 5-hydroxymethylcytosine (5-hmc) by hydroxylation, which can be 
catalysed, at least in vitro, by TET1 (Tahiliani et al., 2009). The DNMT1 machinery has a low 
affinity for 5-hmc, and thus may not be recruited to replication complexes if 5-hmc is 
present. The 5-hmc modification has been found mainly in brain tissue and ES cells 
(Kriaucionis and Heintz, 2009) but is also present in aged tissues (Song et al., 2011). The 
bisulfite sequencing technique described in Chapters 2 and 3 cannot distinguish between 5–
mc and 5-hmc (Huang et al., 2010). Thus whether 5-hmc modifications play a role in 
demethylation of the PLS3 promoter in CRC remains to be established. Recently developed 
5-hmc-specific antibodies and a newly established 5hmC-qPCR technique (Nestor et al., 
2012) could be used to revisit the PLS3 locus (Chapter 3) and to reanalyze bowel tissue 
sections (Chapter 5) for 5hmc expression.  
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7.5 PLS3 methylation is strongly associated with sex and 
tumour location 
In Chapter 3, we observed that there was a remarkable difference in PLS3 promoter 
methylation and the sexes (p = <0.0001) (Figure 3.14). Over 85% of the female samples 
analysed were methylated for PLS3 and over 85% of male samples were unmethylated for 
PLS3. DNA methylation helps maintain the inactivation of one of the X chromosomes in 
females, where PLS3 is located. Promoters on the inactive, but not the active, X chromosome 
are often methylated (Lock et al., 1987), so one possibility is that X chromosome-specific 
regulatory factors could modulate T-plastin expression in the female CRC patients examined 
in our study. However, it has been shown that DNMT1-deficient mice embryos can maintain 
imprinted X inactivation in non-embryonic cell lineages, despite extensive CpG 
demethylation (Sado et al., 2000). Although this paper implies that demethylation of X 
chromosomal genes (such as PLS3) would not necessarily lead to their activation, further 
detailed methylation studies of both X-chromosomes in the T-plastin expressing female 
cohort would be required to investigate this further.  
 
The extent to which LOH affects the sex chromosomes is not clear. For example, Cheng and 
colleagues showed that the inactivated X-chromosome had the ability to influence the 
development of ovarian epithelial cancers (Cheng et al., 1996), suggesting that some genes 
on the silenced X-chromosome may escape inactivation and may subsequently be subject to 
transforming mutations, epigenetic dysregulation, or chromosomal gene rearrangements 
that influence cancer onset. Interestingly, a number of leukaemias and lymphomas are 
associated with X-chromosome rearrangements (Shaknovich et al., 2011). Notably, Sezary 
syndrome is also a rare type of cutaneous lymphoma (discussed above). It is tempting to 
speculate that PLS3 could therefore be associated with sex linked lymphoma as well as sex 
linked CRC. Sezary syndrome has a male: female incidence ratio of 2.5:1, so it would be 
interesting to determine the epigenetic regulation of PLS3 expression in male and female 
Sezary patients and to determine whether there was any correlation with PLS3 expression 
levels and metastasis from the primary lymphoma in this type of cancer. 
 
In this thesis, we have also demonstrated that there is a statistically significant relationship 
between PLS3 promoter methylation and tumour location (p = 0.044) (Figure 3.15). The 
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frequency of PLS3 methylation was higher in the proximal (right-sided) colon compared to 
the distal (left-sided) colon. As previously discussed, there is a large body of evidence which 
suggests that there are sex-specific differences between left-sided and right-sided CRC 
(Benedix et al., 2010). More men than women have LCCs and the survival of cancer patients 
with LCCs tends to be higher than those with RCCs. According to the work in this thesis, the 
PLS3 promoter is more likely to be methylated in both RCC and in females, consistent with 
the literature. A study of differential gene expression in CRC that compared the caecum and 
sigmoid/rectosigmoid bowel is informative in this regard. They showed that keratins 8, 19, 
20 and carbonic anhydrases II, IV and VII were downregulated in left sided cancers whereas 
other genes such as COX2 were upregulated in left sided adenocarcinomas. T-plastin was 
identified by this study as one of 30 genes differentially expressed more than 3-fold in at 
least one Dukes’ stage compared to normal mucosa, with T-plastin expression being highest 
on the left side (Birkenkamp-Demtroder et al. 2005). This would support the assertion in this 
thesis that methylation controls T-plastin expression in colon cancer. This could be followed 
up by examining more patients from the NLCS and improving the recovery of methylated 
DNA from fixed tissues so that historical samples from RCCs and LCCs can be studied for the 
methylation of PLS3 in these patients. 
 
7.6 T/L-plastin expression is switched on in CRC and 
frequently observed at the invasive front of the tumour 
After investigating PLS3 promoter methylation in Chapter 3, we went on to examine plastin 
protein expression. Six polyclonal antibodies were raised and tested for their specificity and 
suitability using immunoblotting. The Dann1a antibody was taken forward for 
immunohistochemical staining of patient tissue (Chapter 5), based on its relative specificity 
and ability to detect T- and L-plastins using a range of techniques. In support of the 
literature, no T/L-plastin expression was observed in histologically normal colonic mucosa by 
immunohistochemical analysis (Delanote et al., 2005). Remarkably, when we turned to the 
tumour tissue from the NLCS archive, we found that ~80% of samples were positive for 
plastin expression (Chapter 5, Figure 5.5). A recent investigation reported the expression of 
L-plastin in ~82% of CRCs (Li and Zhao, 2011). This group also observed a correlation 
between L-plastin and tumour stage, size and lymph node metastasis. Conversely, we found 
no association between plastin expression and clinicopathological features or survival. 
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However, the interpretation of our results is limited because Dann1a detects both T- and L-
plastin. To overcome this limitation, T- and L-plastin monoclonal antibodies could be 
developed, northern blotting could be used, or laser capture microdissection (LCM) could be 
employed to firmly establish which plastin is expressed in a cohort of CRC patients. 
Furthermore, it would be useful to assess plastin expression using other tissue archives such 
as the Western Australia tissue bank. It would also be appealing to see whether T/L-plastin 
and lamin A is switched on in other epithelial cancers. 
  
Having discussed how epigenetics might control gene expression in CRC, it is of interest to 
consider how those changes in gene expression might influence cellular function and confer 
a growth advantage to the transformed cell. As an actin bundling protein, plastin is involved 
in controlling actin dynamics. We noted in our study that T/L-plastin expression was 
significantly increased at the invasive front of tumours (Chapter 5, Figures 5.6-5.7). One 
possible explanation for this observation is that plastin expression at the leading edge 
increases cellular movement and hence encourages cells to break away from the tissue mass 
and metastasise (Figure 7.1). 
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Figure 7.1: Upregulation of plastin at the invasive front may lead to increased formation of 
specialised membrane protrusions and hence metastasis 
 
 
This hypothesis is supported by the observations of Giganti et al. (2005) who showed that T-
plastin increased the rate of movement of beads coated with actin (and actin nucleating 
proteins) and stabilized the actin comets. In future, immunofluorescence studies will be 
required to determine whether T-plastin is preferentially co-localised with actin in cells at 
the leading edge, or in transformed CRC cells in culture. If so, studies could be performed to 
test whether over-expression of plastin (by transfection) is sufficient to induce a migratory 
phenotype in CRC cell lines. An alternative explanation for the role of T/L-plastin at the 
leading edge is that plastin plays a role in modulating the mechanical stiffness of cells, 
possibly together with lamin A. An interesting study from Leight et al. has shown that 
culturing epithelial cells on gels with varying rigidity induces changes in signalling through 
the PI3K/AKT pathway (Leight et al., 2012). EGFR is upregulated in the lamin-A responsive 
network described in Chapter 6, and also signals through the PI3K/AKT pathway; therefore, 
plastin may be one of a number of proteins that helps modify cell stiffness and hence 
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modulates signal transduction as transformed cells ‘prepare’ for EMT (Swaminathan et al., 
2011). 
 
Moreover, there is evidence to suggest that there is a direct mechanical link between 
chromatin and the cytoskeleton, via nuclear lamins, and that the application of force can be 
sensed by adhesion molecules and transmitted to DNA to induce remodeling events. Thus 
plastin could be an important player in the ‘tensegrity’ network model (which achieves 
complex architecture through tensional integrity) developed by Donald Ingber (Ingber, 
1993).  
 
Although plastin expression was observed at the leading edge, it was expressed at all Dukes’ 
stages of CRC. Thus, another possible explanation for the elevated expression of plastin in 
CRC is that plastin may cause aberrant signalling processes to occur that pave the way for 
EMT. In this scenario, plastin overexpression may prevent transmembrane receptors from 
being clustered appropriately, may prevent signalling complexes from being disassembled in 
a timely fashion, or may prevent regulatory molecules from being recruited to the signalling 
node (Stephenson et al., 2012). The hypothesis that aberrant signalling caused by plastin 
overexpression results in cancer progression could be tested in a number of ways. For 
example, one could analyse global signalling patterns in cells expressing plastin by probing 
the phosphoproteome e.g. using anti-phosphotyrosine antibodies in a proteomic 
experiment. Changes in the phosphorylation pattern (compared with non-plastin expressing 
cells) could be determined by mass spectrometry, and signalling through candidate 
receptors could be confirmed using receptor specific antibodies in a western blotting or 
radiolabeling experiment. Alternatively, tagged plastin could be used as bait to 
immunoprecipitate cross-linked associated proteins, and any candidate signalling receptors 
or signal transduction regulators identified by mass spectrometry could be confirmed by 
follow up blotting studies. Another possibility is that aberrant plastin expression perturbs 
cell polarity, which is essential for normal tissue homeostasis and is known to be disrupted in 
tumourigenesis (Royer and Lu, 2011). Actin bundling is important in the polarity of and 
positioning of epithelial cells, so inappropriate expression of plastin could lead to 
perturbations in the normal cytoskeletal architecture thus promoting neoplastic 
transformation (Stevenson et al, 2012).  
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Although T-plastin is predominantly found in the cytoskeleton, there are reports that actin 
and other actin binding proteins can be functionally active in the nucleus, for example in 
muscle cells, where actin may regulate transcription factor complexes (Zheng et al., 2009). 
The staining observed in Chapter 5 of skin epithelial cells also suggested that T/L-plastin was 
found in the nucleus. However, the staining of potentially nuclear-localised T/L-plastin was 
harder to observe it CRC because of the stronger co-staining with haematoxylin. A potential 
role for nuclear localised plastins in the control of gene expression cannot be ruled out and 
further work is required to confirm immunohistochemically whether plastin expression 
occurs in the nucleus of CRC tissue, preferably using T- and L-plastin specific antibodies. 
 
7.7 Identification of a candidate gene network based on the 
expression of GFP-lamin A in CRC cell line SW480 
Finally, in order to address the mechanism by which lamin A causes CRC cells to adopt a 
more motile phenotype, and to identify candidate genes for biomarker/drug development, 
we performed IPA on a microarray dataset from a model cell line overexpressing GFP-lamin 
A. The IPA analysis identified a candidate gene network linked to cancer, cellular movement, 
cellular growth and proliferation (p < 0.05). The validity of this network was confirmed using 
a qPCR and Western blotting approach. Upon the expression of GFP-lamin A in CRC cell line 
SW480, we observed a significant increase in EGFR and decrease in E-cadherin both at the 
mRNA and protein level. Interestingly, both EGFR and E-cadherin are involved in the EMT 
pathway, whereby stationary polarised epithelial cells, communicating by cell-cell junctions, 
break up their junctions and switch to a non-polarised, mobile and invasive mesenchymal 
cell state. EGFR signalling has been shown to induce the down regulation of E-cadherin and 
induce EMT in ovarian cancer cells (Cheng et al., 2012). Given the data presented in this 
thesis, lamin A may have an important role in the transition of epithelial cells to a more 
mesenchymal state, and thus metastasis (Figure 7.2). 
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Figure 7.2: Increased expression of lamin A in SW480 cells may induce EMT through the 
upregulation of EGFR, down regulation of E-cadherin and upregulation of T-plastin  
 
T-plastin was not identified as part of this network, despite being upregulated 13-fold in the 
SW480/lamA cells compared to the SW480/cntl cells. This highlights the limitations of this 
type of computational analysis, as this IPA is based on literature-curated interactions. 
Experiments will now be required to establish whether T-plastin is upstream, downstream or 
acting in parallel with other members of this network. This could be tested by transfecting T-
plastin into T-plastin negative CRC cells and analyzing whether EGFR is upregulated, E-
cadherin is downregulated, and whether other lamin A responsive genes are influenced by T-
plastin expression. The findings from Chapter 6 provide a framework to revisit the NLCS 
tissue archive and examine the expression of key genes such as EGFR and E-cadherin, in 
combination with lamin A and T-plastin in a multi-factorial biomarker study.  
 
7.8 Conclusion 
In conclusion, the data described in this thesis suggests that PLS3 promoter methylation is an 
important mechanism of controlling T-plastin expression. Strikingly, T/L-plastin was 
aberrantly expressed in CRC suggesting that plastin has a potential role in neoplastic 
transformation. Finally, we identified a novel gene network based on the overexpression of 
lamin A in CRC cells. The data suggests that lamin A is potentially a master regulator of a 
pathway that co-ordinates the cytoskeletal changes required for cell motility and tumour 
Lamin A 
EGFR 
E-cadherin T-plastin + 
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invasiveness. Overall, PLS3 methylation status will not be a stand-alone biomarker for CRC 
and combining a promoter methylation approach (e.g. for PLS3) together with an 
immunohistochemical approach (e.g. for lamin A) may prove to be too complex for routine 
diagnostic/prognostic use. However, improvements in the technology used to detect 
methylation may be required before combined methylation/protein biomarker panels can 
be taken forward into the clinic. Advances in our technological capacity to perform 
microarrays on large datasets, and to sequence individual cancer genomes in a time and 
cost-effective manner, will help us to understand how these multiple and complex factors 
are related in cancer biology and will pave the way for the development of personalised 
medicine. 
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Appendix: supplementary figures 
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Figure S1: Representative graphs generated from qPCR experiments 
In this case, all graphs were generated using CDH1 primers and performing qPCR on cDNA from CRC 
cell line SW480 (A) qPCR was performed on a cDNA dilution series. Standard curve (where X axis = 
log10 and Y axis = CT value) shows that that CDH1 primers are specific as the gradient of the graph is 
between -3.3 +/-0.3. (B) Melt curve analysis was performed to confirm the integrity of the PCR 
product. A single peak corresponds to the decreased fluoresce at the melting point of the PCR 
product. (C) Amplification plot indicating the changes in SYBR green fluorescence during the reaction. 
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Figure S2: ELISA analysis for Dann antibodies  
Affinity purified rabbit polyclonal anti-plastin antibodies characterised by ELISA against the 
immunising peptides over a range of dilutions up to 1/100000 and compared with the crude antisera. 
From this the antibody titre (antibody dilution at half maximum response) can be determined. The 
antibody concentration is determined from the UV absorbance at 405 nm. Antisera obtained from 
each animal displayed varying titres of anti-peptide antibody (A) 1:4383 (Dann1a antibody) (B) 
1:5816 (Dann1b antibody) (C) 1:43658 (Dann2a antibody) (D) 1:21646 (Dann2b antibody) (E) 1:7664 
(Dann3a antibody) (F) 1:6413 (Dann3b antibody). Dann2a has the highest titre of antibody (1:43658) 
compared with Dann1a, which has the lowest (1:4283).  
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atttcctcaacaaaatggttaCGactggaacaggaaagggcttagactttttcttctacagctatcccacaagtcagt
ctcttgacctgaccctgcaaaatccctcaaactctggctctctgagttgattttggatataCGatgaaccataggttt
ggaatgcagataacctccaCGtgtattaatgaaagaggtcagctatgaCGtggaagccatctcctgggcagagaagga
gaagaaatggcagtctggggagtagtaacatgtctccaaattttctctggtgaaaggagactgatgagaattgatacc
catttcCGgtcaaaagagtggaaccaatgtacttccaaccacctcctctcaacccctctcCGcatggacaaacatacc
agacaggtgatgtgggctaacaatttacttggcatgaggccaaaggcttgagggccctgccctgcccatattcttctc
ccttgacttcttaaggaaaggaatgattgctgatgtttccctctgcaccctttggcacctggactgattgttgcagat
gtaattaggaatgttccccaacatgcCGttattcttctcaCGattctgggagaaactgtacccctcccccatagactt
atataggtggcattcaaattcttgttcccaactttttcatctgtttattaatcccacaagattgtgtgaatgtgtact
cCGagccaggcaCGttggacttctaacttcctcttagcccaagtaggaaggggagactcaggCGctggggaccattct
cctctccctgcagcagagttgcagtccctatccctcctgggtgcccatcccCGtgcctattttcctggatccccaccc
agttgatgtgacaggctCGtggcccaatccccttcctggttcccaggcCGactgctagcaccaccCGagccaatggCG
gCGgcCGaggggCGgagggggctggcaggaggggagggagCGctggctttagagccacagctgcaaagattcCGaggt
gcagaagttgtctgagtgCGttggtCGgCGgcagtCGggccagacccaggactctgCGactttaCGtaagtgctttgt
aggCGcCGgCGggcactaggggagCGggtttcctgggCGtgggcaggagtgggtccCGgggagagcatctCGgttaag
ctcagcaggaaCGtgCGgCGcacCGtggggCGggggttgggggagagggaggtCGgagaaatttcagttggagccctC
GggCGccCGggCGatCGgtCGcaacCGaaatgggtgtgagtgaCGgggagtttccctactagcatcCGcCGcagacaC
Gttttctgcacttcactgtattaagtggtgttttcttactagttgctcttaacttgttgccagtcttgggctggagtc
ctagaCGccagcccttgccctgattcccctcCGCGgctgCGgcccCGaagtggaaagggagCGcacaacttccctctg
tCGtccttctccagctactgccatcccctcttccctccCGccCGgactcaggaaatccCGgagccagcagcctgctac
tcctccagcccccacaCGccCGcctCGggtgacctggctggcttaagcCGaccctggggctctggagagggggggcCG
tggcCGagggaaggcaCGaggtttgggttgcctgccttctgcctgcttccctcccttgtccttagCGagggCGtCGCG
aaCGcacctagtctccctatgagtaagcactttttttcctttcagtaggagaacatctctgggctagtaggacagtac
ctttcCGttctcccctggccccacaccccctgtccttttttcagctcctttgactttgCGgcccCGggCGCGCGgtCG
gggCGgCGgcagtccCGgacctctccCGactcttggagagagagaggcaaaggggCGaCGggagggaggtaatagtct
accccccCGccctttcccCGcacagctgcacttgcctgtgtttacttttct 
 
 
Figure S3: PLS3 promoter sequence: location of the CpG island 
The CpG island is 431 bp (highlighted in yellow). CG dinucleotides are highligted in red. The 
transcription initation start site (TSS) is indicated in purple. Note that the PLS3 promoter sequence 
displayed is post sodium-bisulphite modification.  
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atttttttaataaaatggttaCGattggaataggaaagggtttagatttttttttttatagttattttataagttagt
tttttgatttgattttgtaaaattttttaaattttggttttttgagttgattttggatataCGatgaattataggttt
ggaatgtagataatttttaCGtgtattaatgaaagaggttagttatgaCGtggaagttattttttgggtagagaagga
gaagaaatggtagtttggggagtagtaatatgtttttaaattttttttggtgaaaggagattgatgagaattgatatt
tattttCGgttaaaagagtggaattaatgtatttttaattatttttttttaattttttttCGtatggataaatatatt
agataggtgatgtgggttaataatttatttggtatgaggttaaaggtttgagggttttgttttgtttatatttttttt
ttttgattttttaaggaaaggaatgattgttgatgtttttttttgtattttttggtatttggattgattgttgtagat
gtaattaggaatgttttttaatatgtCGttattttttttaCGattttgggagaaattgtattttttttttatagattt
atataggtggtatttaaatttttgtttttaatttttttatttgtttattaattttataagattgtgtgaatgtgtatt
tCGagttaggtaCGttggatttttaatttttttttagtttaagtaggaaggggagatttaggCGttggggattatttt
tttttttttgtagtagagttgtagtttttattttttttgggtgtttattttCGtgtttatttttttggatttttattt
agttgatgtgataggttCGtggtttaattttttttttggtttttaggtCGattgttagtattattCGagttaatggCG
gCGgtCGaggggCGgagggggttggtaggaggggagggagCGttggttttagagttatagttgtaaagatttCGaggt
gtagaagttgtttgagtgCGttggtCGgCGgtagtCGggttagatttaggattttgCGattttaCGtaagtgttttgt
aggCGtCGgCGggtattaggggagCGggttttttgggCGtgggtaggagtgggtttCGgggagagtatttCGgttaag
tttagtaggaaCGtgCGgCGtatCGtggggCGggggttgggggagagggaggtCGgagaaattttagttggagttttC
GggCGttCGggCGatCGgtCGtaatCGaaatgggtgtgagtgaCGgggagtttttttattagtattCGtCGtagataC
Gttttttgtattttattgtattaagtggtgtttttttattagttgtttttaatttgttgttagttttgggttggagtt
ttagaCGttagtttttgttttgattttttttCGCGgttgCGgtttCGaagtggaaagggagCGtataatttttttttg
tCGtttttttttagttattgttatttttttttttttttCGttCGgatttaggaaatttCGgagttagtagtttgttat
ttttttagtttttataCGttCGtttCGggtgatttggttggtttaagtCGattttggggttttggagagggggggtCG
tggtCGagggaaggtaCGaggtttgggttgtttgttttttgtttgttttttttttttgtttttagCGagggCGtCGCG
aaCGtatttagtttttttatgagtaagtattttttttttttttagtaggagaatatttttgggttagtaggatagtat
tttttCGtttttttttggttttatattttttgttttttttttagtttttttgattttgCGgtttCGggCGCGCGgtCG
gggCGgCGgtagtttCGgatttttttCGatttttggagagagagaggtaaaggggCGaCGggagggaggtaatagttt
attttttCGtttttttttCGtatagttgtatttgtttgtgtttattttttt 
 
Primer set 1 
Outside  165bp 
Flank up GAGAGTATTTYGGTTAAGTTTAGTAGG 55.7-57.6°C 27 bp 
Flank down ACRAATACTAATAAAAAAACTCCCC  56.1-58.0°C 25 bp 
 
Inside  115 bp – 123 bp 
US  GGTTAAGTTTAGTAGGAATGTGTGGT  58.1°C  26 bp 
MS  AGTTTAGTAGGAACGTGCGGC   58.5°C  21bp 
UAS  CACACCCATTTCAATTACAACCA  59.5°C  23 bp 
MAS  ACCCATTTCGATTACGACCG   59.1°C  20 bp 
  
Primer set 2 
Outside  166bp        
Flank up GATTGTTAGTATTATTYGAGTTAATGG 54.3-56.7°C  27 bp 
Flank down TCRCAAAATCCTAAATCTAACCC  55.2-59.9°C 23 bp 
 
Inside  144 bp-155 bp 
US  TTGTTAGTATTATTTGAGTTAATGGTGGT 60.1°C  29 bp 
MS  GTATTATTCGAGTTAATGGCGGC  60.3°C  23 bp 
UAS  CCTAAATCTAACCCAACTACCACCA  61.2°C  25 bp 
MAS  ATCTAACCCGACTACCGCCG   60.9°C  20 bp 
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Figure S4: PLS3 promoter sequence: location of N-MSP primer sets 1 and 2 
The ‘outside’ primer sets are underlined. The blue (primer pair 1) and purple (primer pair 2) regions 
highlight methylated primers. The green (primer pair 1) and yellow (primer pair 2) regions highlight 
the unmethylated primers. The TSS is highlighted in pink. CG dinucleotides are highlighted in red. 
Note that the PLS3 promoter sequence displayed is post sodium-bisulfite modification. US = 
umethylated sense, MS  = methylated sense, UAS = unmethylated antisense, MAS = methylated 
sense.  
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atttttttaataaaatggttaCGattggaataggaaagggtttagatttttttttttatagttattttataagttagt
tttttgatttgattttgtaaaattttttaaattttggttttttgagttgattttggatataCGatgaattataggttt
ggaatgtagataatttttaCGtgtattaatgaaagaggttagttatgaCGtggaagttattttttgggtagagaagga
gaagaaatggtagtttggggagtagtaatatgtttttaaattttttttggtgaaaggagattgatgagaattgatatt
tattttCGgttaaaagagtggaattaatgtatttttaattatttttttttaattttttttCGtatggataaatatatt
agataggtgatgtgggttaataatttatttggtatgaggttaaaggtttgagggttttgttttgtttatatttttttt
ttttgattttttaaggaaaggaatgattgttgatgtttttttttgtattttttggtatttggattgattgttgtagat
gtaattaggaatgttttttaatatgtCGttattttttttaCGattttgggagaaattgtattttttttttatagattt
atataggtggtatttaaatttttgtttttaatttttttatttgtttattaattttataagattgtgtgaatgtgtatt
tCGagttaggtaCGttggatttttaatttttttttagtttaagtaggaaggggagatttaggCGttggggattatttt
tttttttttgtagtagagttgtagtttttattttttttgggtgtttattttCGtgtttatttttttggatttttattt
agttgatgtgataggttCGtggtttaattttttttttggtttttaggtCGattgttagtattattCGagttaatggCG
gCGgtCGaggggCGgagggggttggtaggaggggagggagCGttggttttagagttatagttgtaaagatttCGaggt
gtagaagttgtttgagtgCGttggtCGgCGgtagtCGggttagatttaggattttgCGattttaCGtaagtgttttgt
aggCGtCGgCGggtattaggggagCGggttttttgggCGtgggtaggagtgggtttCGgggagagtatttCGgttaag
tttagtaggaaCGtgCGgCGtatCGtggggCGggggttgggggagagggaggtCGgagaaattttagttggagttttC
GggCGttCGggCGatCGgtCGtaatCGaaatgggtgtgagtgaCGgggagtttttttattagtattCGtCGtagataC
Gttttttgtattttattgtattaagtggtgtttttttattagttgtttttaatttgttgttagttttgggttggagtt
ttagaCGttagtttttgttttgattttttttCGCGgttgCGgtttCGaagtggaaagggagCGtataatttttttttg
tCGtttttttttagttattgttatttttttttttttttCGttCGgatttaggaaatttCGgagttagtagtttgttat
ttttttagtttttataCGttCGtttCGggtgatttggttggtttaagtCGattttggggttttggagagggggggtCG
tggtCGagggaaggtaCGaggtttgggttgtttgttttttgtttgttttttttttttgtttttagCGagggCGtCGCG
aaCGtatttagtttttttatgagtaagtattttttttttttttagtaggagaatatttttgggttagtaggatagtat
tttttCGtttttttttggttttatattttttgttttttttttagtttttttgattttgCGgtttCGggCGCGCGgtCG
gggCGgCGgtagtttCGgatttttttCGatttttggagagagagaggtaaaggggCGaCGggagggaggtaatagttt
attttttCGtttttttttCGtatagttgtatttgtttgtgtttattttttt 
 
Primer set 3 
Outside  131 bp      
Flank up YGGAGAAATTTTAGTTGGAGTTTT  57.0-58.9°C  24 bp 
Flank down CCACTTAATACAATAAAATACAAAAAAC 57.0°C   28 bp 
 
 
Inside     104 bp – 113 bp 
US  TGGAGTTTTTGGGTGTTTGGGT   62.6°C  22 bp 
MS  TTTCGGGCGTTCGGGC    61.7°C  16 bp 
UAS  CTTAATACAATAAAATACAAAAAACATATCTACA 60.9°C  34 bp 
MAS  AATACAATAAAATACAAAAAACGTATCTACG              61.4°C  31 bp 
 
 
Figure S5: PLS3 promoter sequence: location of N-MSP primer set 3 
The ‘outside’ primer set is underlined. The methylated primer pair is highlighted in blue. The 
unmethylated primer pair is highlighed in green. The TSS is highlighted in pink. CG dinucleotides are 
highlighted in red. Note that the PLS3 promoter sequence displayed is post sodium-bisulfite 
modification. US = umethylated sense, MS  = methylated sense, UAS = unmethylated antisense, MAS 
= methylated sense.  
     
 
208 
 
atttttttaataaaatggttaCGattggaataggaaagggtttagatttttttttttatagttattttataagttagt
tttttgatttgattttgtaaaattttttaaattttggttttttgagttgattttggatataCGatgaattataggttt
ggaatgtagataatttttaCGtgtattaatgaaagaggttagttatgaCGtggaagttattttttgggtagagaagga
gaagaaatggtagtttggggagtagtaatatgtttttaaattttttttggtgaaaggagattgatgagaattgatatt
tattttCGgttaaaagagtggaattaatgtatttttaattatttttttttaattttttttCGtatggataaatatatt
agataggtgatgtgggttaataatttatttggtatgaggttaaaggtttgagggttttgttttgtttatatttttttt
ttttgattttttaaggaaaggaatgattgttgatgtttttttttgtattttttggtatttggattgattgttgtagat
gtaattaggaatgttttttaatatgtCGttattttttttaCGattttgggagaaattgtattttttttttatagattt
atataggtggtatttaaatttttgtttttaatttttttatttgtttattaattttataagattgtgtgaatgtgtatt
tCGagttaggtaCGttggatttttaatttttttttagtttaagtaggaaggggagatttaggCGttggggattatttt
tttttttttgtagtagagttgtagtttttattttttttgggtgtttattttCGtgtttatttttttggatttttattt
agttgatgtgataggttCGtggtttaattttttttttggtttttaggtCGattgttagtattattCGagttaatggCG
gCGgtCGaggggCGgagggggttggtaggaggggagggagCGttggttttagagttatagttgtaaagatttCGaggt
gtagaagttgtttgagtgCGttggtCGgCGgtagtCGggttagatttaggattttgCGattttaCGtaagtgttttgt
aggCGtCGgCGggtattaggggagCGggttttttgggCGtgggtaggagtgggtttCGgggagagtatttCGgttaag
tttagtaggaaCGtgCGgCGtatCGtggggCGggggttgggggagagggaggtCGgagaaattttagttggagttttC
GggCGttCGggCGatCGgtCGtaatCGaaatgggtgtgagtgaCGgggagtttttttattagtattCGtCGtagataC
Gttttttgtattttattgtattaagtggtgtttttttattagttgtttttaatttgttgttagttttgggttggagtt
ttagaCGttagtttttgttttgattttttttCGCGgttgCGgtttCGaagtggaaagggagCGtataatttttttttg
tCGtttttttttagttattgttatttttttttttttttCGttCGgatttaggaaatttCGgagttagtagtttgttat
ttttttagtttttataCGttCGtttCGggtgatttggttggtttaagtCGattttggggttttggagagggggggtCG
tggtCGagggaaggtaCGaggtttgggttgtttgttttttgtttgttttttttttttgtttttagCGagggCGtCGCG
aaCGtatttagtttttttatgagtaagtattttttttttttttagtaggagaatatttttgggttagtaggatagtat
tttttCGtttttttttggttttatattttttgttttttttttagtttttttgattttgCGgtttCGggCGCGCGgtCG
gggCGgCGgtagtttCGgatttttttCGatttttggagagagagaggtaaaggggCGaCGggagggaggtaatagttt
attttttCGtttttttttCGtatagttgtatttgtttgtgtttattttttt 
 
 
Outside  131 bp      
Forward YGGAGAAATTTTAGTTGGAGTTTT  57.0-58.9°C 24 bp 
Reverse CCACTTAATACAATAAAATACAAAAAAC 57.0°C  28 bp 
 
 
Figure S6: PLS3 promoter sequence: location of bisulfite sequencing primers 
The bisulpfite sequencing primers were designed to amplify sodium bisulfite-modified DNA and are 
highlighed in purple. The TSS is highlighted in pink. CG dinucleotides are highlighted in red. he size of 
the amplicon is 309 bp and this region encompasses the N-MSP primers shown in Supplementary 
Figure S5. 
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Figure S7: Colony PCR: CRC cells  
Colony PCR was performed to check the validity of the recombinants. The PCR products were 
analysed on a 2% agarose gel and compared with empty vector (245 bp). PCR products containing 
the correct insert (~550 bp) were selected for DNA sequencing. 
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Figure S8: Bisulfite sequencing analysis of PLS3 CpG island in SW948 CRC cell line 
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Figure S9: Bisulfite sequencing analysis of PLS3 CpG island in SW620 CRC cell line 
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Figure S10: Bisulphite sequence alignment of methylated T-plastin (M), unmethylated T-plastin (U) 
and consensus sequence (C) for (A) SW948 CRC cell line (B) SW620 CRC cell line. 
 
    35
    35
    40
.....AGTCGGGTTAGATTTAGGATTTTGCGATTTTACGT
.....AGTTGGGTTAGATTTAGGATTTTGTGATTTTATGT
GGCTTAGTTGGGTTAGATTTAGGATTTTGCGATTTTACGT
agt gggttagatttaggattttg gatttta gt
    75
    75
    80
AAGTGTTTTGTAGGCGTCGGCGGGTATTAGGGGAGCGGGT
AAGTGTTTTGTAGGTGTTGGTGGGTATTAGGGGAGTGGGT
AAGTGTTTTGTAGGCGTCGGCGGGTATTAGGGGAGCGGGT
aagtgttttgtagg gt gg gggtattaggggag gggt
   115
   115
   120
TTTTTGGGCGTGGGTAGGAGTGGGTTTCGGGGAGAGTATT
TTTTTGGGTGTGGGTAGGAGTGGGTTTTGGGGAGAGTATT
TTTTTGGGTGTGGGTAGGAGTGGGTTTCGGGGAGAGTATT
tttttggg gtgggtaggagtgggttt ggggagagtatt
   155
   155
   160
TCGGTTAAGTTTAGTAGGAACGTGCGGCGTATCGTGGGGC
TTGGTTAAGTTTAGTAGGAATGTGTGGTGTATTGTGGGGT
TTGGTTAAGTTTAGTAGGAACGTGCGGCGTATCGTGGGGC
t ggttaagtttagtaggaa gtg gg gtat gtgggg
   195
   195
   200
GGGGGTTGGGGGAGAGGGAGGTCGGAGAAATTTTAGTTGG
GGGGGTTGGGGGAGAGGGAGGTTGGAGAAATTTTAGTTGG
GGGGGTTGGGGGAGAGGGAGGTCGGAGAAATCTTAGTTGG
gggggttgggggagagggaggt ggagaaat ttagttgg
   235
   235
   240
AGTTTTCGGGCGTTCGGGCGATCGGTCGTAATCGAAATGG
AGTTTTTGGGTGTTTGGGTGATTGGTTGTAATTGAAATGG
AGTTTTCGGGCGTTCGGGCGATCGGTCGTAATCGAAATGG
agtttt ggg gtt ggg gat ggt gtaat gaaatgg
   275
   275
   280
GTGTGAGTGACGGGGAGTTTTTTTATTAGTATTCGTCGTA
GTGTGAGTGATGGGGAGTTTTTTTATTAGTATTTGTTGTA
GTGTGAGTGACGGGGAGTTTTTTTATTAGTATTTGTCGTA
gtgtgagtga ggggagtttttttattagtatt gt gta
   309
   309
   317
GATACGTTTTTTGTATTTTATTGTATTAAGTGGT...
GATATGTTTTTTGTATTTTATTGTATTAAGTGGT...
GATACGTTTTTTGTATTTTATTGTATTAAGTGGAAGC
gata gttttttgtattttattgtattaagtgg
 
    36
    36
    40
....AGTCGGGTTAGATTTAGGATTTTGCGATTTTACGTA
....AGTTGGGTTAGATTTAGGATTTTGTGATTTTATGTA
GCTTAGTTGGGTTAGATTTAGGATTTTGTGATTTTATGTA
agt gggttagatttaggattttg gatttta gta
    76
    76
    80
AGTGTTTTGTAGGCGTCGGCGGGTATTAGGGGAGCGGGTT
AGTGTTTTGTAGGTGTTGGTGGGTATTAGGGGAGTGGGTT
AGTGTTTTGTAGGTGTTGGTGGGTATTAGGGGAGTGGGTT
agtgttttgtagg gt gg gggtattaggggag gggtt
   116
   116
   120
TTTTGGGCGTGGGTAGGAGTGGGTTTCGGGGAGAGTATTT
TTTTGGGTGTGGGTAGGAGTGGGTTTTGGGGAGAGTATTT
TTTTGGGTGTGGGTAGGAGTGGGTTTTGGGGAGAGTATTT
ttttggg gtgggtaggagtgggttt ggggagagtattt
   156
   156
   160
CGGTTAAGTTTAGTAGGAACGTGCGGCGTATCGTGGGGCG
TGGTTAAGTTTAGTAGGAATGTGTGGTGTATTGTGGGGTG
TGGTTAAGTTTAGTAGGAATGTGTGGTGTATTGTGGGGTG
ggttaagtttagtaggaa gtg gg gtat gtgggg g
   196
   196
   200
GGGGTTGGGGGAGAGGGAGGTCGGAGAAATTTTAGTTGGA
GGGGTTGGGGGAGAGGGAGGTTGGAGAAATTTTAGTTGGA
GGGGTTGGGGGAGAGGGAGGTTGGAGAAATTTTAGTTGGA
ggggttgggggagagggaggt ggagaaattttagttgga
   236
   236
   240
GTTTTCGGGCGTTCGGGCGATCGGTCGTAATCGAAATGGG
GTTTTTGGGTGTTTGGGTGATTGGTTGTAATTGAAATGGG
GTTTTTGGGTGTTTGGGTGATTGGTTGTAATTGAAATGGG
gtttt ggg gtt ggg gat ggt gtaat gaaatggg
   276
   276
   280
TGTGAGTGACGGGGAGTTTTTTTATTAGTATTCGTCGTAG
TGTGAGTGATGGGGAGTTTTTTTATTAGTATTTGTTGTAG
TGTGAGTGATGGGGAGTTTTTTTATTAGTATTTGTTGTAG
tgtgagtga ggggagtttttttattagtatt gt gtag
   309
   309
   317
ATACGTTTTTTGTATTTTATTGTATTAAGTGGT....
ATATGTTTTTTGTATTTTATTGTATTAAGTGGT....
ATATGTTTTTTGTATTTTATTGTATTAAGTGGTAAGC
ata gttttttgtattttattgtattaagtggt
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Figure S11: Colony PCR: patient DNA  
Colony PCR was performed to check the validity of the recombinants. The PCR products were 
analysed on a 2% agarose gel and compared with empty vector (245 bp). PCR products containing 
the correct insert (~550 bp) were selected for DNA sequencing. 
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   Figure S12: Bisulfite sequencing analysis of PLS3 CpG island in normal colonic mucosa (Patient 1) 
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Figure S13: Bisulphite sequence alignment of methylated T-plastin (M), unmethylated T-plastin (U) 
and consensus sequence (C) for (A) normal colonic mucosa and (B) corresponding tumour tissue from 
patient 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    35
    35
    40
.....AGTCGGGTTAGATTTAGGATTTTGCGATTTTACGT
.....AGTTGGGTTAGATTTAGGATTTTGTGATTTTATGT
GGCTTAGTTGGGTTAGATTTAGGATTTTGTGATTTTATGT
agt gggttagatttaggattttg gatttta gt
    75
    75
    80
AAGTGTTTTGTAGGCGTCGGCGGGTATTAGGGGAGCGGGT
AAGTGTTTTGTAGGTGTTGGTGGGTATTAGGGGAGTGGGT
AAGTGTTTTGTAGGTGTTGGTGGGTATTAGGGGAGTGGGT
aagtgttttgtagg gt gg gggtattaggggag gggt
   115
   115
   120
TTTTTGGGCGTGGGTAGGAGTGGGTTTCGGGGAGAGTATT
TTTTTGGGTGTGGGTAGGAGTGGGTTTTGGGGAGAGTATT
TTTTTGGGTGTGGGTAGGAGTGGGTTTTGGGGAGAGTATT
tttttggg gtgggtaggagtgggttt ggggagagtatt
   155
   155
   160
TCGGTTAAGTTTAGTAGGAACGTGCGGCGTATCGTGGGGC
TTGGTTAAGTTTAGTAGGAATGTGTGGTGTATTGTGGGGT
TTGGTTAAGTTTAGTAGGAATGTGTGGTGTATTGTGGGGT
t ggttaagtttagtaggaa gtg gg gtat gtgggg
   195
   195
   200
GGGGGTTGGGGGAGAGGGAGGTCGGAGAAATTTTAGTTGG
GGGGGTTGGGGGAGAGGGAGGTTGGAGAAATTTTAGTTGG
GGGGGTTGGGGGAGAGGGAGGTTGGAGAAATTTTAGTTGG
gggggttgggggagagggaggt ggagaaattttagttgg
   235
   235
   240
AGTTTTCGGGCGTTCGGGCGATCGGTCGTAATCGAAATGG
AGTTTTTGGGTGTTTGGGTGATTGGTTGTAATTGAAATGG
AGTTTTTGGGTGTTTGGGTGATTGGTTGTAATTGAAATGG
agtttt ggg gtt ggg gat ggt gtaat gaaatgg
   275
   275
   280
GTGTGAGTGACGGGGAGTTTTTTTATTAGTATTCGTCGTA
GTGTGAGTGATGGGGAGTTTTTTTATTAGTATTTGTTGTA
GTGTGAGTGATGGGGAGTTTTTTTATTAGTATTTGTTGTA
gtgtgagtga ggggagtttttttattagtatt gt gta
   309
   309
   317
GATACGTTTTTTGTATTTTATTGTATTAAGTGGT...
GATATGTTTTTTGTATTTTATTGTATTAAGTGGT...
GATATGTTTTTTGTATTTTATTGTATTAAGTGGTAAG
gata gttttttgtattttattgtattaagtggt
 
    35
    35
    40
.....AGTCGGGTTAGATTTAGGATTTTGCGATTTTACGT
.....AGTTGGGTTAGATTTAGGATTTTGTGATTTTATGT
GGCTTAGTCGGGTTAGATTTAGGATTTTGTGATTTTATGT
agt gggttagatttaggattttg gatttta gt
    75
    75
    80
AAGTGTTTTGTAGGCGTCGGCGGGTATTAGGGGAGCGGGT
AAGTGTTTTGTAGGTGTTGGTGGGTATTAGGGGAGTGGGT
AAGTGTTTTGTAGGTGTTGGTGGGTATTAGGGGAGTGGGT
aagtgttttgtagg gt gg gggtattaggggag gggt
   115
   115
   120
TTTTTGGGCGTGGGTAGGAGTGGGTTTCGGGGAGAGTATT
TTTTTGGGTGTGGGTAGGAGTGGGTTTTGGGGAGAGTATT
TTTTTGGGTGTGGGTAGGAGTGGGTTTTGGGGAGAGTATT
tttttggg gtgggtaggagtgggttt ggggagagtatt
   155
   155
   160
TCGGTTAAGTTTAGTAGGAACGTGCGGCGTATCGTGGGGC
TTGGTTAAGTTTAGTAGGAATGTGTGGTGTATTGTGGGGT
TTGGTTAAGTTTAGTAGGAATGTGTGGTGTATTGTGGGGT
t ggttaagtttagtaggaa gtg gg gtat gtgggg
   195
   195
   200
GGGGGTTGGGGGAGAGGGAGGTCGGAGAAATTTTAGTTGG
GGGGGTTGGGGGAGAGGGAGGTTGGAGAAATTTTAGTTGG
GGGGGTTGGGGGAGAGGGAGGTTGGAGAAATTTTAGTTGG
gggggttgggggagagggaggt ggagaaattttagttgg
   235
   235
   240
AGTTTTCGGGCGTTCGGGCGATCGGTCGTAATCGAAATGG
AGTTTTTGGGTGTTTGGGTGATTGGTTGTAATTGAAATGG
AGTTTTTGGGTGTTTGGGTGATTGGTTGTAATTGAAATGG
agtttt ggg gtt ggg gat ggt gtaat gaaatgg
   275
   275
   280
GTGTGAGTGACGGGGAGTTTTTTTATTAGTATTCGTCGTA
GTGTGAGTGATGGGGAGTTTTTTTATTAGTATTTGTTGTA
GTGTGAGTGATGGGGAGTTTTTTTATTAGTATTTGTTGTA
gtgtgagtga ggggagtttttttattagtatt gt gta
   309
   309
   318
GATACGTTTTTTGTATTTTATTGTATTAAGTGGT....
GATATGTTTTTTGTATTTTATTGTATTAAGTGGT....
GATATGTTTTTTGTATTTTATTGTATTAAGTGGTAAGC
gata gttttttgtattttattgtattaagtggt
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